<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Pharmacological treatment for attention deficit hyperactivity disorder (ADHD) in children with comorbid tic disorders - Osland, ST - 2018 | Cochrane Library</title> <meta content="Pharmacological treatment for attention deficit hyperactivity disorder (ADHD) in children with comorbid tic disorders - Osland, ST - 2018 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007990.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Pharmacological treatment for attention deficit hyperactivity disorder (ADHD) in children with comorbid tic disorders - Osland, ST - 2018 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007990.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD007990.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Pharmacological treatment for attention deficit hyperactivity disorder (ADHD) in children with comorbid tic disorders" name="citation_title"/> <meta content="Sydney T Osland" name="citation_author"/> <meta content="University of Calgary" name="citation_author_institution"/> <meta content="Thomas DL Steeves" name="citation_author"/> <meta content="University of Toronto" name="citation_author_institution"/> <meta content="Tamara Pringsheim" name="citation_author"/> <meta content="University of Calgary" name="citation_author_institution"/> <meta content="tmprings@ucalgary.ca" name="citation_author_email"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="6" name="citation_issue"/> <meta content="10.1002/14651858.CD007990.pub3" name="citation_doi"/> <meta content="2018" name="citation_date"/> <meta content="2018/06/26" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007990.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007990.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007990.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Atomoxetine Hydrochloride [therapeutic use]; Attention Deficit Disorder with Hyperactivity [*drug therapy]; Central Nervous System Stimulants [adverse effects, *therapeutic use]; Clonidine [therapeutic use]; Desipramine [therapeutic use]; Dextroamphetamine [therapeutic use]; Guanfacine [therapeutic use]; Methylphenidate [therapeutic use]; Randomized Controlled Trials as Topic; Selegiline; Tic Disorders [*complications, drug therapy]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007990.pub3&amp;doi=10.1002/14651858.CD007990.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007990.pub3&amp;doi=10.1002/14651858.CD007990.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007990.pub3&amp;doi=10.1002/14651858.CD007990.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007990.pub3&amp;doi=10.1002/14651858.CD007990.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007990.pub3&amp;doi=10.1002/14651858.CD007990.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007990.pub3&amp;doi=10.1002/14651858.CD007990.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007990.pub3&amp;doi=10.1002/14651858.CD007990.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007990.pub3&amp;doi=10.1002/14651858.CD007990.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007990.pub3&amp;doi=10.1002/14651858.CD007990.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007990.pub3&amp;doi=10.1002/14651858.CD007990.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007990.pub3&amp;doi=10.1002/14651858.CD007990.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007990.pub3&amp;doi=10.1002/14651858.CD007990.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007990.pub3&amp;doi=10.1002/14651858.CD007990.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007990.pub3&amp;doi=10.1002/14651858.CD007990.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007990.pub3&amp;doi=10.1002/14651858.CD007990.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007990.pub3&amp;doi=10.1002/14651858.CD007990.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007990.pub3&amp;doi=10.1002/14651858.CD007990.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007990.pub3&amp;doi=10.1002/14651858.CD007990.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007990.pub3&amp;doi=10.1002/14651858.CD007990.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007990.pub3&amp;doi=10.1002/14651858.CD007990.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007990.pub3&amp;doi=10.1002/14651858.CD007990.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007990.pub3&amp;doi=10.1002/14651858.CD007990.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007990.pub3&amp;doi=10.1002/14651858.CD007990.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="mvgXlmVk";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD007990\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD007990\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007990\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007990\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","ms","fa","zh_HANS"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD007990.pub3",title:"Pharmacological treatment for attention deficit hyperactivity disorder (ADHD) in children with comorbid tic disorders",firstPublishedDate:"Jun 26, 2018 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Developmental, Psychosocial and Learning Problems Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=mvgXlmVk&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007990.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD007990.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD007990.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD007990.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007990.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD007990.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD007990.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD007990.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD007990.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD007990.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD007990.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD007990.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD007990.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD007990.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>12792 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD007990.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007990.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007990.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007990.pub3/full#CD007990-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007990.pub3/full#CD007990-sec-0092"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007990.pub3/full#CD007990-sec-0022"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007990.pub3/full#CD007990-sec-0023"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007990.pub3/full#CD007990-sec-0028"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007990.pub3/full#CD007990-sec-0029"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007990.pub3/full#CD007990-sec-0053"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007990.pub3/full#CD007990-sec-0086"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD007990.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007990.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007990.pub3/appendices#CD007990-sec-0096"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007990.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007990.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007990.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007990.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD007990.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD007990.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD007990.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2018 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD007990.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Pharmacological treatment for attention deficit hyperactivity disorder (ADHD) in children with comorbid tic disorders </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007990.pub3/information#CD007990-cr-0002">Sydney T Osland</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007990.pub3/information#CD007990-cr-0003">Thomas DL Steeves</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007990.pub3/information#CD007990-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Tamara Pringsheim</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD007990.pub3/information/en#CD007990-sec-0143">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 26 June 2018 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD007990.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD007990.pub3">https://doi.org/10.1002/14651858.CD007990.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD007990-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD007990-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD007990-abs-0004">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD007990-abs-0006">فارسی</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD007990-abs-0008">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD007990-abs-0001" lang="en"> <section id="CD007990-sec-0001"> <h3 class="title" id="CD007990-sec-0001">Background</h3> <p>This is an update of the original Cochrane Review published in Issue 4, 2011.</p> <p>Attention deficit hyperactivity disorder (ADHD) is the most prevalent of the comorbid psychiatric disorders that complicate tic disorders. Medications commonly used to treat ADHD symptoms include stimulants such as methylphenidate and amphetamine; non‐stimulants, such as atomoxetine; tricyclic antidepressants; and alpha agonists. Alpha agonists are also used as a treatment for tics. Due to the impact of ADHD symptoms on the child with tic disorder, treatment of ADHD is often of greater priority than the medical management of tics. However, for many decades, clinicians have been reluctant to use stimulants to treat children with ADHD and tics for fear of worsening their tics.  </p> </section> <section id="CD007990-sec-0002"> <h3 class="title" id="CD007990-sec-0002">Objectives</h3> <p>To assess the effects of pharmacological treatments for ADHD in children with comorbid tic disorders on symptoms of ADHD and tics. </p> </section> <section id="CD007990-sec-0003"> <h3 class="title" id="CD007990-sec-0003">Search methods</h3> <p>In September 2017, we searched CENTRAL, MEDLINE, Embase, and 12 other databases. We also searched two trial registers and contacted experts in the field for any ongoing or unpublished studies. </p> </section> <section id="CD007990-sec-0004"> <h3 class="title" id="CD007990-sec-0004">Selection criteria</h3> <p>We included randomized, double‐blind, controlled trials of any pharmacological treatment for ADHD used specifically in children with comorbid tic disorders. We included both parallel‐group and cross‐over study designs. </p> </section> <section id="CD007990-sec-0005"> <h3 class="title" id="CD007990-sec-0005">Data collection and analysis</h3> <p>We used standard methodological procedures of Cochrane, in that two review authors independently selected studies, extracted data using standardized forms, assessed risk of bias, and graded the overall quality of the evidence by using the GRADE approach. </p> </section> <section id="CD007990-sec-0006"> <h3 class="title" id="CD007990-sec-0006">Main results</h3> <p>We included eight randomized controlled trials (four of which were cross‐over trials) with 510 participants (443 boys, 67 girls) in this review. Participants in these studies were children with both ADHD and a chronic tic disorder. All studies took place in the USA and ranged from three to 22 weeks in duration. Five of the eight studies were funded by charitable organizations or government agencies, or both. One study was funded by the drug manufacturer. The other two studies did not specify the source of funding. Risk of bias of included studies was low for blinding; low or unclear for random sequence generation, allocation concealment, and attrition bias; and low or high for selective outcome reporting. We were unable to combine any of the studies in a meta‐analysis due to important clinical heterogeneity and unit‐of‐analysis issues. </p> <p>Several of the trials assessed multiple agents. Medications assessed included methylphenidate, clonidine, desipramine, dextroamphetamine, guanfacine, atomoxetine, and deprenyl. There was low‐quality evidence for methylphenidate, atomoxetine, and clonidine, and very low‐quality evidence for desipramine, dextroamphetamine, guanfacine and deprenyl in the treatment of ADHD in children with tics. All studies, with the exception of a study using deprenyl, reported improvement in symptoms of ADHD. Tic symptoms also improved in children treated with guanfacine, desipramine, methylphenidate, clonidine, and a combination of methylphenidate and clonidine. In one study, tics limited further dosage increases of methylphenidate. High‐dose dextroamphetamine appeared to worsen tics in one study, although the length of this study was limited to three weeks. There was appetite suppression or weight loss in association with methylphenidate, dextroamphetamine, atomoxetine, and desipramine. There was insomnia associated with methylphenidate and dextroamphetamine, and sedation associated with clonidine. </p> </section> <section id="CD007990-sec-0007"> <h3 class="title" id="CD007990-sec-0007">Authors' conclusions</h3> <p>Following an updated search of potentially relevant studies, we found no new studies that matched our inclusion criteria and thus our conclusions have not changed. </p> <p>Methylphenidate, clonidine, guanfacine, desipramine, and atomoxetine appear to reduce ADHD symptoms in children with tics though the quality of the available evidence was low to very low. Although stimulants have not been shown to worsen tics in most people with tic disorders, they may, nonetheless, exacerbate tics in individual cases. In these instances, treatment with alpha agonists or atomoxetine may be an alternative. Although there is evidence that desipramine may improve tics and ADHD in children, safety concerns will likely continue to limit its use in this population.    </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD007990-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD007990-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD007990-abs-0005">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD007990-abs-0007">فارسی</a> </li> <li class="section-language"> <a class="" href="full/ms#CD007990-abs-0003">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD007990-abs-0009">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD007990-abs-0002" lang="en"> <h3>Medications for attention deficit hyperactivity disorder (ADHD) in children with tics</h3> <p><b>Review question</b> </p> <p>In children with ADHD and tics, how do medications for ADHD affect symptoms of both disorders? </p> <p><b>Background</b> </p> <p>As many as half of all children with tic disorders (a combination of repetitive motions vocalizations), also have ADHD (issues with hyperactivity, impulsivity and maintaining attention). Symptoms of ADHD are often more disabling for children than their tics. Historically, the reported ability of stimulant medications to worsen tics has limited their use in children who have both a chronic tic disorder (lasting over a year since the first tic onset) and ADHD. To evaluate evidence for this reported phenomenon, we searched for clinical trials of medications for ADHD used specifically in children with tic disorders. </p> <p><b>Search date</b> </p> <p>The evidence is current to September 2017.</p> <p><b>Study characteristics</b> </p> <p>We included eight studies with 510 participants (443 boys, 67 girls) in our review. Participants in these studies were children with both ADHD and a chronic tic disorder. The included studies evaluated several different medications for ADHD, including stimulants (methylphenidate, dextroamphetamine) and non‐stimulants (clonidine, guanfacine, desipramine, atomoxetine, and deprenyl). All studies took place in the USA and ranged from three to 22 weeks in duration. </p> <p><b>Study funding sources</b> </p> <p>Five of the eight studies were funded by charitable organizations or government agencies, or both. One study was funded by the drug manufacturer. The other two studies did not specify the source of funding for the study. </p> <p><b>Key results</b> </p> <p>The trials in this review suggested that several stimulant and non‐stimulant medications may improve ADHD symptoms in children with ADHD and tics. At high doses, dextroamphetamine may initially worsen tics in some children, and dose increases of both dextroamphetamine and methylphenidate may be limited due to tic exacerbation. However, for most children, both tics and ADHD symptoms can improve with use of stimulant medications. </p> <p><b>Quality of evidence</b> </p> <p>There is low‐quality evidence for methylphenidate, atomoxetine, and clonidine, and very low‐quality evidence for desipramine, dextroamphetamine, guanfacine, and deprenyl in the treatment of ADHD in children with tics. The evidence was limited by the small number of trials, small number of participants, and risk of bias of the included studies. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD007990-sec-0092" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD007990-sec-0092"></div> <h3 class="title" id="CD007990-sec-0093">Implications for practice</h3> <section id="CD007990-sec-0093"> <p>Drugs of the stimulant class have generally been thought to provide the most reliable and robust treatment responses for symptoms of ADHD in children with tics. Given the methodological difficulties inherent in comparing effect sizes across studies with divergent inclusion criteria, efficacy measures, and designs, this review can provide no evidence‐based recommendations for choosing between treatment options. Stimulants will likely continue to be considered as first‐line treatment for children with moderate‐to‐severe symptoms of ADHD in children with tic disorders. Although, overall, stimulants have not been shown to worsen tics in most participants with tic disorders, they may still exacerbate tics in individual cases. In these instances, treatment with alpha agonists or atomoxetine could be considered as alternatives. Although there is evidence that desipramine may improve both tics and ADHD in children, safety concerns will likely continue to limit its use. </p> </section> <h3 class="title" id="CD007990-sec-0094">Implications for research</h3> <section id="CD007990-sec-0094"> <p>This study highlights the need for adherence to minimal common standards of study design and efficacy measures of pharmacological treatments of tics and ADHD for different agents to enable subsequent comparison of results. A variety of newer agents appear to improve symptoms of ADHD and therefore are candidates for double‐blind, placebo‐controlled, head‐to‐head trials in children with tic disorders and ADHD. These agents include: lisdexamfetamine, a long‐acting stimulant prodrug (<a href="./references#CD007990-bbs2-0020" title="BiedermanJ , BoellnerSW , ChildressA , LopezFA , KrishnanS , ZhangY . Lisdexamfetamine dimesylate and mixed amphetamine salts extended‐release in children with ADHD: a double‐blind, placebo‐controlled, crossover analog classroom study. Biological Psychiatry2007;62(9):970‐6. [DOI: 10.1016/j.biopsych.2007.04.015; PUBMED: 17631866] ">Biederman 2007</a>); the newer antidepressant bupropion, a dual norepinephrine and dopamine reuptake inhibitor (<a href="./references#CD007990-bbs2-0027" title="ConnersCK , CasatCD , GualtieriCT , WellerE , ReaderM , ReissA , et al. Buproprion hydrochloride in attention deficit disorder with hyperactivity. Journal of the American Academy of Child and Adolescent Psychiatry1996;35(10):1314‐21. [DOI: 10.1097/00004583‐199610000‐00018; PUBMED: 8885585] ">Conners 1996</a>); the novel non‐stimulant, modafinil, an agent with both dopaminergic and postsynaptic alpha‐1 adrenergic effects (<a href="./references#CD007990-bbs2-0035" title="KahbaziM , GhoreishiA , RahiminejadF , MohammadiMR , KamalipourA , AkhondzadehS . A randomized double blind and placebo controlled trial of modafanil in children and adolescents with attention deficit and hyperactivity disorder. Psychiatry Research2009;168(3):234‐7. [DOI: 10.1016/j.psychres.2008.06.024; PUBMED: 19439364] ">Kahbazi 2009</a>); and nicotine, which enhances noradrenergic and dopaminergic transmission (<a href="./references#CD007990-bbs2-0044" title="PotterAS , NewhousePA . Effects of acute nicotine administration on behavioural inhibition in adolescents with attention‐deficit/hyperactivity disorder. Psychopharmacology2004;176(2):182‐94. [DOI: 10.1007/s00213‐004‐1874‐y; PUBMED: 15083253] ">Potter 2004</a>; <a href="./references#CD007990-bbs2-0050" title="ShytleRD , SilverAA , WilkinsonBJ , SanbergPR . A pilot controlled trial of transdermal nicotine in the treatment of attention deficit hyperactivity disorder. World Journal of Biological Psychiatry2002;3(3):150‐5. [PUBMED: 12478880] ">Shytle 2002</a>).   </p> <p>Larger, confirmatory studies with the existing agents used for treatment of ADHD would be desirable, including studies of guanfacine and clonidine, as well as studies of the established stimulants in the longer‐acting forms that are now more commonly used, and the long‐acting form of guanfacine. Longer‐term evaluation of dextroamphetamine would also be warranted given ongoing concerns over its ability to exacerbate tics in a small number of participants.  </p> <p>The agents used to treat isolated ADHD may improve ADHD symptoms in participants with comorbid tic disorders. This suggests that the pathophysiology of ADHD may be similar in both groups. Each of the agents reviewed in this study has a different mechanism of action or has preferential effects on different receptor subtypes. A more detailed analysis of the interaction between the specific mechanism of action of each agent and its symptomatic effects on ADHD and tics may provide further insights into the underlying pathophysiology of both conditions. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD007990-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD007990-sec-0022"></div> <div class="table" id="CD007990-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Methylphenidate compared with placebo for attention deficit hyperactivity disorder (ADHD) in children with comorbid tic disorders</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Methylphenidate compared with placebo for attention deficit hyperactivity disorder (ADHD) in children with comorbid tic disorders</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Patient or population:</b> children with ADHD and comorbid tic disorders </p> <p><b>Intervention:</b> methylphenidate </p> <p><b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Effect of treatment</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>ADHD symptom‐related behavior</b> </p> <p>Measured by standardized rating scales: Conners' Abbreviated Teacher Rating Scale, Conners' Abbreviated Parent Rating Scale, IOWA Conners' Teacher Rating Scale, Mothers' Objective Method for Subgrouping, Continuous Performance Task, Conners' Teacher Rating Scale, Conners' Continuous Performance Task </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007990-bbs2-0008" title="Tourette's Syndrome Study Group. Treatment of ADHD in children with tics: a randomized controlled trial. Neurology2002;58(4):527‐36. [PUBMED: 11865128] ">Tourette's Syndrome Study Group 2002</a> showed a significant treatment effect using the Conners' Abbreviated Teacher Rating Scale (3.3 points, 98.3% CI −0.2 to 6.8; P = 0.02). </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="3" valign="top"> <p>229 (3 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low<sup>a</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>–</p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007990-bbs2-0004" title="GadowKD , NolanEE , SprafkinJ , SverdJ . School observations of children with attention deficit hyperactivity disorder and comorbid tic disorder: effects of methylphenidate treatment. Journal of Developmental and Behavioural Pediatrics1995;16(3):167‐76. [PUBMED: 7560119] GadowKD , NolanEE , SverdJ . Methylphenidate in hyperactive boys with comorbid tic disorder: II. Short‐term behavioral effects in school settings. Journal of the American Academy of Child and Adolescent Psychiatry1992;31(3):462‐71. [DOI: 10.1097/00004583‐199205000‐00012; PUBMED: 1592778] GadowKD , NolanEE , SverdJ , SprafkinJ , ScheiderJ . Methylphenidate in children with oppositional defiant disorder and both comorbid chronic multiple tic disorder and ADHD. Journal of Child Neurology2008;23(9):981‐90. [DOI: 10.1177/0883073808315412; PUBMED: 18474932] GadowKD , NolanEE , SverdJ , SprafkinJ , SchwartzJ . Anxiety and depression symptoms and response to methylphenidate in children with attention deficit hyperactivity disorder and tic disorder. Journal of Clinical Psychopharmacology2002;22(3):267‐74. [PUBMED: 12006897] GadowKD , SverdJ , NolanEE , SprafkinJ , SchneiderJ . Immediate‐release methylphenidate for ADHD in children with comorbid chronic multiple tic disorder. Journal of the American Academy of Child and Adolescent Psychiatry2007;46(7):840‐8. [DOI: 10.1097/chi.0b013e31805c0860; PUBMED: 17581448] GadowKD , SverdJ , SprafkinJ , NolanEE , EzorSN . Efficacy of methylphenidate for attention deficit hyperactivity disorder in children with tic disorder. Archives of General Psychiatry1995;52(6):444‐55. [PUBMED: 7771914] GadowKD , SverdJ , SprafkinJ , NolanEE , GrossmanS . Long‐term methylphenidate therapy in children with comorbid attention deficit hyperactivity disorder and chronic multiple tic disorder. Archives of General Psychiatry1999;56(4):330‐6. [PUBMED: 10197827] NolanEE , GadowKD . Children with ADHD and tic disorder and their classmates: behavioural normalization with methylphenidate. Journal of the American Academy of Child and Adolescent Psychiatry1997;36(5):597‐604. [DOI: 10.1097/00004583‐199705000‐00009; PUBMED: 9136493] ">Gadow 2007</a> showed that all doses (0.1 mg/kg, 0.3 mg/kg, 0.5 mg/kg) of methylphenidate were superior to placebo on all rating scales (Conners' Abbreviated Teacher/Parent Rating Scale, IOWA Conners' Teacher Rating Scale, Mothers' Objective Method for Subgrouping, Continuous Performance Test), with a dose‐dependent effect (F = 24.7; P = 0.001) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007990-bbs2-0002" title="CastellanosFX , GieddJN , EliaJ , MarshWL , RitchieGF , HamburgerSD , et al. Controlled stimulant treatment of ADHD and comorbid Tourette's syndrome: effects of stimulant and dose. Journal of the American Academy of Child and Adolescent Psychiatry1997;36(5):589‐96. [DOI: 10.1097/00004583‐199705000‐00008; PUBMED: 9136492] ">Castellanos 1997</a> showed significantly decreased hyperactivity at all doses (15 mg, 25 mg, 45 mg). </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Tic severity</b> </p> <p>Measured by standardized rating scales: Yale Global Tic Severity Scale, Tourette Syndrome Severity Scale, Tourette Syndrome Clinical Global Impression Scale, Global Tic Rating Scale, 2‐Minute Tic and Habit Count, Tic Symptom Self‐Report </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007990-bbs2-0008" title="Tourette's Syndrome Study Group. Treatment of ADHD in children with tics: a randomized controlled trial. Neurology2002;58(4):527‐36. [PUBMED: 11865128] ">Tourette's Syndrome Study Group 2002</a> found a significant treatment effect using the Yale Global Tic Severity Scale (11.0 points, 98.3% CI 2.1 to 19.8; P = 0.003). </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="3" valign="top"> <p>229 (3 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low<sup>a</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>–</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007990-bbs2-0004" title="GadowKD , NolanEE , SprafkinJ , SverdJ . School observations of children with attention deficit hyperactivity disorder and comorbid tic disorder: effects of methylphenidate treatment. Journal of Developmental and Behavioural Pediatrics1995;16(3):167‐76. [PUBMED: 7560119] GadowKD , NolanEE , SverdJ . Methylphenidate in hyperactive boys with comorbid tic disorder: II. Short‐term behavioral effects in school settings. Journal of the American Academy of Child and Adolescent Psychiatry1992;31(3):462‐71. [DOI: 10.1097/00004583‐199205000‐00012; PUBMED: 1592778] GadowKD , NolanEE , SverdJ , SprafkinJ , ScheiderJ . Methylphenidate in children with oppositional defiant disorder and both comorbid chronic multiple tic disorder and ADHD. Journal of Child Neurology2008;23(9):981‐90. [DOI: 10.1177/0883073808315412; PUBMED: 18474932] GadowKD , NolanEE , SverdJ , SprafkinJ , SchwartzJ . Anxiety and depression symptoms and response to methylphenidate in children with attention deficit hyperactivity disorder and tic disorder. Journal of Clinical Psychopharmacology2002;22(3):267‐74. [PUBMED: 12006897] GadowKD , SverdJ , NolanEE , SprafkinJ , SchneiderJ . Immediate‐release methylphenidate for ADHD in children with comorbid chronic multiple tic disorder. Journal of the American Academy of Child and Adolescent Psychiatry2007;46(7):840‐8. [DOI: 10.1097/chi.0b013e31805c0860; PUBMED: 17581448] GadowKD , SverdJ , SprafkinJ , NolanEE , EzorSN . Efficacy of methylphenidate for attention deficit hyperactivity disorder in children with tic disorder. Archives of General Psychiatry1995;52(6):444‐55. [PUBMED: 7771914] GadowKD , SverdJ , SprafkinJ , NolanEE , GrossmanS . Long‐term methylphenidate therapy in children with comorbid attention deficit hyperactivity disorder and chronic multiple tic disorder. Archives of General Psychiatry1999;56(4):330‐6. [PUBMED: 10197827] NolanEE , GadowKD . Children with ADHD and tic disorder and their classmates: behavioural normalization with methylphenidate. Journal of the American Academy of Child and Adolescent Psychiatry1997;36(5):597‐604. [DOI: 10.1097/00004583‐199705000‐00009; PUBMED: 9136493] ">Gadow 2007</a> found no difference on the Yale Global Tic Severity Scale but found an improvement in tic severity at all doses (0.1 mg/kg, 0.3 mg/kg, 0.5 mg/kg) on the Global Tic Rating Scale completed by teachers (F = 5.33; P = 0.002) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007990-bbs2-0002" title="CastellanosFX , GieddJN , EliaJ , MarshWL , RitchieGF , HamburgerSD , et al. Controlled stimulant treatment of ADHD and comorbid Tourette's syndrome: effects of stimulant and dose. Journal of the American Academy of Child and Adolescent Psychiatry1997;36(5):589‐96. [DOI: 10.1097/00004583‐199705000‐00008; PUBMED: 9136492] ">Castellanos 1997</a> found no effect of drug on tic severity for second and third cohorts. Tic severity was significantly greater during week 2 in the first cohort (P &lt; 0.01) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><b>ADHD:</b> attention deficit hyperactivity disorder; <b>CI:</b> confidence interval. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> we are very confidence that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p><sup>a</sup>Downgraded two levels due to limitations in study design and implementation, and imprecision of results. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD007990-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Clonidine compared with placebo for attention deficit hyperactivity disorder (ADHD) in children with comorbid tic disorders</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Clonidine compared with placebo for attention deficit hyperactivity disorder (ADHD) in children with comorbid tic disorders</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Patient or population:</b> children with ADHD and comorbid tic disorders </p> <p><b>Intervention:</b> clonidine </p> <p><b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Effect of treatment</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>ADHD symptom‐related behavior</b> </p> <p>Measured by standardized rating scales: Conners' Abbreviated Teacher Rating Scale, Conners' Abbreviated Parent Rating Scale, IOWA Conners' Teacher Rating Scale, Conners' Continuous Performance Task, Child Behaviour Checklist, Gordon Diagnostic System, Clinical Evaluation of Language Function, Matching Familial Figures Test, Porteus Maze Test, Restricted Academic Test </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007990-bbs2-0008" title="Tourette's Syndrome Study Group. Treatment of ADHD in children with tics: a randomized controlled trial. Neurology2002;58(4):527‐36. [PUBMED: 11865128] ">Tourette's Syndrome Study Group 2002</a> found a significant treatment effect using the Conners' Abbreviated Teacher Rating Scale (3.3 points, 98.3% CI −0.2 to 6.8; P = 0.02). </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>170 (2 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low<sup>a</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>–</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007990-bbs2-0006" title="SingerHS , BrownJ , QuaskeyS , RosenbergLA , MellitsED , DencklaMB . The treatment of attention deficit hyperactivity disorder in Tourette's syndrome: a double blind placebo‐controlled study with clonidine and desipramine. Pediatrics1995;95(1):74‐81. [PUBMED: 7770313] ">Singer 1995</a> found no significant difference on any ADHD outcome measures, except the nervous/overactive subscale of the Child Behaviour Checklist (boys aged 6‐11 years). </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Tic severity</b> </p> <p>Measured by standardized rating scales: Yale Global Tic Severity Scale, Tourette Syndrome Severity Scale, Global Tic Rating Scale, Tic Symptom Self‐Report, Hopkins Motor/Vocal Scale </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007990-bbs2-0008" title="Tourette's Syndrome Study Group. Treatment of ADHD in children with tics: a randomized controlled trial. Neurology2002;58(4):527‐36. [PUBMED: 11865128] ">Tourette's Syndrome Study Group 2002</a> showed a significant treatment effect using the Yale Global Tic Severity Scale (10.9 points, 98.3% CI 2.1 to 19.7; P = 0.003). </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>170 (2 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low<sup>a</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>–</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007990-bbs2-0006" title="SingerHS , BrownJ , QuaskeyS , RosenbergLA , MellitsED , DencklaMB . The treatment of attention deficit hyperactivity disorder in Tourette's syndrome: a double blind placebo‐controlled study with clonidine and desipramine. Pediatrics1995;95(1):74‐81. [PUBMED: 7770313] ">Singer 1995</a> found no significant difference on measures of tic severity. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>ADHD:</b> attention deficit hyperactivity disorder; <b>CI:</b> confidence interval. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> we are very confidence that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p><sup>a</sup>Downgraded two levels due to limitations in study design and implementation, and imprecision of results. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD007990-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Desipramine compared with placebo for attention deficit hyperactivity disorder (ADHD) in children with comorbid tic disorders</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Desipramine compared with placebo for attention deficit hyperactivity disorder (ADHD) in children with comorbid tic disorders</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Patient or population:</b> children with ADHD and comorbid tic disorders </p> <p><b>Intervention:</b> desipramine </p> <p><b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Effect of treatment</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>ADHD symptom‐related behavior</b> </p> <p>Measured by standardized rating scales: Child Behaviour Checklist, Gordon Diagnostic System, Clinical Evaluation of Language Function, Matching Familial Figures Test, Porteus Maze Test, Restricted Academic Test, ADHD Rating Scale IV ‐ Parent Version; ADHD Parent Linear Analogue Scale </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007990-bbs2-0007" title="SpencerT , BiedermannJ , CoffeyB , GellerD , CrawfordM , BearmanSK , et al. A double‐blind comparison of desipramine and placebo in children and adolescents with chronic tic disorder and comorbid attention‐deficit/hyperactivity disorder. Archives of General Psychiatry2002;59(7):649‐56. [PUBMED: 12090818] ">Spencer 2002</a> showed a decrease in scores on the ADHD Rating Scale IV ‐ Parent Version (week 0 = 46 (SD 5.9) points; week 6 = 24 (SD 12) points; P &lt; 0.001). </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>75 (2 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low<sup>a</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>–</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007990-bbs2-0006" title="SingerHS , BrownJ , QuaskeyS , RosenbergLA , MellitsED , DencklaMB . The treatment of attention deficit hyperactivity disorder in Tourette's syndrome: a double blind placebo‐controlled study with clonidine and desipramine. Pediatrics1995;95(1):74‐81. [PUBMED: 7770313] ">Singer 1995</a> showed that desipramine was superior to placebo on the Parent Linear Analogue Scale for Hyperactivity (desipramine: 32.8 (SD 1.3) points; placebo: 64.4 (SD 0.6) points; P &lt; 0.05). Hyperactivity subscale of the Child Behavior Checklist showed drug effects for males aged 6 to 11 years (desipramine: 68.6 (SD 1.4) points; placebo: 75.8 (SD 1.0) points; P &lt; 0.05). </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Tic severity</b> </p> <p>Measured by standardized rating scales: Yale Global Tic Severity Scale, Tourette Syndrome Severity Scale, Hopkins Motor/Vocal Scale; ADHD Parent Linear Analogue Scale </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007990-bbs2-0007" title="SpencerT , BiedermannJ , CoffeyB , GellerD , CrawfordM , BearmanSK , et al. A double‐blind comparison of desipramine and placebo in children and adolescents with chronic tic disorder and comorbid attention‐deficit/hyperactivity disorder. Archives of General Psychiatry2002;59(7):649‐56. [PUBMED: 12090818] ">Spencer 2002</a> showed a decrease in scores on the Yale Global Tic Severity Scale (week 0 = 63 (SD 18) points; week 6: 43 (SD 23) points; P &lt; 0.001). </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>75 (2 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low<sup>a</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>–</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007990-bbs2-0006" title="SingerHS , BrownJ , QuaskeyS , RosenbergLA , MellitsED , DencklaMB . The treatment of attention deficit hyperactivity disorder in Tourette's syndrome: a double blind placebo‐controlled study with clonidine and desipramine. Pediatrics1995;95(1):74‐81. [PUBMED: 7770313] ">Singer 1995</a> showed that desipramine was superior to placebo on the Parent Linear Analogue Scale of tic severity (desipramine: 30.0 (SD 0.7) points; placebo: 47.4 SD 1.8 points; P &lt; 0.05). There were no differences on the other measures of tic severity (Tourette Syndrome Severity Scale, Hopkins Motor/vocal scale, Yale Global Tic Severity Scale). </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><b>ADHD:</b> attention deficit hyperactivity disorder; <b>SD:</b> standard deviation. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p>GRADE Working Group grades of evidence</p> <p><b>High quality:</b> we are very confidence that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p><sup>a</sup>Downgraded two levels due to limitations in study design and implementation, and imprecision of results. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD007990-sec-0023" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD007990-sec-0023"></div> <section id="CD007990-sec-0024"> <h3 class="title" id="CD007990-sec-0024">Description of the condition</h3> <p>The <i>Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition,</i> currently recognizes three chronic tic disorders: Tourette syndrome, chronic motor tic disorder, and chronic vocal tic disorder (<a href="./references#CD007990-bbs2-0019" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th Edition. Washington (DC): American Psychiatric Association, 2013. ">APA 2013</a>). Tourette syndrome consists of multiple motor tics and one or more vocal tics that have persisted for longer than one year. In both chronic motor tic disorder and chronic vocal disorder, tics must also persist for longer than one year but the spectrum of tics is limited to either motor or vocal subtypes, respectively. Together these disorders affect just over 2% of children (<a href="./references#CD007990-bbs2-0036" title="KnightT , SteevesT , DayL , LowerisonM , JetteN , PringsheimT . Prevalence of tic disorders: a systematic review and meta‐analysis. Pediatric Neurology2012;47(2):77‐90. ">Knight 2012</a>). They fall within a clinical spectrum, with a presumed shared underlying neurobiology. </p> <p>Chronic tic disorders are frequently complicated by the presence of comorbid psychiatric disorders, of which attention deficit hyperactivity disorder (ADHD) is one of the most prevalent (<a href="./references#CD007990-bbs2-0042" title="MartinoD , MinkJ . Tic disorders. Continuum2013;19(5):1287‐311. ">Martino 2013</a>). The clinical implications of a comorbid diagnosis of ADHD in children with tic disorders are significant. The risk for aggressive and delinquent behavior, and conduct difficulties in children with tic disorders is posed largely by the presence of ADHD (<a href="./references#CD007990-bbs2-0024" title="CavannaA , ServoS , MonacoF , RobertsonM . The behavioral spectrum of Gilles de la Tourette Syndrome. Journal of Neuropsychiatry and Clinical Neurosciences2009;21(1):13‐23. ">Cavanna 2009</a>), and the greatest independent predictor of psychosocial quality of life in children with tic disorders is ADHD symptom severity (<a href="./references#CD007990-bbs2-0045" title="PringsheimT , LangA , KurlanR , PearceM , SandorP . Health related quality of life in children with TS. Neurology2007;68(12 Suppl 1):A294. ">Pringsheim 2007</a>). In contrast, the presence of a tic disorder has limited impact on ADHD outcomes (<a href="./references#CD007990-bbs2-0051" title="SpencerTJ , BiedermanJ , FaraoneS , MickE , CoffeyB , GellerD , et al. Impact of tic disorders on ADHD outcome across the life cycle: findings from a large group of adults with and without ADHD. American Journal of Psychiatry2001;158(4):611‐7. [DOI: 10.1176/appi.ajp.158.4.611; PUBMED: 11282697] ">Spencer 2001</a>). </p> <p>Rates of association between tic disorders and ADHD are much higher than would be expected due to chance alone. <a href="./references#CD007990-bbs2-0037" title="KurlanR , ComoPG , MillerB , PalumboD , DeeleyC , AndresenEM , et al. The behavioural spectrum of tic disorders: a community‐based study. Neurology2002;59(3):414‐20. [PUBMED: 12177376] ">Kurlan 2002</a> used direct interviews in a community‐based study of school children to determine the prevalence of tic disorders and any comorbid psychopathology. They included 1596 children aged nine to 17 years from 10 New York state school districts over a four‐year period. In this study, 38% of children with tics had a comorbid diagnosis of ADHD. Clinic‐based studies yield even higher rates of comorbid ADHD. In a review of a multi‐site, international database of 3500 people with tic disorders, <a href="./references#CD007990-bbs2-0032" title="FreemanRD , FastDK , BurdL , KerbeshianJ , RobertsonMM , SandorP . An international perspective on Tourette syndrome: selected findings from 3,500 individuals in 22 countries. Developmental Medicine and Child Neurology2000;42(7):436‐47. [PUBMED: 10972415] ">Freeman 2000</a> reported that 60% of children with tic disorders also had ADHD, with a range of 33% to 91% among sites reporting more than 50 cases. </p> <p>The association between tic disorders and ADHD is a compelling one and a number of investigators have proposed that the disorders share a common pathophysiology, reflecting alterations in noradrenergic and dopaminergic transmission inadequately modulating corticostriatal circuits, and thus failing to inhibit intrusive thoughts, sensory input, and motor responses (<a href="./references#CD007990-bbs2-0052" title="SteevesTDL , FoxSH . Neurological basis of serotonin‐dopamine antagonists in the treatment of Gilles de la Tourette syndrome. In: DiGiovannG , DiMatteoV , EspositoE editor(s). Progress in Brain Research. Vol. 172, London (UK): Elsevier, 2008:495‐513. ">Steeves 2008</a>). Neurochemical models based on dopaminergic and noradrenergic dysfunction have likewise guided considerations for their treatment. </p> </section> <section id="CD007990-sec-0025"> <h3 class="title" id="CD007990-sec-0025">Description of the intervention</h3> <p>Medications most commonly used to treat ADHD symptoms include the stimulants methylphenidate and amphetamine, followed by non‐stimulants (such as atomoxetine), tricyclic antidepressants, and alpha agonists (<a href="./references#CD007990-bbs2-0054" title="WilensTE . Mechanism of action of agents used in attention‐deficit/hyperactivity disorder. Journal of Clinical Psychiatry2006;67(Suppl 8):32‐8. [PUBMED: 16961428] ">Wilens 2006</a>). Due to the impact of ADHD on the child with a tic disorder, treatment for ADHD symptoms is a greater priority than medical treatment for tics. For many decades, clinicians were reluctant to use stimulants to treat symptoms of ADHD in children with tics for fear of worsening the tics. In the 1970s and early 1980s, several case reports and small case series were published of children who experienced the onset or worsening of tics after the use of stimulants for the treatment of ADHD (<a href="./references#CD007990-bbs2-0033" title="GoldenGS . Gilles de la Tourette's syndrome following methylphenidate administration. Developmental Medicine and Child Neurology1974;16(1):76‐8. [PUBMED: 4521612] ">Golden 1974</a>; <a href="./references#CD007990-bbs2-0041" title="LoweTL , CohenDJ , DetlorM , KremenitzerMW , ShaywitzBA . Stimulant medications precipitate Tourette's syndrome. JAMA1982;247(12):1729‐31. [PUBMED: 6950128] ">Lowe 1982</a>). Despite new evidence that suggests that this relationship was temporal and not causal (<a href="./references#CD007990-bbs2-0008" title="Tourette's Syndrome Study Group. Treatment of ADHD in children with tics: a randomized controlled trial. Neurology2002;58(4):527‐36. [PUBMED: 11865128] ">Tourette's Syndrome Study Group 2002</a>), package inserts and advertising for US Food and Drug Administration‐approved stimulants for ADHD continue to include warnings against the use of these medications for children with comorbid tic disorders.  </p> </section> <section id="CD007990-sec-0026"> <h3 class="title" id="CD007990-sec-0026">How the intervention might work</h3> <p>There appears to be some commonality in the mechanisms of action of medications used for ADHD that may be related to either direct or indirect modulation of dopamine and norepinephrine neurotransmission. Stimulants block the reuptake of dopamine and norepinephrine into the presynaptic neuron (methylphenidate) or increase the release of these monoamines into the extraneuronal space (amphetamines) (<a href="./references#CD007990-bbs2-0048" title="SeidenLS , SabolKE , RicaurteGA . Amphetamine: effects on catecholamine systems and behavior. Annual Review of Pharmacology and Toxicology1993;33:639‐77. [DOI: 10.1146/annurev.pa.33.040193.003231; PUBMED: 8494354] ">Seiden 1993</a>). Atomoxetine specifically inhibits presynaptic reuptake of norepinephrine, resulting in increased norepinephrine levels in the synapse (<a href="./references#CD007990-bbs2-0023" title="BymasterFP , KatnerJS , NelsoDL , Hemrick‐LueckeSK , ThrelkeldPG , HeiligensteinJH , et al. Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology2002;27(5):699‐711. [DOI: 10.1016/S0893‐133X(02)00346‐9; PUBMED: 12431845] ">Bymaster 2002</a>). The efficacy of tricyclic antidepressants in the treatment of ADHD is likewise thought to be mediated by their action on catecholamine reuptake, particularly on norepinephrine. The alpha‐2 adrenergic agonists appear to alter basal adrenergic tone (<a href="./references#CD007990-bbs2-0022" title="BuccafuscoJJ . Neuropharmacologic and behavioural actions of clonidine: interactions with central neurotransmitters. International Review of Neurobiology1992;33:55‐107. [PUBMED: 1350577] ">Buccafusco 1992</a>). Clonidine stimulates alpha‐2A, ‐2B, and ‐2C receptors, while guanfacine is selective for alpha‐2A receptors. Alpha‐2A and ‐2C receptors are mainly found in the central nervous system, while the alpha‐2B receptors are in vascular smooth muscle. Alpha‐2 agonism inhibits norepinephrine release from the presynaptic neuron, resulting in a reduction of activity in noradrenergic pathways and an attenuation of the sympathetic stress response. </p> </section> <section id="CD007990-sec-0027"> <h3 class="title" id="CD007990-sec-0027">Why it is important to do this review</h3> <p>Given the high frequency of comorbidity of chronic tic disorders and ADHD, the effects of ADHD symptoms on psychosocial quality of life in people with tics, and the concern amongst clinicians about the potential of worsening tics with use of stimulant medications, an up‐to‐date systematic review of pharmacological treatments of ADHD in children with tics is needed. We synthesized the existing evidence for clinicians serving this patient population on the efficacy of these agents for treatment of symptoms of ADHD and their effect on tics. While physicians specializing in this area of practice may already be aware of this literature, children and families affected by ADHD and comorbid tic disorders frequently have concerns about the use of medications and potential worsening of the symptoms of either condition, and often seek advice on these points. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD007990-sec-0028" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD007990-sec-0028"></div> <p>To assess the effects of pharmacological treatments for ADHD in children with comorbid tic disorders on symptoms of ADHD and tics.  </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD007990-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD007990-sec-0029"></div> <section id="CD007990-sec-0030"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD007990-sec-0031"> <h4 class="title">Types of studies</h4> <p>Randomized, double‐blind, controlled trials of any pharmacological treatment for ADHD used specifically in children with comorbid tic disorders. The term double‐blind implies that trial participants, clinicians, and outcome assessors were blinded to treatment allocation. We included both parallel‐group and cross‐over study designs. </p> </section> <section id="CD007990-sec-0032"> <h4 class="title">Types of participants</h4> <p>Children aged 18 years or younger with a clinical diagnosis of ADHD and a chronic tic disorder (Tourette syndrome, chronic motor tic disorder, or chronic vocal tic disorder). With respect to diagnostic classification systems, acceptable ADHD diagnoses included: </p> <p> <ul id="CD007990-list-0001"> <li> <p>attention‐deficit/hyperactivity disorder (<a href="./references#CD007990-bbs2-0017" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 3rd Edition. Washington (DC): American Psychiatric Association, 1987. ">APA 1987</a>; <a href="./references#CD007990-bbs2-0018" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th Edition. Washington (DC): American Psychiatric Association, 2000. ">APA 2000</a>; <a href="./references#CD007990-bbs2-0019" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th Edition. Washington (DC): American Psychiatric Association, 2013. ">APA 2013</a>); </p> </li> <li> <p>attention deficit disorder (<a href="./references#CD007990-bbs2-0016" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 3rd Edition. Washington (DC): American Psychiatric Association, 1980. ">APA 1980</a>); and </p> </li> <li> <p>hyperkinetic disorder (<a href="./references#CD007990-bbs2-0053" title="World Health Organization. ICD‐10: International Statistical Classification of Diseases and Related Health Problems: 10th Revision. Geneva: World Health Organization, 2005. ">WHO 2005</a>). </p> </li> </ul> </p> </section> <section id="CD007990-sec-0033"> <h4 class="title">Types of interventions</h4> <p>Any pharmacological treatment for ADHD (stimulant and non‐stimulant), at any dose, taken orally alone or in combination with another drug, compared to placebo. </p> </section> <section id="CD007990-sec-0034"> <h4 class="title">Types of outcome measures</h4> <section id="CD007990-sec-0035"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD007990-list-0002"> <li> <p>ADHD and tic symptom severity measured by validated clinician, teacher, or parent report scales. Specifically, we evaluated: </p> <ul id="CD007990-list-0003"> <li> <p>ADHD symptom‐related behavior in the home setting assessed with, for example, Conners Abbreviated Symptom Questionnaire (ASQ) for Parents (<a href="./references#CD007990-bbs2-0026" title="ConnersCK . Conners' Abbreviated Symptom Questionnaire. Multi‐Health Systems1990. ">Conners 1990</a>), or ADHD Rating Scale (<a href="./references#CD007990-bbs2-0029" title="DuPaulG , PowerTJ , AnastopoulosAD , ReidR . ADHD Rating Scale‐5 for children and adolescents: checklists, norms and clinical interpretation. Guildford Publications, 2016. ">DuPaul 2016</a>); </p> </li> <li> <p>ADHD symptom‐related behavior in the school setting assessed with, for example, Conners ASQ for Teachers (<a href="./references#CD007990-bbs2-0026" title="ConnersCK . Conners' Abbreviated Symptom Questionnaire. Multi‐Health Systems1990. ">Conners 1990</a>); and </p> </li> <li> <p>tic severity assessed with, for example, Yale Global Tic Severity Scale (TGTSS) (<a href="./references#CD007990-bbs2-0038" title="LeckmanJF , RiddleMA , HardinMT , OrtSI , SwartzKL , StevensonJ , et al. The Yale Global Tic Severity Scale: initial testing of a clinician‐rated scale of tic severity. Journal of the American Academy of Child and Adolescent Psychiatry1989;28(4):566‐73. [DOI: 10.1097/00004583‐198907000‐00015; PUBMED: 2768151] ">Leckman 1989</a>), Tic Symptom Self‐Report Scale (<a href="./references#CD007990-bbs2-0039" title="LeckmanJF , CohenDJ . Tourette's Syndrome ‐ Tics, Obsessions, Compulsions: Developmental Psychopathology and Clinical Care. New York (NY): John Wiley &amp; Sons, 1998. ">Leckman 1998</a>), or the Tourette Syndrome Severity Scale (<a href="./references#CD007990-bbs2-0049" title="ShapiroAK , ShapiroES , YoungJG , FeinbergTE . Gilles de la Tourette Syndrome. New York (NY): Raven Press, 1988. ">Shapiro 1988</a>). </p> </li> </ul> </li> </ul> </p> </section> <section id="CD007990-sec-0036"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD007990-list-0004"> <li> <p> Adverse effects, including:</p> <ul id="CD007990-list-0005"> <li> <p>cardiovascular effects such as changes in heart rate, blood pressure, or the electrocardiogram; and </p> </li> <li> <p>weight changes.</p> </li> </ul> </li> </ul> </p> </section> </section> </section> <section id="CD007990-sec-0037"> <h3 class="title">Search methods for identification of studies</h3> <p>We ran searches for this update in June 2016 and again on 20 September 2017. Search strategies for each database are reported in <a href="./appendices#CD007990-sec-0097">Appendix 1</a>. Search strategies from the previous version of this review are in <a href="./appendices#CD007990-sec-0113">Appendix 2</a>. </p> <section id="CD007990-sec-0038"> <h4 class="title">Electronic searches</h4> <p>For this update, we searched the electronic databases and trial registers listed below. Some new databases have been added since the previous review and others were no longer available to us. These changes are reported in <a href="#CD007990-sec-0147">Differences between protocol and review</a>. </p> <p> <ul id="CD007990-list-0006"> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL; 2017, Issue 8), in the Cochrane Library, and which includes the Cochrane Developmental, Psychosocial and Learning Problem Specialised Register (searched 20 September 2017). </p> </li> <li> <p>MEDLINE Ovid (1946 to September week 1 2017).</p> </li> <li> <p>MEDLINE In‐Process and Other Non‐Indexed Citations Ovid (searched 20 September 2017).</p> </li> <li> <p>MEDLINE E‐pub Ahead of Print Ovid (searched 20 September 2017).</p> </li> <li> <p>Embase Ovid (1974 to 19 September 2017).</p> </li> <li> <p>CINAHL EBSCO (Cumulative Index to Nursing and Allied Health Literature; 1937 to 20 September 2017). </p> </li> <li> <p>PsycINFO Ovid (1806 to September week 2 2017).</p> </li> <li> <p>Science Citation Index ‐ Expanded Web of Science (SCI; 1970 to 19 September 2017).</p> </li> <li> <p>Social Sciences Citation Index Web of Science (SSCI; 1970 to 19 September 2017).</p> </li> <li> <p>Conference Proceedings Citation Index ‐ Science Web of Science (1990 to 19 September 2017). </p> </li> <li> <p>Conference Proceedings Citation Index ‐ Social Science and Humanities Web of Science (1990 to 19 September 2017). </p> </li> <li> <p><i>Cochrane Database of Systemic Reviews</i> (CDSR; 2017, Issue 9) part of the Cochrane Library (searched 20 September 2017). </p> </li> <li> <p>Database of Abstracts and Reviews of Effects (DARE; 2015, Issue 2. Final Issue) part of the Cochrane Library (searched 6 July 2016). </p> </li> <li> <p>Epistemonikos (<a href="http://www.epistemonikos.org/" target="_blank">www.epistemonikos.org</a>; searched 20 September 2017). </p> </li> <li> <p>WorldCat (<a href="http://www.worldcat.org/" target="_blank">www.worldcat.org</a>; searched 20 September 2017). </p> </li> <li> <p>ClinicalTrials.gov (<a href="https://clinicaltrials.gov/" target="_blank">clinicaltrials.gov</a>; searched 20 September 2017). </p> </li> <li> <p>World Health Organization International Clinical Trials Registry Platform (WHO ICTRP; <a href="http://www.who.int/ictrp/en/" target="_blank">www.who.int/ictrp/en</a>; searched 20 September 2017). </p> </li> </ul> </p> </section> <section id="CD007990-sec-0039"> <h4 class="title">Searching other resources</h4> <p>We contacted the Tourette Syndrome Study Group (based in North America) and other experts in the field, including investigators from all review articles and primary studies identified through searches for this review, to determine if there were any ongoing trials or unpublished results in this area. </p> </section> </section> <section id="CD007990-sec-0040"> <h3 class="title" id="CD007990-sec-0040">Data collection and analysis</h3> <section id="CD007990-sec-0041"> <h4 class="title">Selection of studies</h4> <p>Two review authors (TP and TS) independently assessed titles and abstracts of references retrieved from the searches and selected all potentially relevant studies. Next, they retrieved copies of these articles, which they read in detail and assessed for eligibility (<a href="#CD007990-sec-0030">Criteria for considering studies for this review</a>). We resolved any disputes regarding the fulfilment of inclusion criteria by discussion. Review authors were not blinded to the names of the trial authors, institutions, or journals of publication. </p> <p>We recorded our decisions in a study flow diagram (<a href="./references#CD007990-bbs2-0043" title="MoherD , LiberatiA , TetzlaffJ , AltmanDG , PRISMA Group. Preferred reporting items for systematic reviews and meta‐analyses: the PRISMA statement. PLoS Medicine2009;6(7):e1000097. [DOI: 10.1371/journal.pmed.1000097; PMC2707599; PUBMED: 19621072] ">Moher 2009</a>). </p> </section> <section id="CD007990-sec-0042"> <h4 class="title">Data extraction and management</h4> <p>Two review authors (TP and TS) independently extracted the following data from each included study and entered it into predesigned summary forms.  </p> <p> <ul id="CD007990-list-0007"> <li> <p>Study procedures, including recruitment, diagnosis, medication, dosage, duration, and clinical setting. </p> </li> <li> <p>Study design (i.e. randomized or quasi‐randomized).</p> </li> <li> <p>Randomization method.</p> </li> <li> <p>Method of allocation concealment.</p> </li> <li> <p>Method of blinding.</p> </li> <li> <p>Inclusion and exclusion criteria for participants.</p> </li> <li> <p>Number of participants (total/per group).</p> </li> <li> <p>Age distribution.</p> </li> <li> <p>Gender.</p> </li> <li> <p>Loss of follow‐up.</p> </li> <li> <p>Premature discontinuation of study, and reasons for discontinuation.</p> </li> <li> <p>Outcome.</p> </li> <li> <p>Method of analysis (intention‐to‐treat, per protocol).</p> </li> <li> <p>Comparability of groups at baseline.</p> </li> </ul> </p> <p>They then compared the extracted data to ensure accuracy. Next, one review author (TP) entered the data into Review Manager 5 (RevMan 5) (<a href="./references#CD007990-bbs2-0046" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">Review Manager 2014</a>), and a second review author (TS) checked them. We resolved discrepancies by consensus. As no further studies were included following the July 2016 search, this process was not repeated. </p> </section> <section id="CD007990-sec-0043"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (TP and TS) independently assessed the risk of bias in the included studies for each of the seven domains in <a href="./appendices#CD007990-sec-0120">Appendix 3</a>, and assigned ratings of low risk of bias, high risk of bias, and unclear risk of bias (<a href="./references#CD007990-bbs2-0034" title="HigginsJP , AltmanDG , SterneJA , editor(s) . Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Churchill R, Chandler J, Cumpston MS, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.2.0 (updated June 2017). Cochrane, 2017. Available from training.cochrane.org/handbook. ">Higgins 2017</a>). We resolved any discrepancies by consensus. </p> </section> <section id="CD007990-sec-0044"> <h4 class="title">Measures of treatment effect</h4> <p>Due to significant clinical heterogeneity (differences between studies in the interventions used and how they were administered, and differences in outcomes measured), and incomplete reporting of the results from cross‐over trials, we were unable to conduct a meta‐analysis of study data. We attempted to obtain additional information from authors, but, due to the length of time since many of the trials were performed, this information was either not available or our queries went unanswered. Thus, we have presented the results for studies individually. We recorded the methods that were not pertinent to this version of the review in <a href="./appendices#CD007990-sec-0128">Appendix 4</a>, for use in an update. See our protocol (<a href="./references#CD007990-bbs2-0055" title="PringsheimT , SteevesT . Pharmacological treatment for attention deficit hyperactivity disorder in children with co‐morbid tic disorders. Cochrane Database of Systematic Reviews2009, Issue 3. [DOI: 10.1002/14651858.CD007990] ">Pringsheim 2009</a>). </p> </section> <section id="CD007990-sec-0045"> <h4 class="title">Unit of analysis issues</h4> <p>Unit‐of‐analysis issues occurred in this review as none of the included cross‐over studies presented paired data for analysis but rather provided the means and standard deviations (SD) for each treatment type. See <a href="./appendices#CD007990-sec-0128">Appendix 4</a> and <a href="./references#CD007990-bbs2-0055" title="PringsheimT , SteevesT . Pharmacological treatment for attention deficit hyperactivity disorder in children with co‐morbid tic disorders. Cochrane Database of Systematic Reviews2009, Issue 3. [DOI: 10.1002/14651858.CD007990] ">Pringsheim 2009</a>. </p> </section> <section id="CD007990-sec-0046"> <h4 class="title">Dealing with missing data</h4> <p>We attempted to obtain missing information directly from study authors; however, this did not yield the missing information. We contacted Castellanos regarding additional results from his trial (<a href="./references#CD007990-bbs2-0002" title="CastellanosFX , GieddJN , EliaJ , MarshWL , RitchieGF , HamburgerSD , et al. Controlled stimulant treatment of ADHD and comorbid Tourette's syndrome: effects of stimulant and dose. Journal of the American Academy of Child and Adolescent Psychiatry1997;36(5):589‐96. [DOI: 10.1097/00004583‐199705000‐00008; PUBMED: 9136492] ">Castellanos 1997</a>), but, due to the long period which had elapsed since his study was performed, the information was no longer accessible. We also contacted the authors of <a href="./references#CD007990-bbs2-0008" title="Tourette's Syndrome Study Group. Treatment of ADHD in children with tics: a randomized controlled trial. Neurology2002;58(4):527‐36. [PUBMED: 11865128] ">Tourette's Syndrome Study Group 2002</a> and <a href="./references#CD007990-bbs2-0003" title="FeiginA , KurlanR , McDermottMP , BeachJ , DimitsopulosT , BrowerCA , et al. A controlled trial of deprenyl in children with Tourette's syndrome and attention deficit hyperactivity disorder. Neurology1996;46(4):965‐8. [PUBMED: 8780073] ">Feigin 1996</a> requesting more information on results but received no replies to our letters. See <a href="./appendices#CD007990-sec-0128">Appendix 4</a> and <a href="./references#CD007990-bbs2-0055" title="PringsheimT , SteevesT . Pharmacological treatment for attention deficit hyperactivity disorder in children with co‐morbid tic disorders. Cochrane Database of Systematic Reviews2009, Issue 3. [DOI: 10.1002/14651858.CD007990] ">Pringsheim 2009</a>. </p> </section> <section id="CD007990-sec-0047"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed clinical heterogeneity by comparing the distribution of important participant factors between trials and methodological heterogeneity by comparing trial designs. See also <a href="./appendices#CD007990-sec-0128">Appendix 4</a> and <a href="./references#CD007990-bbs2-0055" title="PringsheimT , SteevesT . Pharmacological treatment for attention deficit hyperactivity disorder in children with co‐morbid tic disorders. Cochrane Database of Systematic Reviews2009, Issue 3. [DOI: 10.1002/14651858.CD007990] ">Pringsheim 2009</a>. </p> </section> <section id="CD007990-sec-0048"> <h4 class="title">Assessment of reporting biases</h4> <p>As there was an insufficient number of studies found for each treatment type, we did not create funnel plots to assess publication bias. See <a href="./appendices#CD007990-sec-0128">Appendix 4</a> and <a href="./references#CD007990-bbs2-0055" title="PringsheimT , SteevesT . Pharmacological treatment for attention deficit hyperactivity disorder in children with co‐morbid tic disorders. Cochrane Database of Systematic Reviews2009, Issue 3. [DOI: 10.1002/14651858.CD007990] ">Pringsheim 2009</a>. </p> </section> <section id="CD007990-sec-0049"> <h4 class="title">Data synthesis</h4> <p>We did not synthesize results in a meta‐analysis by treatment type because of important clinical heterogeneity and unit‐of‐analysis issues (see the <a href="./full#CD007990-sec-0053">Results</a> section for descriptions of the nature of the heterogeneity encountered). Thus, we have presented the data for each study individually. See <a href="./appendices#CD007990-sec-0128">Appendix 4</a> and <a href="./references#CD007990-bbs2-0055" title="PringsheimT , SteevesT . Pharmacological treatment for attention deficit hyperactivity disorder in children with co‐morbid tic disorders. Cochrane Database of Systematic Reviews2009, Issue 3. [DOI: 10.1002/14651858.CD007990] ">Pringsheim 2009</a>. </p> <section id="CD007990-sec-0050"> <h5 class="title">'Summary of findings' table</h5> <p>We created 'Summary of findings' tables using <a href="./references#CD007990-bbs2-0046" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">Review Manager 2014</a>, which report the effect estimate for our primary outcomes (ADHD and tic symptom severity) measured at study endpoint, the number of participants, and our ratings for the quality of the evidence. Two review authors (TP and SO) used the GRADE method to assess the quality of the body of evidence for each outcome. While randomized trials are considered high‐quality evidence, we downgraded the level of evidence to moderate or low for all outcomes due to the presence of limitations in the design of available studies, and the overall small number of studies and participants included in studies in this area. This means it is likely that further research could have an important impact on our confidence in the estimate of the effect and may change the estimate. </p> </section> </section> <section id="CD007990-sec-0051"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We did not perform a subgroup analysis. See <a href="./appendices#CD007990-sec-0128">Appendix 4</a> and <a href="./references#CD007990-bbs2-0055" title="PringsheimT , SteevesT . Pharmacological treatment for attention deficit hyperactivity disorder in children with co‐morbid tic disorders. Cochrane Database of Systematic Reviews2009, Issue 3. [DOI: 10.1002/14651858.CD007990] ">Pringsheim 2009</a>. </p> </section> <section id="CD007990-sec-0052"> <h4 class="title">Sensitivity analysis</h4> <p>We did not perform a sensitivity analysis due to the small number of trials and the inability to conduct a meta‐analysis. See <a href="./appendices#CD007990-sec-0128">Appendix 4</a> and <a href="./references#CD007990-bbs2-0055" title="PringsheimT , SteevesT . Pharmacological treatment for attention deficit hyperactivity disorder in children with co‐morbid tic disorders. Cochrane Database of Systematic Reviews2009, Issue 3. [DOI: 10.1002/14651858.CD007990] ">Pringsheim 2009</a>. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD007990-sec-0053" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD007990-sec-0053"></div> <section id="CD007990-sec-0054"> <h3 class="title">Description of studies</h3> <section id="CD007990-sec-0055"> <h4 class="title">Results of the search</h4> <p>In the original review, we found 599 citations, of which 21 qualified for further review. Of these, eight met our inclusion criteria (<a href="#CD007990-sec-0030">Criteria for considering studies for this review</a>). Of the remaining 13, eight were republications of data already presented in the eight studies included in the review and were listed as secondary publications. The remaining five studies were excluded with reasons (see <a href="#CD007990-sec-0062">Excluded studies</a>). </p> <p>For this update, our search yielded 508 records, once duplicates were removed. We excluded 507 records at title and abstract stage, and retrieved one full‐text report for further inspection. This was subsequently excluded due to lack of double‐blinding (see <a href="#CD007990-sec-0062">Excluded studies</a>). </p> <p>The study review process is summarized in a PRISMA flow diagram (<a href="#CD007990-fig-0001">Figure 1</a>). </p> <div class="figure" id="CD007990-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram illustrating the process for inclusion of studies." data-id="CD007990-fig-0001" src="/cdsr/doi/10.1002/14651858.CD007990.pub3/media/CDSR/CD007990/image_n/nCD007990-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram illustrating the process for inclusion of studies.</p> </div> </div> </div> </section> <section id="CD007990-sec-0056"> <h4 class="title">Included studies</h4> <p>See <a href="./references#CD007990-sec-0149" title="">Characteristics of included studies</a> tables. </p> <section id="CD007990-sec-0057"> <h5 class="title">Study designs</h5> <p>We included eight randomized controlled trials (RCTs) of pharmacological treatments for ADHD in children with comorbid tic disorders (<a href="./references#CD007990-bbs2-0001" title="AllenAJ , KurlanRM , GilbertDL , CoffeyBJ , LinderSL , LewisDW , et al. Atomoxetine treatment in children and adolescents with ADHD and comorbid tic disorders. Neurology2005;65(12):1941‐9. [DOI: 10.1212/01.wnl.0000188869.58300.a7; PUBMED: 16380617] SpencerTJ , SalleFR , GilbertDL , DunnDW , McCrackenJT , CoffeyBJ , et al. Atomoxetine treatment of ADHD in children with comorbid Tourette syndrome. Journal of Attention Disorders2008;11(4):470‐81. [DOI: 10.1177/1087054707306109; PUBMED: 17934184] ">Allen 2005</a>; <a href="./references#CD007990-bbs2-0002" title="CastellanosFX , GieddJN , EliaJ , MarshWL , RitchieGF , HamburgerSD , et al. Controlled stimulant treatment of ADHD and comorbid Tourette's syndrome: effects of stimulant and dose. Journal of the American Academy of Child and Adolescent Psychiatry1997;36(5):589‐96. [DOI: 10.1097/00004583‐199705000‐00008; PUBMED: 9136492] ">Castellanos 1997</a>; <a href="./references#CD007990-bbs2-0003" title="FeiginA , KurlanR , McDermottMP , BeachJ , DimitsopulosT , BrowerCA , et al. A controlled trial of deprenyl in children with Tourette's syndrome and attention deficit hyperactivity disorder. Neurology1996;46(4):965‐8. [PUBMED: 8780073] ">Feigin 1996</a>; <a href="./references#CD007990-bbs2-0004" title="GadowKD , NolanEE , SprafkinJ , SverdJ . School observations of children with attention deficit hyperactivity disorder and comorbid tic disorder: effects of methylphenidate treatment. Journal of Developmental and Behavioural Pediatrics1995;16(3):167‐76. [PUBMED: 7560119] GadowKD , NolanEE , SverdJ . Methylphenidate in hyperactive boys with comorbid tic disorder: II. Short‐term behavioral effects in school settings. Journal of the American Academy of Child and Adolescent Psychiatry1992;31(3):462‐71. [DOI: 10.1097/00004583‐199205000‐00012; PUBMED: 1592778] GadowKD , NolanEE , SverdJ , SprafkinJ , ScheiderJ . Methylphenidate in children with oppositional defiant disorder and both comorbid chronic multiple tic disorder and ADHD. Journal of Child Neurology2008;23(9):981‐90. [DOI: 10.1177/0883073808315412; PUBMED: 18474932] GadowKD , NolanEE , SverdJ , SprafkinJ , SchwartzJ . Anxiety and depression symptoms and response to methylphenidate in children with attention deficit hyperactivity disorder and tic disorder. Journal of Clinical Psychopharmacology2002;22(3):267‐74. [PUBMED: 12006897] GadowKD , SverdJ , NolanEE , SprafkinJ , SchneiderJ . Immediate‐release methylphenidate for ADHD in children with comorbid chronic multiple tic disorder. Journal of the American Academy of Child and Adolescent Psychiatry2007;46(7):840‐8. [DOI: 10.1097/chi.0b013e31805c0860; PUBMED: 17581448] GadowKD , SverdJ , SprafkinJ , NolanEE , EzorSN . Efficacy of methylphenidate for attention deficit hyperactivity disorder in children with tic disorder. Archives of General Psychiatry1995;52(6):444‐55. [PUBMED: 7771914] GadowKD , SverdJ , SprafkinJ , NolanEE , GrossmanS . Long‐term methylphenidate therapy in children with comorbid attention deficit hyperactivity disorder and chronic multiple tic disorder. Archives of General Psychiatry1999;56(4):330‐6. [PUBMED: 10197827] NolanEE , GadowKD . Children with ADHD and tic disorder and their classmates: behavioural normalization with methylphenidate. Journal of the American Academy of Child and Adolescent Psychiatry1997;36(5):597‐604. [DOI: 10.1097/00004583‐199705000‐00009; PUBMED: 9136493] ">Gadow 2007</a>; <a href="./references#CD007990-bbs2-0005" title="ScahillL , ChappellPB , KimYS , SchultzRT , KatsovichL , ShepherdE , et al. A placebo‐controlled study of guanfacine in the treatment of children with tic disorders and attention deficit hyperactivity disorder. American Journal of Psychiatry2001;158(7):1067‐74. [DOI: 10.1176/appi.ajp.158.7.1067; PUBMED: 11431228] ">Scahill 2001</a>; <a href="./references#CD007990-bbs2-0006" title="SingerHS , BrownJ , QuaskeyS , RosenbergLA , MellitsED , DencklaMB . The treatment of attention deficit hyperactivity disorder in Tourette's syndrome: a double blind placebo‐controlled study with clonidine and desipramine. Pediatrics1995;95(1):74‐81. [PUBMED: 7770313] ">Singer 1995</a>; <a href="./references#CD007990-bbs2-0007" title="SpencerT , BiedermannJ , CoffeyB , GellerD , CrawfordM , BearmanSK , et al. A double‐blind comparison of desipramine and placebo in children and adolescents with chronic tic disorder and comorbid attention‐deficit/hyperactivity disorder. Archives of General Psychiatry2002;59(7):649‐56. [PUBMED: 12090818] ">Spencer 2002</a>; <a href="./references#CD007990-bbs2-0008" title="Tourette's Syndrome Study Group. Treatment of ADHD in children with tics: a randomized controlled trial. Neurology2002;58(4):527‐36. [PUBMED: 11865128] ">Tourette's Syndrome Study Group 2002</a>), four of which were cross‐over trials (<a href="./references#CD007990-bbs2-0002" title="CastellanosFX , GieddJN , EliaJ , MarshWL , RitchieGF , HamburgerSD , et al. Controlled stimulant treatment of ADHD and comorbid Tourette's syndrome: effects of stimulant and dose. Journal of the American Academy of Child and Adolescent Psychiatry1997;36(5):589‐96. [DOI: 10.1097/00004583‐199705000‐00008; PUBMED: 9136492] ">Castellanos 1997</a>; <a href="./references#CD007990-bbs2-0003" title="FeiginA , KurlanR , McDermottMP , BeachJ , DimitsopulosT , BrowerCA , et al. A controlled trial of deprenyl in children with Tourette's syndrome and attention deficit hyperactivity disorder. Neurology1996;46(4):965‐8. [PUBMED: 8780073] ">Feigin 1996</a>; <a href="./references#CD007990-bbs2-0004" title="GadowKD , NolanEE , SprafkinJ , SverdJ . School observations of children with attention deficit hyperactivity disorder and comorbid tic disorder: effects of methylphenidate treatment. Journal of Developmental and Behavioural Pediatrics1995;16(3):167‐76. [PUBMED: 7560119] GadowKD , NolanEE , SverdJ . Methylphenidate in hyperactive boys with comorbid tic disorder: II. Short‐term behavioral effects in school settings. Journal of the American Academy of Child and Adolescent Psychiatry1992;31(3):462‐71. [DOI: 10.1097/00004583‐199205000‐00012; PUBMED: 1592778] GadowKD , NolanEE , SverdJ , SprafkinJ , ScheiderJ . Methylphenidate in children with oppositional defiant disorder and both comorbid chronic multiple tic disorder and ADHD. Journal of Child Neurology2008;23(9):981‐90. [DOI: 10.1177/0883073808315412; PUBMED: 18474932] GadowKD , NolanEE , SverdJ , SprafkinJ , SchwartzJ . Anxiety and depression symptoms and response to methylphenidate in children with attention deficit hyperactivity disorder and tic disorder. Journal of Clinical Psychopharmacology2002;22(3):267‐74. [PUBMED: 12006897] GadowKD , SverdJ , NolanEE , SprafkinJ , SchneiderJ . Immediate‐release methylphenidate for ADHD in children with comorbid chronic multiple tic disorder. Journal of the American Academy of Child and Adolescent Psychiatry2007;46(7):840‐8. [DOI: 10.1097/chi.0b013e31805c0860; PUBMED: 17581448] GadowKD , SverdJ , SprafkinJ , NolanEE , EzorSN . Efficacy of methylphenidate for attention deficit hyperactivity disorder in children with tic disorder. Archives of General Psychiatry1995;52(6):444‐55. [PUBMED: 7771914] GadowKD , SverdJ , SprafkinJ , NolanEE , GrossmanS . Long‐term methylphenidate therapy in children with comorbid attention deficit hyperactivity disorder and chronic multiple tic disorder. Archives of General Psychiatry1999;56(4):330‐6. [PUBMED: 10197827] NolanEE , GadowKD . Children with ADHD and tic disorder and their classmates: behavioural normalization with methylphenidate. Journal of the American Academy of Child and Adolescent Psychiatry1997;36(5):597‐604. [DOI: 10.1097/00004583‐199705000‐00009; PUBMED: 9136493] ">Gadow 2007</a>; <a href="./references#CD007990-bbs2-0006" title="SingerHS , BrownJ , QuaskeyS , RosenbergLA , MellitsED , DencklaMB . The treatment of attention deficit hyperactivity disorder in Tourette's syndrome: a double blind placebo‐controlled study with clonidine and desipramine. Pediatrics1995;95(1):74‐81. [PUBMED: 7770313] ">Singer 1995</a>). </p> </section> <section id="CD007990-sec-0058"> <h5 class="title">Location</h5> <p>All studies took place in the USA (<a href="./references#CD007990-bbs2-0001" title="AllenAJ , KurlanRM , GilbertDL , CoffeyBJ , LinderSL , LewisDW , et al. Atomoxetine treatment in children and adolescents with ADHD and comorbid tic disorders. Neurology2005;65(12):1941‐9. [DOI: 10.1212/01.wnl.0000188869.58300.a7; PUBMED: 16380617] SpencerTJ , SalleFR , GilbertDL , DunnDW , McCrackenJT , CoffeyBJ , et al. Atomoxetine treatment of ADHD in children with comorbid Tourette syndrome. Journal of Attention Disorders2008;11(4):470‐81. [DOI: 10.1177/1087054707306109; PUBMED: 17934184] ">Allen 2005</a>; <a href="./references#CD007990-bbs2-0002" title="CastellanosFX , GieddJN , EliaJ , MarshWL , RitchieGF , HamburgerSD , et al. Controlled stimulant treatment of ADHD and comorbid Tourette's syndrome: effects of stimulant and dose. Journal of the American Academy of Child and Adolescent Psychiatry1997;36(5):589‐96. [DOI: 10.1097/00004583‐199705000‐00008; PUBMED: 9136492] ">Castellanos 1997</a>; <a href="./references#CD007990-bbs2-0003" title="FeiginA , KurlanR , McDermottMP , BeachJ , DimitsopulosT , BrowerCA , et al. A controlled trial of deprenyl in children with Tourette's syndrome and attention deficit hyperactivity disorder. Neurology1996;46(4):965‐8. [PUBMED: 8780073] ">Feigin 1996</a>; <a href="./references#CD007990-bbs2-0004" title="GadowKD , NolanEE , SprafkinJ , SverdJ . School observations of children with attention deficit hyperactivity disorder and comorbid tic disorder: effects of methylphenidate treatment. Journal of Developmental and Behavioural Pediatrics1995;16(3):167‐76. [PUBMED: 7560119] GadowKD , NolanEE , SverdJ . Methylphenidate in hyperactive boys with comorbid tic disorder: II. Short‐term behavioral effects in school settings. Journal of the American Academy of Child and Adolescent Psychiatry1992;31(3):462‐71. [DOI: 10.1097/00004583‐199205000‐00012; PUBMED: 1592778] GadowKD , NolanEE , SverdJ , SprafkinJ , ScheiderJ . Methylphenidate in children with oppositional defiant disorder and both comorbid chronic multiple tic disorder and ADHD. Journal of Child Neurology2008;23(9):981‐90. [DOI: 10.1177/0883073808315412; PUBMED: 18474932] GadowKD , NolanEE , SverdJ , SprafkinJ , SchwartzJ . Anxiety and depression symptoms and response to methylphenidate in children with attention deficit hyperactivity disorder and tic disorder. Journal of Clinical Psychopharmacology2002;22(3):267‐74. [PUBMED: 12006897] GadowKD , SverdJ , NolanEE , SprafkinJ , SchneiderJ . Immediate‐release methylphenidate for ADHD in children with comorbid chronic multiple tic disorder. Journal of the American Academy of Child and Adolescent Psychiatry2007;46(7):840‐8. [DOI: 10.1097/chi.0b013e31805c0860; PUBMED: 17581448] GadowKD , SverdJ , SprafkinJ , NolanEE , EzorSN . Efficacy of methylphenidate for attention deficit hyperactivity disorder in children with tic disorder. Archives of General Psychiatry1995;52(6):444‐55. [PUBMED: 7771914] GadowKD , SverdJ , SprafkinJ , NolanEE , GrossmanS . Long‐term methylphenidate therapy in children with comorbid attention deficit hyperactivity disorder and chronic multiple tic disorder. Archives of General Psychiatry1999;56(4):330‐6. [PUBMED: 10197827] NolanEE , GadowKD . Children with ADHD and tic disorder and their classmates: behavioural normalization with methylphenidate. Journal of the American Academy of Child and Adolescent Psychiatry1997;36(5):597‐604. [DOI: 10.1097/00004583‐199705000‐00009; PUBMED: 9136493] ">Gadow 2007</a>; <a href="./references#CD007990-bbs2-0005" title="ScahillL , ChappellPB , KimYS , SchultzRT , KatsovichL , ShepherdE , et al. A placebo‐controlled study of guanfacine in the treatment of children with tic disorders and attention deficit hyperactivity disorder. American Journal of Psychiatry2001;158(7):1067‐74. [DOI: 10.1176/appi.ajp.158.7.1067; PUBMED: 11431228] ">Scahill 2001</a>; <a href="./references#CD007990-bbs2-0006" title="SingerHS , BrownJ , QuaskeyS , RosenbergLA , MellitsED , DencklaMB . The treatment of attention deficit hyperactivity disorder in Tourette's syndrome: a double blind placebo‐controlled study with clonidine and desipramine. Pediatrics1995;95(1):74‐81. [PUBMED: 7770313] ">Singer 1995</a>; <a href="./references#CD007990-bbs2-0007" title="SpencerT , BiedermannJ , CoffeyB , GellerD , CrawfordM , BearmanSK , et al. A double‐blind comparison of desipramine and placebo in children and adolescents with chronic tic disorder and comorbid attention‐deficit/hyperactivity disorder. Archives of General Psychiatry2002;59(7):649‐56. [PUBMED: 12090818] ">Spencer 2002</a>; <a href="./references#CD007990-bbs2-0008" title="Tourette's Syndrome Study Group. Treatment of ADHD in children with tics: a randomized controlled trial. Neurology2002;58(4):527‐36. [PUBMED: 11865128] ">Tourette's Syndrome Study Group 2002</a>). </p> </section> <section id="CD007990-sec-0059"> <h5 class="title">Participants</h5> <p>The studies included 510 children (443 boys, 67 girls) with diagnoses of ADHD and Tourette syndrome or chronic motor or vocal tic disorder. Sample sizes ranged from 22 in <a href="./references#CD007990-bbs2-0002" title="CastellanosFX , GieddJN , EliaJ , MarshWL , RitchieGF , HamburgerSD , et al. Controlled stimulant treatment of ADHD and comorbid Tourette's syndrome: effects of stimulant and dose. Journal of the American Academy of Child and Adolescent Psychiatry1997;36(5):589‐96. [DOI: 10.1097/00004583‐199705000‐00008; PUBMED: 9136492] ">Castellanos 1997</a> to 148 in <a href="./references#CD007990-bbs2-0001" title="AllenAJ , KurlanRM , GilbertDL , CoffeyBJ , LinderSL , LewisDW , et al. Atomoxetine treatment in children and adolescents with ADHD and comorbid tic disorders. Neurology2005;65(12):1941‐9. [DOI: 10.1212/01.wnl.0000188869.58300.a7; PUBMED: 16380617] SpencerTJ , SalleFR , GilbertDL , DunnDW , McCrackenJT , CoffeyBJ , et al. Atomoxetine treatment of ADHD in children with comorbid Tourette syndrome. Journal of Attention Disorders2008;11(4):470‐81. [DOI: 10.1177/1087054707306109; PUBMED: 17934184] ">Allen 2005</a>. </p> </section> <section id="CD007990-sec-0060"> <h5 class="title">Interventions</h5> <p>Three trials assessed multiple agents (<a href="./references#CD007990-bbs2-0002" title="CastellanosFX , GieddJN , EliaJ , MarshWL , RitchieGF , HamburgerSD , et al. Controlled stimulant treatment of ADHD and comorbid Tourette's syndrome: effects of stimulant and dose. Journal of the American Academy of Child and Adolescent Psychiatry1997;36(5):589‐96. [DOI: 10.1097/00004583‐199705000‐00008; PUBMED: 9136492] ">Castellanos 1997</a>; <a href="./references#CD007990-bbs2-0006" title="SingerHS , BrownJ , QuaskeyS , RosenbergLA , MellitsED , DencklaMB . The treatment of attention deficit hyperactivity disorder in Tourette's syndrome: a double blind placebo‐controlled study with clonidine and desipramine. Pediatrics1995;95(1):74‐81. [PUBMED: 7770313] ">Singer 1995</a>; <a href="./references#CD007990-bbs2-0008" title="Tourette's Syndrome Study Group. Treatment of ADHD in children with tics: a randomized controlled trial. Neurology2002;58(4):527‐36. [PUBMED: 11865128] ">Tourette's Syndrome Study Group 2002</a>), and ranged in duration from three (<a href="./references#CD007990-bbs2-0002" title="CastellanosFX , GieddJN , EliaJ , MarshWL , RitchieGF , HamburgerSD , et al. Controlled stimulant treatment of ADHD and comorbid Tourette's syndrome: effects of stimulant and dose. Journal of the American Academy of Child and Adolescent Psychiatry1997;36(5):589‐96. [DOI: 10.1097/00004583‐199705000‐00008; PUBMED: 9136492] ">Castellanos 1997</a>) to 22 weeks (<a href="./references#CD007990-bbs2-0006" title="SingerHS , BrownJ , QuaskeyS , RosenbergLA , MellitsED , DencklaMB . The treatment of attention deficit hyperactivity disorder in Tourette's syndrome: a double blind placebo‐controlled study with clonidine and desipramine. Pediatrics1995;95(1):74‐81. [PUBMED: 7770313] ">Singer 1995</a>). </p> <p> <ul id="CD007990-list-0008"> <li> <p><a href="./references#CD007990-bbs2-0002" title="CastellanosFX , GieddJN , EliaJ , MarshWL , RitchieGF , HamburgerSD , et al. Controlled stimulant treatment of ADHD and comorbid Tourette's syndrome: effects of stimulant and dose. Journal of the American Academy of Child and Adolescent Psychiatry1997;36(5):589‐96. [DOI: 10.1097/00004583‐199705000‐00008; PUBMED: 9136492] ">Castellanos 1997</a> was a complex placebo‐controlled, cross‐over study, which randomized 22 children into three cohorts, each sequentially receiving for three weeks either placebo or one of three different dosage titrations of methylphenidate (low: 15 mg, medium: 25 mg, high: 45 mg), and one of three different dosage titrations of dextroamphetamine (low: 7.5 mg, medium: 15 mg, high: 22.5 mg). </p> </li> <li> <p><a href="./references#CD007990-bbs2-0006" title="SingerHS , BrownJ , QuaskeyS , RosenbergLA , MellitsED , DencklaMB . The treatment of attention deficit hyperactivity disorder in Tourette's syndrome: a double blind placebo‐controlled study with clonidine and desipramine. Pediatrics1995;95(1):74‐81. [PUBMED: 7770313] ">Singer 1995</a> was a placebo‐controlled, three‐phase cross‐over study in 34 children, of clonidine, desipramine, and placebo. Each treatment was taken four times daily for six weeks, separated by a one‐week washout period. </p> </li> <li> <p><a href="./references#CD007990-bbs2-0008" title="Tourette's Syndrome Study Group. Treatment of ADHD in children with tics: a randomized controlled trial. Neurology2002;58(4):527‐36. [PUBMED: 11865128] ">Tourette's Syndrome Study Group 2002</a> was a parallel‐group trial, which randomized 136 children to a flexible dose of methylphenidate (37 children), clonidine (34 children), clonidine plus methylphenidate (33 children), or placebo (32 children) for 16 weeks each (see <a href="#CD007990-tbl-0004">Table 1</a>). </p> </li> </ul> </p> <div class="table" id="CD007990-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Comparisons</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Comparisons</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Trial(s)</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Methylphenidate versus placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007990-bbs2-0002" title="CastellanosFX , GieddJN , EliaJ , MarshWL , RitchieGF , HamburgerSD , et al. Controlled stimulant treatment of ADHD and comorbid Tourette's syndrome: effects of stimulant and dose. Journal of the American Academy of Child and Adolescent Psychiatry1997;36(5):589‐96. [DOI: 10.1097/00004583‐199705000‐00008; PUBMED: 9136492] ">Castellanos 1997</a> </p> <p><a href="./references#CD007990-bbs2-0004" title="GadowKD , NolanEE , SprafkinJ , SverdJ . School observations of children with attention deficit hyperactivity disorder and comorbid tic disorder: effects of methylphenidate treatment. Journal of Developmental and Behavioural Pediatrics1995;16(3):167‐76. [PUBMED: 7560119] GadowKD , NolanEE , SverdJ . Methylphenidate in hyperactive boys with comorbid tic disorder: II. Short‐term behavioral effects in school settings. Journal of the American Academy of Child and Adolescent Psychiatry1992;31(3):462‐71. [DOI: 10.1097/00004583‐199205000‐00012; PUBMED: 1592778] GadowKD , NolanEE , SverdJ , SprafkinJ , ScheiderJ . Methylphenidate in children with oppositional defiant disorder and both comorbid chronic multiple tic disorder and ADHD. Journal of Child Neurology2008;23(9):981‐90. [DOI: 10.1177/0883073808315412; PUBMED: 18474932] GadowKD , NolanEE , SverdJ , SprafkinJ , SchwartzJ . Anxiety and depression symptoms and response to methylphenidate in children with attention deficit hyperactivity disorder and tic disorder. Journal of Clinical Psychopharmacology2002;22(3):267‐74. [PUBMED: 12006897] GadowKD , SverdJ , NolanEE , SprafkinJ , SchneiderJ . Immediate‐release methylphenidate for ADHD in children with comorbid chronic multiple tic disorder. Journal of the American Academy of Child and Adolescent Psychiatry2007;46(7):840‐8. [DOI: 10.1097/chi.0b013e31805c0860; PUBMED: 17581448] GadowKD , SverdJ , SprafkinJ , NolanEE , EzorSN . Efficacy of methylphenidate for attention deficit hyperactivity disorder in children with tic disorder. Archives of General Psychiatry1995;52(6):444‐55. [PUBMED: 7771914] GadowKD , SverdJ , SprafkinJ , NolanEE , GrossmanS . Long‐term methylphenidate therapy in children with comorbid attention deficit hyperactivity disorder and chronic multiple tic disorder. Archives of General Psychiatry1999;56(4):330‐6. [PUBMED: 10197827] NolanEE , GadowKD . Children with ADHD and tic disorder and their classmates: behavioural normalization with methylphenidate. Journal of the American Academy of Child and Adolescent Psychiatry1997;36(5):597‐604. [DOI: 10.1097/00004583‐199705000‐00009; PUBMED: 9136493] ">Gadow 2007</a> </p> <p><a href="./references#CD007990-bbs2-0008" title="Tourette's Syndrome Study Group. Treatment of ADHD in children with tics: a randomized controlled trial. Neurology2002;58(4):527‐36. [PUBMED: 11865128] ">Tourette's Syndrome Study Group 2002</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clonidine versus placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007990-bbs2-0006" title="SingerHS , BrownJ , QuaskeyS , RosenbergLA , MellitsED , DencklaMB . The treatment of attention deficit hyperactivity disorder in Tourette's syndrome: a double blind placebo‐controlled study with clonidine and desipramine. Pediatrics1995;95(1):74‐81. [PUBMED: 7770313] ">Singer 1995</a> </p> <p><a href="./references#CD007990-bbs2-0008" title="Tourette's Syndrome Study Group. Treatment of ADHD in children with tics: a randomized controlled trial. Neurology2002;58(4):527‐36. [PUBMED: 11865128] ">Tourette's Syndrome Study Group 2002</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Methylphenidate plus clonidine versus placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007990-bbs2-0008" title="Tourette's Syndrome Study Group. Treatment of ADHD in children with tics: a randomized controlled trial. Neurology2002;58(4):527‐36. [PUBMED: 11865128] ">Tourette's Syndrome Study Group 2002</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dextroamphetamine versus placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007990-bbs2-0002" title="CastellanosFX , GieddJN , EliaJ , MarshWL , RitchieGF , HamburgerSD , et al. Controlled stimulant treatment of ADHD and comorbid Tourette's syndrome: effects of stimulant and dose. Journal of the American Academy of Child and Adolescent Psychiatry1997;36(5):589‐96. [DOI: 10.1097/00004583‐199705000‐00008; PUBMED: 9136492] ">Castellanos 1997</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Guanfacine versus placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007990-bbs2-0005" title="ScahillL , ChappellPB , KimYS , SchultzRT , KatsovichL , ShepherdE , et al. A placebo‐controlled study of guanfacine in the treatment of children with tic disorders and attention deficit hyperactivity disorder. American Journal of Psychiatry2001;158(7):1067‐74. [DOI: 10.1176/appi.ajp.158.7.1067; PUBMED: 11431228] ">Scahill 2001</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Atomoxetine versus placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007990-bbs2-0001" title="AllenAJ , KurlanRM , GilbertDL , CoffeyBJ , LinderSL , LewisDW , et al. Atomoxetine treatment in children and adolescents with ADHD and comorbid tic disorders. Neurology2005;65(12):1941‐9. [DOI: 10.1212/01.wnl.0000188869.58300.a7; PUBMED: 16380617] SpencerTJ , SalleFR , GilbertDL , DunnDW , McCrackenJT , CoffeyBJ , et al. Atomoxetine treatment of ADHD in children with comorbid Tourette syndrome. Journal of Attention Disorders2008;11(4):470‐81. [DOI: 10.1177/1087054707306109; PUBMED: 17934184] ">Allen 2005</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Desipramine versus placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007990-bbs2-0006" title="SingerHS , BrownJ , QuaskeyS , RosenbergLA , MellitsED , DencklaMB . The treatment of attention deficit hyperactivity disorder in Tourette's syndrome: a double blind placebo‐controlled study with clonidine and desipramine. Pediatrics1995;95(1):74‐81. [PUBMED: 7770313] ">Singer 1995</a> </p> <p><a href="./references#CD007990-bbs2-0007" title="SpencerT , BiedermannJ , CoffeyB , GellerD , CrawfordM , BearmanSK , et al. A double‐blind comparison of desipramine and placebo in children and adolescents with chronic tic disorder and comorbid attention‐deficit/hyperactivity disorder. Archives of General Psychiatry2002;59(7):649‐56. [PUBMED: 12090818] ">Spencer 2002</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Deprenyl versus placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007990-bbs2-0003" title="FeiginA , KurlanR , McDermottMP , BeachJ , DimitsopulosT , BrowerCA , et al. A controlled trial of deprenyl in children with Tourette's syndrome and attention deficit hyperactivity disorder. Neurology1996;46(4):965‐8. [PUBMED: 8780073] ">Feigin 1996</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Desipramine versus clonidine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007990-bbs2-0006" title="SingerHS , BrownJ , QuaskeyS , RosenbergLA , MellitsED , DencklaMB . The treatment of attention deficit hyperactivity disorder in Tourette's syndrome: a double blind placebo‐controlled study with clonidine and desipramine. Pediatrics1995;95(1):74‐81. [PUBMED: 7770313] ">Singer 1995</a> </p> </td> </tr> </tbody> </table> </div> <p>The remaining five trials assessed single agents.</p> <p> <ul id="CD007990-list-0009"> <li> <p><a href="./references#CD007990-bbs2-0001" title="AllenAJ , KurlanRM , GilbertDL , CoffeyBJ , LinderSL , LewisDW , et al. Atomoxetine treatment in children and adolescents with ADHD and comorbid tic disorders. Neurology2005;65(12):1941‐9. [DOI: 10.1212/01.wnl.0000188869.58300.a7; PUBMED: 16380617] SpencerTJ , SalleFR , GilbertDL , DunnDW , McCrackenJT , CoffeyBJ , et al. Atomoxetine treatment of ADHD in children with comorbid Tourette syndrome. Journal of Attention Disorders2008;11(4):470‐81. [DOI: 10.1177/1087054707306109; PUBMED: 17934184] ">Allen 2005</a> assessed atomoxetine 0.5 mg/kg per day to 1.5 mg/kg per day (76 children), a highly selective, non‐stimulant noradrenergic reuptake inhibitor, versus placebo (72 children) in a parallel‐group trial of 18 weeks' duration with 148 children (131 boys, 17 girls). Participants considered to be clinical non‐responders at week 12 of the study were allowed to withdraw early from the double‐blind study and enter an open‐label study of the drug. </p> </li> <li> <p><a href="./references#CD007990-bbs2-0003" title="FeiginA , KurlanR , McDermottMP , BeachJ , DimitsopulosT , BrowerCA , et al. A controlled trial of deprenyl in children with Tourette's syndrome and attention deficit hyperactivity disorder. Neurology1996;46(4):965‐8. [PUBMED: 8780073] ">Feigin 1996</a> assessed the effects of deprenyl, a type B monoamine oxidase inhibitor, compared to placebo in 24 children (21 boys, 3 girls). Children were randomized to treatment with deprenyl 5 mg or matching placebo, given twice daily, for eight weeks and then crossed over to the alternate treatment after a six‐week washout period. </p> </li> <li> <p><a href="./references#CD007990-bbs2-0004" title="GadowKD , NolanEE , SprafkinJ , SverdJ . School observations of children with attention deficit hyperactivity disorder and comorbid tic disorder: effects of methylphenidate treatment. Journal of Developmental and Behavioural Pediatrics1995;16(3):167‐76. [PUBMED: 7560119] GadowKD , NolanEE , SverdJ . Methylphenidate in hyperactive boys with comorbid tic disorder: II. Short‐term behavioral effects in school settings. Journal of the American Academy of Child and Adolescent Psychiatry1992;31(3):462‐71. [DOI: 10.1097/00004583‐199205000‐00012; PUBMED: 1592778] GadowKD , NolanEE , SverdJ , SprafkinJ , ScheiderJ . Methylphenidate in children with oppositional defiant disorder and both comorbid chronic multiple tic disorder and ADHD. Journal of Child Neurology2008;23(9):981‐90. [DOI: 10.1177/0883073808315412; PUBMED: 18474932] GadowKD , NolanEE , SverdJ , SprafkinJ , SchwartzJ . Anxiety and depression symptoms and response to methylphenidate in children with attention deficit hyperactivity disorder and tic disorder. Journal of Clinical Psychopharmacology2002;22(3):267‐74. [PUBMED: 12006897] GadowKD , SverdJ , NolanEE , SprafkinJ , SchneiderJ . Immediate‐release methylphenidate for ADHD in children with comorbid chronic multiple tic disorder. Journal of the American Academy of Child and Adolescent Psychiatry2007;46(7):840‐8. [DOI: 10.1097/chi.0b013e31805c0860; PUBMED: 17581448] GadowKD , SverdJ , SprafkinJ , NolanEE , EzorSN . Efficacy of methylphenidate for attention deficit hyperactivity disorder in children with tic disorder. Archives of General Psychiatry1995;52(6):444‐55. [PUBMED: 7771914] GadowKD , SverdJ , SprafkinJ , NolanEE , GrossmanS . Long‐term methylphenidate therapy in children with comorbid attention deficit hyperactivity disorder and chronic multiple tic disorder. Archives of General Psychiatry1999;56(4):330‐6. [PUBMED: 10197827] NolanEE , GadowKD . Children with ADHD and tic disorder and their classmates: behavioural normalization with methylphenidate. Journal of the American Academy of Child and Adolescent Psychiatry1997;36(5):597‐604. [DOI: 10.1097/00004583‐199705000‐00009; PUBMED: 9136493] ">Gadow 2007</a> assessed methylphenidate in a single agent, cross‐over trial with placebo in which 71 children (57 boys, 14 girls) were randomized to three sequential doses of methylphenidate (0.1 mg/kg, 0.3 mg/kg, and 0.5 mg/kg), given twice daily, seven days a week for two weeks each. </p> </li> <li> <p><a href="./references#CD007990-bbs2-0005" title="ScahillL , ChappellPB , KimYS , SchultzRT , KatsovichL , ShepherdE , et al. A placebo‐controlled study of guanfacine in the treatment of children with tic disorders and attention deficit hyperactivity disorder. American Journal of Psychiatry2001;158(7):1067‐74. [DOI: 10.1176/appi.ajp.158.7.1067; PUBMED: 11431228] ">Scahill 2001</a> assessed guanfacine 1.5 mg to 3 mg per day (an alpha‐2 receptor agonist), divided into three daily doses, versus placebo in a parallel‐group trial of eight weeks' duration. The study randomized 34 children (31 boys, 3 girls) to guanfacine or placebo. </p> </li> <li> <p><a href="./references#CD007990-bbs2-0007" title="SpencerT , BiedermannJ , CoffeyB , GellerD , CrawfordM , BearmanSK , et al. A double‐blind comparison of desipramine and placebo in children and adolescents with chronic tic disorder and comorbid attention‐deficit/hyperactivity disorder. Archives of General Psychiatry2002;59(7):649‐56. [PUBMED: 12090818] ">Spencer 2002</a> compared desipramine versus placebo in 41 children (34 boys, 7 girls) in a parallel‐group trial in which desipramine was titrated weekly up to 3.5 mg/kg per day and given twice daily for six weeks. </p> </li> </ul> </p> </section> <section id="CD007990-sec-0061"> <h5 class="title">Outcome measures</h5> <p>All trials included both ADHD and tic outcomes. Most trials did not specify a primary outcome. The scales chosen to measure ADHD severity varied considerably between studies (<a href="#CD007990-tbl-0005">Table 2</a>). All studies used the YGTSS for one measure of tic severity. <a href="#CD007990-tbl-0006">Table 3</a> lists other measures of tic severity that the studies used. A description of each scales' items and scoring is included in <a href="#CD007990-tbl-0007">Table 4</a>. </p> <div class="table" id="CD007990-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Attention deficit hyperactivity disorder symptom severity scales used in this review</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Scale/measure</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007990-bbs2-0001" title="AllenAJ , KurlanRM , GilbertDL , CoffeyBJ , LinderSL , LewisDW , et al. Atomoxetine treatment in children and adolescents with ADHD and comorbid tic disorders. Neurology2005;65(12):1941‐9. [DOI: 10.1212/01.wnl.0000188869.58300.a7; PUBMED: 16380617] SpencerTJ , SalleFR , GilbertDL , DunnDW , McCrackenJT , CoffeyBJ , et al. Atomoxetine treatment of ADHD in children with comorbid Tourette syndrome. Journal of Attention Disorders2008;11(4):470‐81. [DOI: 10.1177/1087054707306109; PUBMED: 17934184] "><b>Allen 2005</b> </a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007990-bbs2-0002" title="CastellanosFX , GieddJN , EliaJ , MarshWL , RitchieGF , HamburgerSD , et al. Controlled stimulant treatment of ADHD and comorbid Tourette's syndrome: effects of stimulant and dose. Journal of the American Academy of Child and Adolescent Psychiatry1997;36(5):589‐96. [DOI: 10.1097/00004583‐199705000‐00008; PUBMED: 9136492] "><b>Castellanos 1997</b> </a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007990-bbs2-0003" title="FeiginA , KurlanR , McDermottMP , BeachJ , DimitsopulosT , BrowerCA , et al. A controlled trial of deprenyl in children with Tourette's syndrome and attention deficit hyperactivity disorder. Neurology1996;46(4):965‐8. [PUBMED: 8780073] "><b>Feigin 1996</b> </a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007990-bbs2-0004" title="GadowKD , NolanEE , SprafkinJ , SverdJ . School observations of children with attention deficit hyperactivity disorder and comorbid tic disorder: effects of methylphenidate treatment. Journal of Developmental and Behavioural Pediatrics1995;16(3):167‐76. [PUBMED: 7560119] GadowKD , NolanEE , SverdJ . Methylphenidate in hyperactive boys with comorbid tic disorder: II. Short‐term behavioral effects in school settings. Journal of the American Academy of Child and Adolescent Psychiatry1992;31(3):462‐71. [DOI: 10.1097/00004583‐199205000‐00012; PUBMED: 1592778] GadowKD , NolanEE , SverdJ , SprafkinJ , ScheiderJ . Methylphenidate in children with oppositional defiant disorder and both comorbid chronic multiple tic disorder and ADHD. Journal of Child Neurology2008;23(9):981‐90. [DOI: 10.1177/0883073808315412; PUBMED: 18474932] GadowKD , NolanEE , SverdJ , SprafkinJ , SchwartzJ . Anxiety and depression symptoms and response to methylphenidate in children with attention deficit hyperactivity disorder and tic disorder. Journal of Clinical Psychopharmacology2002;22(3):267‐74. [PUBMED: 12006897] GadowKD , SverdJ , NolanEE , SprafkinJ , SchneiderJ . Immediate‐release methylphenidate for ADHD in children with comorbid chronic multiple tic disorder. Journal of the American Academy of Child and Adolescent Psychiatry2007;46(7):840‐8. [DOI: 10.1097/chi.0b013e31805c0860; PUBMED: 17581448] GadowKD , SverdJ , SprafkinJ , NolanEE , EzorSN . Efficacy of methylphenidate for attention deficit hyperactivity disorder in children with tic disorder. Archives of General Psychiatry1995;52(6):444‐55. [PUBMED: 7771914] GadowKD , SverdJ , SprafkinJ , NolanEE , GrossmanS . Long‐term methylphenidate therapy in children with comorbid attention deficit hyperactivity disorder and chronic multiple tic disorder. Archives of General Psychiatry1999;56(4):330‐6. [PUBMED: 10197827] NolanEE , GadowKD . Children with ADHD and tic disorder and their classmates: behavioural normalization with methylphenidate. Journal of the American Academy of Child and Adolescent Psychiatry1997;36(5):597‐604. [DOI: 10.1097/00004583‐199705000‐00009; PUBMED: 9136493] "><b>Gadow 2007</b> </a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007990-bbs2-0005" title="ScahillL , ChappellPB , KimYS , SchultzRT , KatsovichL , ShepherdE , et al. A placebo‐controlled study of guanfacine in the treatment of children with tic disorders and attention deficit hyperactivity disorder. American Journal of Psychiatry2001;158(7):1067‐74. [DOI: 10.1176/appi.ajp.158.7.1067; PUBMED: 11431228] "><b>Scahill 2001</b> </a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007990-bbs2-0006" title="SingerHS , BrownJ , QuaskeyS , RosenbergLA , MellitsED , DencklaMB . The treatment of attention deficit hyperactivity disorder in Tourette's syndrome: a double blind placebo‐controlled study with clonidine and desipramine. Pediatrics1995;95(1):74‐81. [PUBMED: 7770313] "><b>Singer 1995</b> </a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007990-bbs2-0007" title="SpencerT , BiedermannJ , CoffeyB , GellerD , CrawfordM , BearmanSK , et al. A double‐blind comparison of desipramine and placebo in children and adolescents with chronic tic disorder and comorbid attention‐deficit/hyperactivity disorder. Archives of General Psychiatry2002;59(7):649‐56. [PUBMED: 12090818] "><b>Spencer 2002</b> </a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007990-bbs2-0008" title="Tourette's Syndrome Study Group. Treatment of ADHD in children with tics: a randomized controlled trial. Neurology2002;58(4):527‐36. [PUBMED: 11865128] "><b>Tourette's Syndrome Study Group 2002</b> </a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Conners Abbreviated Teacher Rating Scale</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Conners Abbreviated Parent Rating Scale</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IOWA Conners Teacher Rating Scale</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mothers' Objective Method for Subgrouping</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Continuous Performance Task</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ADHD Rating Scale‐IV: Parent Version</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical Global Impression Scale – Overall – Severity</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical Global Impression Scale – ADHD/Psychiatric Symptoms</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ADHD Teacher 39‐Item Conners Rating Scale</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>DuPaul ADHD Scale</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Parent Conners Questionnaire Hyperactivity Index</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Child Behaviour Checklist</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gordon Diagnostic System</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical Evaluation of Language Function</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Matching Familial Figures Test</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Porteus Maze Test</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Restricted Academic Test</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Conners Continuous Performance Task</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>ADHD: attention deficit hyperactivity disorder; IOWA: inattention/overactivity with aggression. </p> </div> </div> <div class="table" id="CD007990-tbl-0006"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Tic severity symptom scales used in this review</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Scale/measure</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007990-bbs2-0001" title="AllenAJ , KurlanRM , GilbertDL , CoffeyBJ , LinderSL , LewisDW , et al. Atomoxetine treatment in children and adolescents with ADHD and comorbid tic disorders. Neurology2005;65(12):1941‐9. [DOI: 10.1212/01.wnl.0000188869.58300.a7; PUBMED: 16380617] SpencerTJ , SalleFR , GilbertDL , DunnDW , McCrackenJT , CoffeyBJ , et al. Atomoxetine treatment of ADHD in children with comorbid Tourette syndrome. Journal of Attention Disorders2008;11(4):470‐81. [DOI: 10.1177/1087054707306109; PUBMED: 17934184] "><b>Allen 2005</b> </a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007990-bbs2-0002" title="CastellanosFX , GieddJN , EliaJ , MarshWL , RitchieGF , HamburgerSD , et al. Controlled stimulant treatment of ADHD and comorbid Tourette's syndrome: effects of stimulant and dose. Journal of the American Academy of Child and Adolescent Psychiatry1997;36(5):589‐96. [DOI: 10.1097/00004583‐199705000‐00008; PUBMED: 9136492] "><b>Castellanos 1997</b> </a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007990-bbs2-0003" title="FeiginA , KurlanR , McDermottMP , BeachJ , DimitsopulosT , BrowerCA , et al. A controlled trial of deprenyl in children with Tourette's syndrome and attention deficit hyperactivity disorder. Neurology1996;46(4):965‐8. [PUBMED: 8780073] "><b>Feigin 1996</b> </a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007990-bbs2-0004" title="GadowKD , NolanEE , SprafkinJ , SverdJ . School observations of children with attention deficit hyperactivity disorder and comorbid tic disorder: effects of methylphenidate treatment. Journal of Developmental and Behavioural Pediatrics1995;16(3):167‐76. [PUBMED: 7560119] GadowKD , NolanEE , SverdJ . Methylphenidate in hyperactive boys with comorbid tic disorder: II. Short‐term behavioral effects in school settings. Journal of the American Academy of Child and Adolescent Psychiatry1992;31(3):462‐71. [DOI: 10.1097/00004583‐199205000‐00012; PUBMED: 1592778] GadowKD , NolanEE , SverdJ , SprafkinJ , ScheiderJ . Methylphenidate in children with oppositional defiant disorder and both comorbid chronic multiple tic disorder and ADHD. Journal of Child Neurology2008;23(9):981‐90. [DOI: 10.1177/0883073808315412; PUBMED: 18474932] GadowKD , NolanEE , SverdJ , SprafkinJ , SchwartzJ . Anxiety and depression symptoms and response to methylphenidate in children with attention deficit hyperactivity disorder and tic disorder. Journal of Clinical Psychopharmacology2002;22(3):267‐74. [PUBMED: 12006897] GadowKD , SverdJ , NolanEE , SprafkinJ , SchneiderJ . Immediate‐release methylphenidate for ADHD in children with comorbid chronic multiple tic disorder. Journal of the American Academy of Child and Adolescent Psychiatry2007;46(7):840‐8. [DOI: 10.1097/chi.0b013e31805c0860; PUBMED: 17581448] GadowKD , SverdJ , SprafkinJ , NolanEE , EzorSN . Efficacy of methylphenidate for attention deficit hyperactivity disorder in children with tic disorder. Archives of General Psychiatry1995;52(6):444‐55. [PUBMED: 7771914] GadowKD , SverdJ , SprafkinJ , NolanEE , GrossmanS . Long‐term methylphenidate therapy in children with comorbid attention deficit hyperactivity disorder and chronic multiple tic disorder. Archives of General Psychiatry1999;56(4):330‐6. [PUBMED: 10197827] NolanEE , GadowKD . Children with ADHD and tic disorder and their classmates: behavioural normalization with methylphenidate. Journal of the American Academy of Child and Adolescent Psychiatry1997;36(5):597‐604. [DOI: 10.1097/00004583‐199705000‐00009; PUBMED: 9136493] "><b>Gadow 2007</b> </a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007990-bbs2-0005" title="ScahillL , ChappellPB , KimYS , SchultzRT , KatsovichL , ShepherdE , et al. A placebo‐controlled study of guanfacine in the treatment of children with tic disorders and attention deficit hyperactivity disorder. American Journal of Psychiatry2001;158(7):1067‐74. [DOI: 10.1176/appi.ajp.158.7.1067; PUBMED: 11431228] "><b>Scahill 2001</b> </a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007990-bbs2-0006" title="SingerHS , BrownJ , QuaskeyS , RosenbergLA , MellitsED , DencklaMB . The treatment of attention deficit hyperactivity disorder in Tourette's syndrome: a double blind placebo‐controlled study with clonidine and desipramine. Pediatrics1995;95(1):74‐81. [PUBMED: 7770313] "><b>Singer 1995</b> </a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007990-bbs2-0007" title="SpencerT , BiedermannJ , CoffeyB , GellerD , CrawfordM , BearmanSK , et al. A double‐blind comparison of desipramine and placebo in children and adolescents with chronic tic disorder and comorbid attention‐deficit/hyperactivity disorder. Archives of General Psychiatry2002;59(7):649‐56. [PUBMED: 12090818] "><b>Spencer 2002</b> </a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007990-bbs2-0008" title="Tourette's Syndrome Study Group. Treatment of ADHD in children with tics: a randomized controlled trial. Neurology2002;58(4):527‐36. [PUBMED: 11865128] "><b>Tourette's Syndrome Study Group 2002</b> </a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yale Global Tic</p> <p>Severity Scale</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tourette Syndrome</p> <p>Severity Scale</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tourette Syndrome</p> <p>Clinical Global</p> <p>Improvement</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Global Tic Rating</p> <p>Scale</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2‐Minute Tic and</p> <p>Habit Count</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tic Symptom Self‐Report</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Goetz Tic Severity</p> <p>Scale</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hopkins Motor/Vocal Scale</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> </tr> </tbody> </table> </div> <div class="table" id="CD007990-tbl-0007"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Description of scales used in included studies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Scale/measure</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number of items</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Scoring</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Conners' Abbreviated Symptoms Questionnaire for Teachers (ASQ)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 items pertaining to the child's behavior</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rated on a 4‐point Likert scale, ranging from 0 (not at all), 1 (just a little), 2 (pretty much) to 3 (very much true), with a possible total score ranging from 0 to 30. Higher scores indicate worse symptoms </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yale Global Tic Severity Scale (YGTSS)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 items on the number, frequency, intensity, complexity, and interference from motor tics, and 5 items on the number, frequency, intensity, complexity, and interference from vocal tics, and 1 item on overall impairment </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The Total Motor Tic Score is derived by adding the 5 motor tics items (each item ranges from 0 to 5, total motor tic score ranges from 0 to 25). The Total Vocal Tic Score is derived by adding the 5 phonic tics items (each item ranges from 0 to 5, total vocal tic ranges from 0 to 25). The Total Tic Score is a summation of the Total Motor Tic and Total Vocal Tic Scores. The Overall Impairment Rating is rated on a 51‐point scale anchored by 0 (no impairment) and 50 (severe impairment). Finally, the Global Severity Score is a summation of the Total Motor Tic Score, Total Vocal Tic Score, and Overall Impairment Rating (range 0 to 100). Higher scores indicate worse symptoms. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Global Tic Rating Scale</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9 items, with the first 5 referring to the frequency of motor (3 items) and phonic tics (2 items) according to body region, which are summed to produce motor and phonic tic frequency subscores, respectively </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All items are rated on a scale from 0 (never) to 3 (very much). Total score ranges from 0 to 27. </p> <p>Higher scores indicate worse symptoms</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ADHD Rating Scale IV ‐ Parent Version</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18‐item questionnaire. 9 questions each on inattention and hyperactivity‐impulsivity, where the odd‐numbered items represent the inattention subscale, and the even‐numbered items represent the hyperactive/impulsive subscale </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Items coded on 4‐point Likert scale using scores 1 (never or rarely), 2 (sometimes), 3 (often), or 4 (very often). Total score ranges from 18 to 52. Raw scores are converted to percentiles. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ADHD Parent Linear Analogue Scale</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10‐cm line on which both the parent and physician separately rank symptoms</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The ends of each line represent 0 (no symptoms) and 10 (most severe)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Child Behaviour Checklist (CBCL)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>113 items across 8 subscales assessing maladaptive behavioral and emotional problems:</p> <p> <ul id="CD007990-list-0010"> <li> <p>withdrawn</p> </li> <li> <p>somatic complaints</p> </li> <li> <p>anxious/depressed</p> </li> <li> <p>social problems</p> </li> <li> <p>thought problems</p> </li> <li> <p>attention problems</p> </li> <li> <p>delinquent problems</p> </li> <li> <p>aggressive behavior</p> </li> </ul> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Items are coded from 0 to 2, scored 0 (not at all), 1 (somewhat true), or 2 (very true). CBCL profile for each category, with scores below the 95th percentile in the normal range, and above the 98th percentile in the clinical range. Higher scores indicate worse symptoms. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Conners' Abbreviated Parent Rating Scale</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48 items across 6 subscales:</p> <p> <ul id="CD007990-list-0011"> <li> <p>conduct problems</p> </li> <li> <p>learning problems</p> </li> <li> <p>psychosomatic</p> </li> <li> <p>impulsive/hyperactive</p> </li> <li> <p>anxiety</p> </li> <li> <p>hyperactivity index</p> </li> </ul> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All items are rated on a scale from 0 (never) to 3 (very much). Total score ranges from 0 to 144. </p> <p>Higher scores indicate worse symptoms</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IOWA Conners' Teacher Rating Scale</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 items. Consists of 5‐item subscales designed to assess inattention/overactivity and aggression </p> <p>Inattention/overactivity: </p> <p> <ul id="CD007990-list-0012"> <li> <p>fidgeting</p> </li> <li> <p>hums and makes other odd noises</p> </li> <li> <p>excitable, impulsive</p> </li> <li> <p>inattentive, easily distracted</p> </li> <li> <p>fails to finish things he starts (short attention span)</p> </li> </ul> </p> <p>Aggression: </p> <p> <ul id="CD007990-list-0013"> <li> <p>quarrelsome</p> </li> <li> <p>acts "smart,"</p> </li> <li> <p>temper outbursts (explosive and unpredictable behavior)</p> </li> <li> <p>defiant</p> </li> <li> <p>unco‐operative</p> </li> </ul> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Scored 0 (not at all), 1 (just a little), 2 (pretty much), or 3 (very much). Total score ranges from 0 to 30. Higher scores indicate worse symptoms </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mothers' Objective Method for Subgrouping</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Contains 10 (hyperactivity or ADHD, or both) symptoms arranged in a checklist format. Generates a hyperactivity scale score and an aggression scale score </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 indicates checked and 0 unchecked. Total score ranges from 0 to 10. Higher scores indicate worse symptoms </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Continuous Performance Task (CPT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Computer‐administered and scored measure of sustained visual attention and motor response inhibition. The test takes about 15 minutes to administer and yields measures of omissions, commissions, and reaction time. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Omission errors measure inattention, commission errors measure impulsivity</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Conners' Teacher Rating Scale</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39 items clustered into 5 factors, including conduct problems, daydreaming, inattention, anxious‐fearful, and hyperactive behavior </p> <p>ADHD Teacher 39‐Item</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All items are rated on a scale from 0 (never) to 3 (very much). Total score ranges from 0 to 137. </p> <p>Raw scores for each scale are converted to T scores, incorporating normative adjustments for age and sex, with scores of at least 70 considered clinically elevated </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Conners' Continuous Performance Task (CPT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Visual‐motor task. Respondents must rapidly and accurately hit the space bar after every letter presented except the letter 'X'. Several variables may be derived from the Conners' CPT, including errors of omission and commission, mean hit reaction time (RT), mean hit RT standard error. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Omission errors measure inattention, commission errors measure impulsivity</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tourette Syndrome Severity Scale</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5‐item scale</p> <p> <ul id="CD007990-list-0014"> <li> <p>Are the tics noticeable to others?</p> </li> <li> <p>Do the tics elicit comments?</p> </li> <li> <p>Is the patient considered odd or bizarre?</p> </li> <li> <p>Do the tics interfere with functioning?</p> </li> <li> <p>Is the patient incapacitated, homebound, or hospitalized?</p> </li> </ul> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Higher scores indicates worse symptoms</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tourette Syndrome Clinical Global Impression (CGI) Scale</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Observer‐rated scale that measures illness severity (CGI‐S), or global improvement (CGI‐I) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7‐point scale, with the severity of illness scale (CGI‐S) using a range of responses from 1 (normal) to 7 (among the most severely ill people). CGI‐I scores range from 1 (very much improved) to 7 (very much worse) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2‐Minute Tic and Habit Count</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The physician counts separately the number of brief, jerky (i.e. tics) and rhythmic (i.e. stereotypic, habit) movements and vocalizations during quiet conversation in an office setting. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Higher scores indicates worse symptoms</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tic Symptom Self‐Report</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40‐item checklist containing 20 motor tic items and 20 phonic tic items</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0–3 scale corresponding with absent (score of 0) to very frequent and forceful (score of 3). Total score ranges from 0 to 120. Higher scores indicate worse symptoms </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Goetz Tic Severity Scale</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Videotape protocol involving a 10‐minute film of people placed in front of a video camera in a quiet room. 2 body views are recorded, full frontal body (far) and head and shoulders only (near), under 2 conditions: relaxed with the examiner in the room, and relaxed with the patient alone in the room </p> <p>5 domains are rated:</p> <p> <ul id="CD007990-list-0015"> <li> <p>number of body areas involved with tics</p> </li> <li> <p>motor tic intensity</p> </li> <li> <p>phonic tic intensity</p> </li> <li> <p>frequency of motor tics</p> </li> <li> <p>frequency of phonic tics</p> </li> </ul> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0–4 scoring format. For all domains, 0 represents normal function without evidence of tic disability. Higher scores indicate worse symptoms </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hopkins Motor/Vocal Scale</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Consists of a series of linear analog scales (10 cm) on which both the parent and physician separately rank each tic (motor and vocal) symptom, taking into consideration its frequency, intensity, degree of interference, and impairment </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The ends of each line represent 0 (no tics) and 10 (most severe). The</p> <p>line can be subdivided roughly into 4 ranges: mild, moderate, moderately severe, and severe </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Du Paul ADHD Rating Scale</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14 items, assessing separate factors of inattention and hyperactivity‐impulsivity</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rated on a 0 (normal) to 3 (severe) scale, yielding a total score ranging from 0 to 42. Higher scores indicate worse symptoms </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Parent Conners' Questionnaire Hyperactivity Index</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10‐item rating scale identifying hyperactive children</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Each item is rated from 0 to 3 (range 0–30). Higher scores indicate worse symptoms</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>ADHD: attention deficit hyperactivity disorder.</p> </div> </div> </section> </section> <section id="CD007990-sec-0062"> <h4 class="title">Excluded studies</h4> <p>We excluded six studies from this review. See <a href="./references#CD007990-sec-0150" title="">Characteristics of excluded studies</a> tables. </p> <p>In the original review, we excluded five studies (<a href="./references#CD007990-bbs2-0009" title="HowsonAL , BatthS , IlivitskyV , BoisjoliA , JaworskiM , MahoneyC , et al. Clinical and attentional effects of acute nicotine treatment in Tourette's syndrome. European Psychiatry2004;19(2):102‐12. [PUBMED: 15132126] ">Howson 2004</a>; <a href="./references#CD007990-bbs2-0010" title="LawSF , SchacharRJ . Do typical clinical doses of methylphenidate cause tics in children treated for attention‐deficit hyperactivity disorder?. Journal of the American Academy of Child and Adolescent Psychiatry1999;38(8):944‐51. [DOI: 10.1097/00004583‐199908000‐00009; PUBMED: 10434485] ">Law 1999</a>; <a href="./references#CD007990-bbs2-0012" title="NiederhoferH , StaffenW , MairA . A placebo controlled study of lofexidine in the treatment of children with tic disorders and attention deficit hyperactivity disorder. Journal of Psychopharmacology2003;17(1):113‐9. [PUBMED: 12680748] ">Niederhofer 2003</a>; <a href="./references#CD007990-bbs2-0013" title="NolanEE , GadowKD , SprafkinJ . Stimulant medication withdrawal during long‐term therapy in children with comorbid attention‐deficit hyperactivity disorder and chronic multiple tic disorder. Pediatrics1999;103(4 Pt 1):730‐7. [PUBMED: 10103294] ">Nolan 1999</a>; <a href="./references#CD007990-bbs2-0014" title="SalleeFR , SethuramanG , RockC . Effects of pimozide on cognition in children with Tourette syndrome: interaction with comorbid attention deficit hyperactivity disorder. Acta Psychiatrica Scandinavica1994;90(1):4‐9. [PUBMED: 7976448] ">Sallee 1994</a>). We excluded: </p> <p> <ul id="CD007990-list-0016"> <li> <p>one study of iofexidine in children with tic disorders and ADHD, as the manuscript was retracted from the journal due to plagiarism and possible fraudulent results (<a href="./references#CD007990-bbs2-0012" title="NiederhoferH , StaffenW , MairA . A placebo controlled study of lofexidine in the treatment of children with tic disorders and attention deficit hyperactivity disorder. Journal of Psychopharmacology2003;17(1):113‐9. [PUBMED: 12680748] ">Niederhofer 2003</a>); </p> </li> <li> <p>one study of methylphenidate in children with ADHD, which excluded children with severe motor or vocal tics and Tourette syndrome from the study and did not report the effects of methylphenidate on ADHD symptoms (<a href="./references#CD007990-bbs2-0010" title="LawSF , SchacharRJ . Do typical clinical doses of methylphenidate cause tics in children treated for attention‐deficit hyperactivity disorder?. Journal of the American Academy of Child and Adolescent Psychiatry1999;38(8):944‐51. [DOI: 10.1097/00004583‐199908000‐00009; PUBMED: 10434485] ">Law 1999</a>); </p> </li> <li> <p>one study that looked at the effects of stimulant withdrawal on tics in children with ADHD (<a href="./references#CD007990-bbs2-0013" title="NolanEE , GadowKD , SprafkinJ . Stimulant medication withdrawal during long‐term therapy in children with comorbid attention‐deficit hyperactivity disorder and chronic multiple tic disorder. Pediatrics1999;103(4 Pt 1):730‐7. [PUBMED: 10103294] ">Nolan 1999</a>), and therefore did not meet the inclusion criteria (<a href="#CD007990-sec-0030">Criteria for considering studies for this review</a>); </p> </li> <li> <p>two studies that assessed the effects of pharmacological treatments on cognition and attention but not the primary outcomes of ADHD or tic severity (<a href="./references#CD007990-bbs2-0009" title="HowsonAL , BatthS , IlivitskyV , BoisjoliA , JaworskiM , MahoneyC , et al. Clinical and attentional effects of acute nicotine treatment in Tourette's syndrome. European Psychiatry2004;19(2):102‐12. [PUBMED: 15132126] ">Howson 2004</a>; <a href="./references#CD007990-bbs2-0014" title="SalleeFR , SethuramanG , RockC . Effects of pimozide on cognition in children with Tourette syndrome: interaction with comorbid attention deficit hyperactivity disorder. Acta Psychiatrica Scandinavica1994;90(1):4‐9. [PUBMED: 7976448] ">Sallee 1994</a>). </p> </li> </ul> </p> <p>In this update, we excluded one study because it did not utilize a double‐blind protocol (<a href="./references#CD007990-bbs2-0011" title="LyonGJ , SamarSM , ConeleaC , TrujilloMR , LipinskiCM , BauerCC , et al. Testing tic suppression: comparing the effects of dexmethylphenidate to no medication in children and adolescents with attention‐deficit/hyperactivity disorder and Tourette's disorder. Journal of Child and Adolescent Psychopharmacology2010;20(4):283‐9. [DOI: 10.1089/cap.2010.0032; PMC2958463; PUBMED: 20807066] ">Lyon 2010</a>). </p> </section> </section> <section id="CD007990-sec-0063"> <h3 class="title">Risk of bias in included studies</h3> <p>See also 'Risk of bias' tables, in the <a href="./references#CD007990-sec-0149" title="">Characteristics of included studies</a> tables, and <a href="#CD007990-fig-0002">Figure 2</a>. </p> <div class="figure" id="CD007990-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD007990-fig-0002" src="/cdsr/doi/10.1002/14651858.CD007990.pub3/media/CDSR/CD007990/image_n/nCD007990-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <section id="CD007990-sec-0064"> <h4 class="title">Allocation</h4> <p>We judged sequence generation to be at low risk of bias for three studies (<a href="./references#CD007990-bbs2-0003" title="FeiginA , KurlanR , McDermottMP , BeachJ , DimitsopulosT , BrowerCA , et al. A controlled trial of deprenyl in children with Tourette's syndrome and attention deficit hyperactivity disorder. Neurology1996;46(4):965‐8. [PUBMED: 8780073] ">Feigin 1996</a>; <a href="./references#CD007990-bbs2-0007" title="SpencerT , BiedermannJ , CoffeyB , GellerD , CrawfordM , BearmanSK , et al. A double‐blind comparison of desipramine and placebo in children and adolescents with chronic tic disorder and comorbid attention‐deficit/hyperactivity disorder. Archives of General Psychiatry2002;59(7):649‐56. [PUBMED: 12090818] ">Spencer 2002</a>; <a href="./references#CD007990-bbs2-0008" title="Tourette's Syndrome Study Group. Treatment of ADHD in children with tics: a randomized controlled trial. Neurology2002;58(4):527‐36. [PUBMED: 11865128] ">Tourette's Syndrome Study Group 2002</a>). The remaining five studies did not describe sequence generation and we judged these studies at unclear risk of bias on this domain. </p> <p>Five studies adequately described allocation concealment (<a href="./references#CD007990-bbs2-0001" title="AllenAJ , KurlanRM , GilbertDL , CoffeyBJ , LinderSL , LewisDW , et al. Atomoxetine treatment in children and adolescents with ADHD and comorbid tic disorders. Neurology2005;65(12):1941‐9. [DOI: 10.1212/01.wnl.0000188869.58300.a7; PUBMED: 16380617] SpencerTJ , SalleFR , GilbertDL , DunnDW , McCrackenJT , CoffeyBJ , et al. Atomoxetine treatment of ADHD in children with comorbid Tourette syndrome. Journal of Attention Disorders2008;11(4):470‐81. [DOI: 10.1177/1087054707306109; PUBMED: 17934184] ">Allen 2005</a>; <a href="./references#CD007990-bbs2-0004" title="GadowKD , NolanEE , SprafkinJ , SverdJ . School observations of children with attention deficit hyperactivity disorder and comorbid tic disorder: effects of methylphenidate treatment. Journal of Developmental and Behavioural Pediatrics1995;16(3):167‐76. [PUBMED: 7560119] GadowKD , NolanEE , SverdJ . Methylphenidate in hyperactive boys with comorbid tic disorder: II. Short‐term behavioral effects in school settings. Journal of the American Academy of Child and Adolescent Psychiatry1992;31(3):462‐71. [DOI: 10.1097/00004583‐199205000‐00012; PUBMED: 1592778] GadowKD , NolanEE , SverdJ , SprafkinJ , ScheiderJ . Methylphenidate in children with oppositional defiant disorder and both comorbid chronic multiple tic disorder and ADHD. Journal of Child Neurology2008;23(9):981‐90. [DOI: 10.1177/0883073808315412; PUBMED: 18474932] GadowKD , NolanEE , SverdJ , SprafkinJ , SchwartzJ . Anxiety and depression symptoms and response to methylphenidate in children with attention deficit hyperactivity disorder and tic disorder. Journal of Clinical Psychopharmacology2002;22(3):267‐74. [PUBMED: 12006897] GadowKD , SverdJ , NolanEE , SprafkinJ , SchneiderJ . Immediate‐release methylphenidate for ADHD in children with comorbid chronic multiple tic disorder. Journal of the American Academy of Child and Adolescent Psychiatry2007;46(7):840‐8. [DOI: 10.1097/chi.0b013e31805c0860; PUBMED: 17581448] GadowKD , SverdJ , SprafkinJ , NolanEE , EzorSN . Efficacy of methylphenidate for attention deficit hyperactivity disorder in children with tic disorder. Archives of General Psychiatry1995;52(6):444‐55. [PUBMED: 7771914] GadowKD , SverdJ , SprafkinJ , NolanEE , GrossmanS . Long‐term methylphenidate therapy in children with comorbid attention deficit hyperactivity disorder and chronic multiple tic disorder. Archives of General Psychiatry1999;56(4):330‐6. [PUBMED: 10197827] NolanEE , GadowKD . Children with ADHD and tic disorder and their classmates: behavioural normalization with methylphenidate. Journal of the American Academy of Child and Adolescent Psychiatry1997;36(5):597‐604. [DOI: 10.1097/00004583‐199705000‐00009; PUBMED: 9136493] ">Gadow 2007</a>; <a href="./references#CD007990-bbs2-0006" title="SingerHS , BrownJ , QuaskeyS , RosenbergLA , MellitsED , DencklaMB . The treatment of attention deficit hyperactivity disorder in Tourette's syndrome: a double blind placebo‐controlled study with clonidine and desipramine. Pediatrics1995;95(1):74‐81. [PUBMED: 7770313] ">Singer 1995</a>; <a href="./references#CD007990-bbs2-0007" title="SpencerT , BiedermannJ , CoffeyB , GellerD , CrawfordM , BearmanSK , et al. A double‐blind comparison of desipramine and placebo in children and adolescents with chronic tic disorder and comorbid attention‐deficit/hyperactivity disorder. Archives of General Psychiatry2002;59(7):649‐56. [PUBMED: 12090818] ">Spencer 2002</a>; <a href="./references#CD007990-bbs2-0008" title="Tourette's Syndrome Study Group. Treatment of ADHD in children with tics: a randomized controlled trial. Neurology2002;58(4):527‐36. [PUBMED: 11865128] ">Tourette's Syndrome Study Group 2002</a>). The remaining three studies inadequately described allocation concealment, preventing us from making a judgement on whether or not it was adequate. </p> </section> <section id="CD007990-sec-0065"> <h4 class="title">Blinding</h4> <p>Blinding of participants, clinicians, and outcome assessors were evaluated separately and was a requirement for inclusion. Therefore, all included studies were at low risk of performance and detection bias. </p> </section> <section id="CD007990-sec-0066"> <h4 class="title">Incomplete outcome data</h4> <p>Three of the eight studies did not adequately addressed incomplete outcome data. <a href="./references#CD007990-bbs2-0003" title="FeiginA , KurlanR , McDermottMP , BeachJ , DimitsopulosT , BrowerCA , et al. A controlled trial of deprenyl in children with Tourette's syndrome and attention deficit hyperactivity disorder. Neurology1996;46(4):965‐8. [PUBMED: 8780073] ">Feigin 1996</a> had a very high dropout of study participants after the first period of the study, especially in the treatment group, and it was unclear if data from participants who dropped out of the study were included in the analysis. <a href="./references#CD007990-bbs2-0004" title="GadowKD , NolanEE , SprafkinJ , SverdJ . School observations of children with attention deficit hyperactivity disorder and comorbid tic disorder: effects of methylphenidate treatment. Journal of Developmental and Behavioural Pediatrics1995;16(3):167‐76. [PUBMED: 7560119] GadowKD , NolanEE , SverdJ . Methylphenidate in hyperactive boys with comorbid tic disorder: II. Short‐term behavioral effects in school settings. Journal of the American Academy of Child and Adolescent Psychiatry1992;31(3):462‐71. [DOI: 10.1097/00004583‐199205000‐00012; PUBMED: 1592778] GadowKD , NolanEE , SverdJ , SprafkinJ , ScheiderJ . Methylphenidate in children with oppositional defiant disorder and both comorbid chronic multiple tic disorder and ADHD. Journal of Child Neurology2008;23(9):981‐90. [DOI: 10.1177/0883073808315412; PUBMED: 18474932] GadowKD , NolanEE , SverdJ , SprafkinJ , SchwartzJ . Anxiety and depression symptoms and response to methylphenidate in children with attention deficit hyperactivity disorder and tic disorder. Journal of Clinical Psychopharmacology2002;22(3):267‐74. [PUBMED: 12006897] GadowKD , SverdJ , NolanEE , SprafkinJ , SchneiderJ . Immediate‐release methylphenidate for ADHD in children with comorbid chronic multiple tic disorder. Journal of the American Academy of Child and Adolescent Psychiatry2007;46(7):840‐8. [DOI: 10.1097/chi.0b013e31805c0860; PUBMED: 17581448] GadowKD , SverdJ , SprafkinJ , NolanEE , EzorSN . Efficacy of methylphenidate for attention deficit hyperactivity disorder in children with tic disorder. Archives of General Psychiatry1995;52(6):444‐55. [PUBMED: 7771914] GadowKD , SverdJ , SprafkinJ , NolanEE , GrossmanS . Long‐term methylphenidate therapy in children with comorbid attention deficit hyperactivity disorder and chronic multiple tic disorder. Archives of General Psychiatry1999;56(4):330‐6. [PUBMED: 10197827] NolanEE , GadowKD . Children with ADHD and tic disorder and their classmates: behavioural normalization with methylphenidate. Journal of the American Academy of Child and Adolescent Psychiatry1997;36(5):597‐604. [DOI: 10.1097/00004583‐199705000‐00009; PUBMED: 9136493] ">Gadow 2007</a> did not explain how they handled incomplete data sets in the analysis. <a href="./references#CD007990-bbs2-0002" title="CastellanosFX , GieddJN , EliaJ , MarshWL , RitchieGF , HamburgerSD , et al. Controlled stimulant treatment of ADHD and comorbid Tourette's syndrome: effects of stimulant and dose. Journal of the American Academy of Child and Adolescent Psychiatry1997;36(5):589‐96. [DOI: 10.1097/00004583‐199705000‐00008; PUBMED: 9136492] ">Castellanos 1997</a> provided few raw data from study results; the reported only F scores and P values for analysis of variance tests. In addition, all of the above studies, which were cross‐over studies, did not provide paired data for analysis. Rather, each study provided only means and SDs for each treatment type and, with the exception of <a href="./references#CD007990-bbs2-0002" title="CastellanosFX , GieddJN , EliaJ , MarshWL , RitchieGF , HamburgerSD , et al. Controlled stimulant treatment of ADHD and comorbid Tourette's syndrome: effects of stimulant and dose. Journal of the American Academy of Child and Adolescent Psychiatry1997;36(5):589‐96. [DOI: 10.1097/00004583‐199705000‐00008; PUBMED: 9136492] ">Castellanos 1997</a>, did not provide original data. The remaining five studies adequately addressed incomplete outcome data. </p> </section> <section id="CD007990-sec-0067"> <h4 class="title">Selective reporting</h4> <p><a href="./references#CD007990-bbs2-0006" title="SingerHS , BrownJ , QuaskeyS , RosenbergLA , MellitsED , DencklaMB . The treatment of attention deficit hyperactivity disorder in Tourette's syndrome: a double blind placebo‐controlled study with clonidine and desipramine. Pediatrics1995;95(1):74‐81. [PUBMED: 7770313] ">Singer 1995</a> did not provide outcome data for many variables described as collected in the Methods section, only presenting data for those scales showing significant changes. Also, they often reported 'male only' results. Consequently, we judged this study at high risk of reporting bias. <a href="./references#CD007990-bbs2-0002" title="CastellanosFX , GieddJN , EliaJ , MarshWL , RitchieGF , HamburgerSD , et al. Controlled stimulant treatment of ADHD and comorbid Tourette's syndrome: effects of stimulant and dose. Journal of the American Academy of Child and Adolescent Psychiatry1997;36(5):589‐96. [DOI: 10.1097/00004583‐199705000‐00008; PUBMED: 9136492] ">Castellanos 1997</a> was at high risk of bias as very few data were presented on the results of the analysis. We judged the remaining five studies at low risk of reporting bias. </p> </section> <section id="CD007990-sec-0068"> <h4 class="title">Other potential sources of bias</h4> <p><a href="./references#CD007990-bbs2-0001" title="AllenAJ , KurlanRM , GilbertDL , CoffeyBJ , LinderSL , LewisDW , et al. Atomoxetine treatment in children and adolescents with ADHD and comorbid tic disorders. Neurology2005;65(12):1941‐9. [DOI: 10.1212/01.wnl.0000188869.58300.a7; PUBMED: 16380617] SpencerTJ , SalleFR , GilbertDL , DunnDW , McCrackenJT , CoffeyBJ , et al. Atomoxetine treatment of ADHD in children with comorbid Tourette syndrome. Journal of Attention Disorders2008;11(4):470‐81. [DOI: 10.1177/1087054707306109; PUBMED: 17934184] ">Allen 2005</a> had a high rate of early treatment termination at 12 weeks in both treatment groups and thus was at high risk of other bias. None of the other studies appeared to have other potential sources of bias and thus were at low risk of other bias. </p> </section> </section> <section id="CD007990-sec-0069"> <h3 class="title" id="CD007990-sec-0069">Effects of interventions</h3> <p>See: <a href="./full#CD007990-tbl-0001"><b>Summary of findings for the main comparison</b> Methylphenidate compared with placebo for attention deficit hyperactivity disorder (ADHD) in children with comorbid tic disorders</a>; <a href="./full#CD007990-tbl-0002"><b>Summary of findings 2</b> Clonidine compared with placebo for attention deficit hyperactivity disorder (ADHD) in children with comorbid tic disorders</a>; <a href="./full#CD007990-tbl-0003"><b>Summary of findings 3</b> Desipramine compared with placebo for attention deficit hyperactivity disorder (ADHD) in children with comorbid tic disorders</a> </p> <p>All treatments, with the exception of deprenyl, were efficacious in treating the symptoms of ADHD. Tic symptoms improved in children treated with methylphenidate, clonidine, methylphenidate plus clonidine, guanfacine and desipramine (see <a href="./full#CD007990-tbl-0001">summary of findings Table for the main comparison</a>; <a href="./full#CD007990-tbl-0002">summary of findings Table 2</a>; <a href="./full#CD007990-tbl-0003">summary of findings Table 3</a>). Fear of worsening tics limited dose increases of methylphenidate in one study (<a href="./references#CD007990-bbs2-0008" title="Tourette's Syndrome Study Group. Treatment of ADHD in children with tics: a randomized controlled trial. Neurology2002;58(4):527‐36. [PUBMED: 11865128] ">Tourette's Syndrome Study Group 2002</a>). High‐dose dextroamphetamine appeared to worsen tics in one study (<a href="./references#CD007990-bbs2-0002" title="CastellanosFX , GieddJN , EliaJ , MarshWL , RitchieGF , HamburgerSD , et al. Controlled stimulant treatment of ADHD and comorbid Tourette's syndrome: effects of stimulant and dose. Journal of the American Academy of Child and Adolescent Psychiatry1997;36(5):589‐96. [DOI: 10.1097/00004583‐199705000‐00008; PUBMED: 9136492] ">Castellanos 1997</a>), although the length of this study was only three weeks. </p> <section id="CD007990-sec-0070"> <h4 class="title">Primary outcomes: attention deficit hyperactivity disorder and tic symptom severity</h4> <section id="CD007990-sec-0071"> <h5 class="title">Methylphenidate</h5> <p>The <a href="./references#CD007990-bbs2-0008" title="Tourette's Syndrome Study Group. Treatment of ADHD in children with tics: a randomized controlled trial. Neurology2002;58(4):527‐36. [PUBMED: 11865128] ">Tourette's Syndrome Study Group 2002</a> parallel‐group study randomized children to: clonidine, flexible dose of methylphenidate, clonidine plus methylphenidate, or placebo, for 16 weeks each. The primary outcome was the change from baseline to week 16 in the ADHD Conners ASQ for Teachers; the main secondary outcome was the change from baseline in the YGTSS. On the ASQ, there was a statistically significant treatment effect in comparison to placebo with methylphenidate alone (3.3 points, 98.3% confidence interval (CI) −0.2 to 6.8; P = 0.02, reported in study) and with clonidine plus methylphenidate (6.3 points, 98.3% CI 2.8 to 9.8; P &lt; 0.001). YGTSS scores also improved compared to placebo, with a statistically significant treatment effect observed for methylphenidate alone (11.0 points, 98.3% CI 2.1 to 19.8; P = 0.003), and for methylphenidate plus clonidine (11.0 points, 98.3% CI 2.1 to 19.8; P = 0.003). </p> <p>The lowest rate of reported adverse effects occurred in the methylphenidate‐only group: 20% of participants treated with methylphenidate reported a worsening of tics as an adverse event compared to 22% receiving placebo (and 26% treated with clonidine alone). Paradoxically, however, tics limited further dosage increases more often for participants assigned to methylphenidate alone (35%) than for participants assigned to methylphenidate plus clonidine (15%), clonidine alone (18%), or placebo (19%). </p> <p>In the <a href="./references#CD007990-bbs2-0004" title="GadowKD , NolanEE , SprafkinJ , SverdJ . School observations of children with attention deficit hyperactivity disorder and comorbid tic disorder: effects of methylphenidate treatment. Journal of Developmental and Behavioural Pediatrics1995;16(3):167‐76. [PUBMED: 7560119] GadowKD , NolanEE , SverdJ . Methylphenidate in hyperactive boys with comorbid tic disorder: II. Short‐term behavioral effects in school settings. Journal of the American Academy of Child and Adolescent Psychiatry1992;31(3):462‐71. [DOI: 10.1097/00004583‐199205000‐00012; PUBMED: 1592778] GadowKD , NolanEE , SverdJ , SprafkinJ , ScheiderJ . Methylphenidate in children with oppositional defiant disorder and both comorbid chronic multiple tic disorder and ADHD. Journal of Child Neurology2008;23(9):981‐90. [DOI: 10.1177/0883073808315412; PUBMED: 18474932] GadowKD , NolanEE , SverdJ , SprafkinJ , SchwartzJ . Anxiety and depression symptoms and response to methylphenidate in children with attention deficit hyperactivity disorder and tic disorder. Journal of Clinical Psychopharmacology2002;22(3):267‐74. [PUBMED: 12006897] GadowKD , SverdJ , NolanEE , SprafkinJ , SchneiderJ . Immediate‐release methylphenidate for ADHD in children with comorbid chronic multiple tic disorder. Journal of the American Academy of Child and Adolescent Psychiatry2007;46(7):840‐8. [DOI: 10.1097/chi.0b013e31805c0860; PUBMED: 17581448] GadowKD , SverdJ , SprafkinJ , NolanEE , EzorSN . Efficacy of methylphenidate for attention deficit hyperactivity disorder in children with tic disorder. Archives of General Psychiatry1995;52(6):444‐55. [PUBMED: 7771914] GadowKD , SverdJ , SprafkinJ , NolanEE , GrossmanS . Long‐term methylphenidate therapy in children with comorbid attention deficit hyperactivity disorder and chronic multiple tic disorder. Archives of General Psychiatry1999;56(4):330‐6. [PUBMED: 10197827] NolanEE , GadowKD . Children with ADHD and tic disorder and their classmates: behavioural normalization with methylphenidate. Journal of the American Academy of Child and Adolescent Psychiatry1997;36(5):597‐604. [DOI: 10.1097/00004583‐199705000‐00009; PUBMED: 9136493] ">Gadow 2007</a> cross‐over trial, which randomized children to three different doses of methylphenidate and placebo for two weeks each, the primary outcome was the YGTSS score. Regarding ADHD symptoms, all three doses of methylphenidate were superior to placebo on all rating scales used, including the ASQ. There was a dose‐dependent effect, with methylphenidate 0.5 mg/kg showing superiority to the lower doses of methylphenidate on the ASQ. Mean scores on the ASQ were: 11.6 (SD 6.9) points during placebo treatment; 8.0 (SD 6.0) points with methylphenidate 0.1 mg/kg; 7.3 (SD 5.8) points with methylphenidate 0.3 mg/kg; and 5.7 (SD 5.1) points with methylphenidate 0.5 mg/kg (F = 24.7; P &lt; 0.001). </p> <p>On the YGTSS, there was no difference in tic severity between treatments with respect to mean total motor, total phonic, impairment, or global severity scores. The teacher ratings on the Global Tic Rating Scale, however, indicated an improvement in tic severity with methylphenidate treatment compared to placebo with all doses (F ratio 5.33; P = 0.002); although one measure, the two‐minute tic/habit count, found an increase in simple motor tics during treatment with methylphenidate 0.3 mg/kg and methylphenidate 0.5 mg/kg compared to placebo (F = 3.96; P = 0.009). </p> <p>In the <a href="./references#CD007990-bbs2-0002" title="CastellanosFX , GieddJN , EliaJ , MarshWL , RitchieGF , HamburgerSD , et al. Controlled stimulant treatment of ADHD and comorbid Tourette's syndrome: effects of stimulant and dose. Journal of the American Academy of Child and Adolescent Psychiatry1997;36(5):589‐96. [DOI: 10.1097/00004583‐199705000‐00008; PUBMED: 9136492] ">Castellanos 1997</a> cross‐over trial in which children were randomized to three weeks each of methylphenidate, dextroamphetamine, and placebo, methylphenidate significantly decreased hyperactivity at all doses. In the first cohort of 10 participants, analysis of variance of total tic severity showed that tic severity was significantly greater during the second week of methylphenidate treatment (P &lt; 0.01) than during any of the placebo weeks, or during the third week of methylphenidate treatment. In the second and third cohorts of participants, there was no significant main effect of drug on tic severity. </p> <p>A meta‐analysis of studies evaluating methylphenidate was not possible for several reasons. First, the cross‐over trial by <a href="./references#CD007990-bbs2-0004" title="GadowKD , NolanEE , SprafkinJ , SverdJ . School observations of children with attention deficit hyperactivity disorder and comorbid tic disorder: effects of methylphenidate treatment. Journal of Developmental and Behavioural Pediatrics1995;16(3):167‐76. [PUBMED: 7560119] GadowKD , NolanEE , SverdJ . Methylphenidate in hyperactive boys with comorbid tic disorder: II. Short‐term behavioral effects in school settings. Journal of the American Academy of Child and Adolescent Psychiatry1992;31(3):462‐71. [DOI: 10.1097/00004583‐199205000‐00012; PUBMED: 1592778] GadowKD , NolanEE , SverdJ , SprafkinJ , ScheiderJ . Methylphenidate in children with oppositional defiant disorder and both comorbid chronic multiple tic disorder and ADHD. Journal of Child Neurology2008;23(9):981‐90. [DOI: 10.1177/0883073808315412; PUBMED: 18474932] GadowKD , NolanEE , SverdJ , SprafkinJ , SchwartzJ . Anxiety and depression symptoms and response to methylphenidate in children with attention deficit hyperactivity disorder and tic disorder. Journal of Clinical Psychopharmacology2002;22(3):267‐74. [PUBMED: 12006897] GadowKD , SverdJ , NolanEE , SprafkinJ , SchneiderJ . Immediate‐release methylphenidate for ADHD in children with comorbid chronic multiple tic disorder. Journal of the American Academy of Child and Adolescent Psychiatry2007;46(7):840‐8. [DOI: 10.1097/chi.0b013e31805c0860; PUBMED: 17581448] GadowKD , SverdJ , SprafkinJ , NolanEE , EzorSN . Efficacy of methylphenidate for attention deficit hyperactivity disorder in children with tic disorder. Archives of General Psychiatry1995;52(6):444‐55. [PUBMED: 7771914] GadowKD , SverdJ , SprafkinJ , NolanEE , GrossmanS . Long‐term methylphenidate therapy in children with comorbid attention deficit hyperactivity disorder and chronic multiple tic disorder. Archives of General Psychiatry1999;56(4):330‐6. [PUBMED: 10197827] NolanEE , GadowKD . Children with ADHD and tic disorder and their classmates: behavioural normalization with methylphenidate. Journal of the American Academy of Child and Adolescent Psychiatry1997;36(5):597‐604. [DOI: 10.1097/00004583‐199705000‐00009; PUBMED: 9136493] ">Gadow 2007</a> presented data as means and SDs for each methylphenidate dosage and placebo, rather than providing a paired analysis. Meta‐analysis of these data, therefore, runs the risk of a unit‐of‐analysis error. Second, the manuscript for <a href="./references#CD007990-bbs2-0002" title="CastellanosFX , GieddJN , EliaJ , MarshWL , RitchieGF , HamburgerSD , et al. Controlled stimulant treatment of ADHD and comorbid Tourette's syndrome: effects of stimulant and dose. Journal of the American Academy of Child and Adolescent Psychiatry1997;36(5):589‐96. [DOI: 10.1097/00004583‐199705000‐00008; PUBMED: 9136492] ">Castellanos 1997</a> only provided F scores from the analysis of variance of tic severity as it related to drug and dosage. No other raw data were provided and, on contacting the study author, these data were no longer available. </p> </section> <section id="CD007990-sec-0072"> <h5 class="title">Dextroamphetamine</h5> <p><a href="./references#CD007990-bbs2-0002" title="CastellanosFX , GieddJN , EliaJ , MarshWL , RitchieGF , HamburgerSD , et al. Controlled stimulant treatment of ADHD and comorbid Tourette's syndrome: effects of stimulant and dose. Journal of the American Academy of Child and Adolescent Psychiatry1997;36(5):589‐96. [DOI: 10.1097/00004583‐199705000‐00008; PUBMED: 9136492] ">Castellanos 1997</a> was a placebo‐controlled, cross‐over study of dextroamphetamine, which randomized 20 children into three cohorts. Each child received one of three different dosage titrations of dextroamphetamine to a target dosage of 7.5 mg, 15 mg, or 22.5 mg, twice daily for three weeks. In all cohorts, dextroamphetamine significantly decreased hyperactivity, measured by teachers using the Conners 39‐item Teacher Rating Scale, but there was no significant interaction between drug and dose, indicating that additional improvements in hyperactivity were not observed for higher doses. </p> <p>In the first cohort of 10 participants, tic severity was significantly greater during the second (15 mg twice daily) and third (22.5 mg twice daily) weeks of dextroamphetamine treatment compared to the weeks on placebo (F = 3.50, 98.3% CI 4 to 36; P = 0.03, reported in study). In the second cohort of six participants, there was no significant main effect of the drug on tic severity. In the third cohort of four participants, there was a trend for tic severity to be greater with dextroamphetamine, but this did not reach statistical significance. </p> </section> <section id="CD007990-sec-0073"> <h5 class="title">Clonidine</h5> <p>In the <a href="./references#CD007990-bbs2-0008" title="Tourette's Syndrome Study Group. Treatment of ADHD in children with tics: a randomized controlled trial. Neurology2002;58(4):527‐36. [PUBMED: 11865128] ">Tourette's Syndrome Study Group 2002</a>, in comparison to placebo, there was a statistically significant treatment effect on the ASQ with clonidine alone (3.3 points, 98.3% CI –0.2 to 6.8; P = 0.02), and with clonidine plus methylphenidate (6.3 points, 98.3% CI 2.8 to 9.8; P &lt; 0.0001). YGTSS scores also improved compared to placebo, with a statistically significant treatment effect observed for clonidine alone (10.9 points, 98.3% CI 2.1 to 19.7; P = 0.003), and for clonidine plus methylphenidate (11.0 points, 98.3% CI 2.1 to 19.8; P = 0.003). </p> <p><a href="./references#CD007990-bbs2-0006" title="SingerHS , BrownJ , QuaskeyS , RosenbergLA , MellitsED , DencklaMB . The treatment of attention deficit hyperactivity disorder in Tourette's syndrome: a double blind placebo‐controlled study with clonidine and desipramine. Pediatrics1995;95(1):74‐81. [PUBMED: 7770313] ">Singer 1995</a> was a three‐arm cross‐over study comparing clonidine 0.05 mg, given four times daily, to placebo and desipramine 25 mg given four times daily. The authors did not define a primary outcome and presented data for only those scales showing significant changes. In this study, clonidine did not show a significant difference compared to either placebo or desipramine on any of the outcome measures of ADHD and tic severity, with the exception of the nervous/overactive subscale of the Child Behavior Checklist in a subgroup of boys aged six to 11 years, in which clonidine was superior to placebo. </p> <p>We were unable to perform a meta‐analysis of the two studies evaluating clonidine for two reasons. The <a href="./references#CD007990-bbs2-0008" title="Tourette's Syndrome Study Group. Treatment of ADHD in children with tics: a randomized controlled trial. Neurology2002;58(4):527‐36. [PUBMED: 11865128] ">Tourette's Syndrome Study Group 2002</a> trial presented data as means and SDs for each treatment type rather than in a paired analysis, creating a risk for a unit‐of‐analysis error. The studies also had significant clinical heterogeneity: duration of treatment of six weeks in <a href="./references#CD007990-bbs2-0006" title="SingerHS , BrownJ , QuaskeyS , RosenbergLA , MellitsED , DencklaMB . The treatment of attention deficit hyperactivity disorder in Tourette's syndrome: a double blind placebo‐controlled study with clonidine and desipramine. Pediatrics1995;95(1):74‐81. [PUBMED: 7770313] ">Singer 1995</a> versus 16 weeks for <a href="./references#CD007990-bbs2-0008" title="Tourette's Syndrome Study Group. Treatment of ADHD in children with tics: a randomized controlled trial. Neurology2002;58(4):527‐36. [PUBMED: 11865128] ">Tourette's Syndrome Study Group 2002</a>. As clinical response times for clonidine can take several months, a difference of 10 weeks of treatment time between studies is likely to be clinically significant. </p> </section> <section id="CD007990-sec-0074"> <h5 class="title">Guanfacine</h5> <p><a href="./references#CD007990-bbs2-0005" title="ScahillL , ChappellPB , KimYS , SchultzRT , KatsovichL , ShepherdE , et al. A placebo‐controlled study of guanfacine in the treatment of children with tic disorders and attention deficit hyperactivity disorder. American Journal of Psychiatry2001;158(7):1067‐74. [DOI: 10.1176/appi.ajp.158.7.1067; PUBMED: 11431228] ">Scahill 2001</a> was an eight‐week, parallel‐group trial of guanfacine versus placebo in 34 children; there was no primary outcome defined. After eight weeks of treatment, guanfacine significantly reduced symptoms of ADHD and tics measured by the ADHD Rating Scale Total Score completed by the teacher (guanfacine: 37.2 (SD 8.4) points at baseline, 23.6 (SD 13.6) points at endpoint; placebo: 34.4 (SD 9.3) points at baseline, 31.7 (SD 11.2) points at endpoint (t = 2.80, df = 32; P &lt; 0.01)), and the YGTSS total tic score (guanfacine: 15.2 (SD 6.6) points at baseline, 10.7 (SD 7.0) points at endpoint; placebo: 15.4 (SD 7.0) points at baseline, 15.4 (SD 5.5) points at endpoint (t = 2.02, df = 30; P = 0.05)). </p> </section> <section id="CD007990-sec-0075"> <h5 class="title">Atomoxetine</h5> <p>In <a href="./references#CD007990-bbs2-0001" title="AllenAJ , KurlanRM , GilbertDL , CoffeyBJ , LinderSL , LewisDW , et al. Atomoxetine treatment in children and adolescents with ADHD and comorbid tic disorders. Neurology2005;65(12):1941‐9. [DOI: 10.1212/01.wnl.0000188869.58300.a7; PUBMED: 16380617] SpencerTJ , SalleFR , GilbertDL , DunnDW , McCrackenJT , CoffeyBJ , et al. Atomoxetine treatment of ADHD in children with comorbid Tourette syndrome. Journal of Attention Disorders2008;11(4):470‐81. [DOI: 10.1177/1087054707306109; PUBMED: 17934184] ">Allen 2005</a>, a parallel‐group study of atomoxetine in 148 children (0.5 mg/kg/day to 1.5 mg/kg/day), the primary stated objective was to test the hypothesis that atomoxetine does not worsen tics in participants with ADHD and a comorbid tic disorder (i.e. is non‐inferior relative to placebo). The primary efficacy measure was the YGTSS total tic score and secondary assessment measures included the ADHD Rating Scale total score, parent version. With respect to measures of ADHD severity, children in the atomoxetine group had a mean decrease of 10.9 (SD 10.9) points on the ADHD Rating Scale total score compared to a decrease of 4.9 (SD 10.3) points in the placebo group (P = 0.002). </p> <p>On the primary outcome measure, tic severity measured using the YGTSS, atomoxetine was non‐inferior relative to placebo after 18 weeks of treatment. The lower limit of the one‐sided CI for the difference in mean change between the two treatment groups (placebo and atomoxetine) was 0.27, which, being greater than the prespecified lower limit of –3.7, indicated non‐inferiority. The atomoxetine group showed a greater mean improvement in the YGTSS at the endpoint (–5.5 (SD 6.9) points) compared to placebo (–3.0 (SD 8.7) points), but this difference was not statistically significant (P = 0.06). </p> </section> <section id="CD007990-sec-0076"> <h5 class="title">Desipramine</h5> <p>Two studies evaluated desipramine in children with ADHD and a chronic tic disorder: the <a href="./references#CD007990-bbs2-0007" title="SpencerT , BiedermannJ , CoffeyB , GellerD , CrawfordM , BearmanSK , et al. A double‐blind comparison of desipramine and placebo in children and adolescents with chronic tic disorder and comorbid attention‐deficit/hyperactivity disorder. Archives of General Psychiatry2002;59(7):649‐56. [PUBMED: 12090818] ">Spencer 2002</a> parallel‐group study of 41 children, comparing placebo to desipramine titrated weekly up to 3.5 mg/kg/day for six weeks, and the <a href="./references#CD007990-bbs2-0006" title="SingerHS , BrownJ , QuaskeyS , RosenbergLA , MellitsED , DencklaMB . The treatment of attention deficit hyperactivity disorder in Tourette's syndrome: a double blind placebo‐controlled study with clonidine and desipramine. Pediatrics1995;95(1):74‐81. [PUBMED: 7770313] ">Singer 1995</a> cross‐over study comparing desipramine to both placebo and clonidine. </p> <p><a href="./references#CD007990-bbs2-0007" title="SpencerT , BiedermannJ , CoffeyB , GellerD , CrawfordM , BearmanSK , et al. A double‐blind comparison of desipramine and placebo in children and adolescents with chronic tic disorder and comorbid attention‐deficit/hyperactivity disorder. Archives of General Psychiatry2002;59(7):649‐56. [PUBMED: 12090818] ">Spencer 2002</a> did not specify a primary outcome, although they assessed ADHD severity using the ADHD rating scale and tic severity with the YGTSS. At week six, compared to baseline, both ADHD symptoms and tic severity significantly improved in children treated with desipramine whereas they did not in children treated with placebo. The ADHD rating scale score decreased from 46 (SD 5.9) points at week zero to 24 (SD 12) points at week six (P &lt; 0.001), and the YGTSS score decreased from 63 (SD 18) points at week zero to 43 (SD 23) points at week six (P &lt; 0.001). There were no changes in measures of anxiety, obsessive‐compulsive behaviors, or depression between desipramine and placebo. </p> <p>In the study by <a href="./references#CD007990-bbs2-0006" title="SingerHS , BrownJ , QuaskeyS , RosenbergLA , MellitsED , DencklaMB . The treatment of attention deficit hyperactivity disorder in Tourette's syndrome: a double blind placebo‐controlled study with clonidine and desipramine. Pediatrics1995;95(1):74‐81. [PUBMED: 7770313] ">Singer 1995</a>, with respect to ADHD symptoms, desipramine was superior to placebo (and clonidine) in the Parent Linear Analogue Scale for Hyperactivity (P &lt; 0.05), with a mean score of 32.8 (SD 1.3) points during desipramine treatment compared to 64.4 (SD 0.6) points during placebo treatment (and 51.6 (SD 2.2) during clonidine treatment). The hyperactivity subscale of the Child Behavior Checklist demonstrated a statistically significant drug effect only for boys aged six to 11 years for desipramine compared to both clonidine and placebo treatment (P &lt; 0.05). Hyperactivity subscale scores were 68.6 (SD 1.4) points during desipramine treatment compared to 75.8 (SD 1.0) points during placebo treatment (and 70.7 (SD 1.2) points during clonidine treatment). </p> <p>With respect to effect on tic severity, desipramine was superior to both placebo and clonidine (P &lt; 0.05) on the Parent Linear Analogue Scale. Mean scores were 30.0 (SD 0.7) points during desipramine treatment compared to 47.4 (SD 1.8) points during placebo treatment (and 41.4 (SD 1.1) points during clonidine treatment). Other measures of tic severity, including the Tourette Syndrome Severity Scale and the YGTSS, did not demonstrate significant differences between treatment groups. </p> <p><a href="./references#CD007990-bbs2-0006" title="SingerHS , BrownJ , QuaskeyS , RosenbergLA , MellitsED , DencklaMB . The treatment of attention deficit hyperactivity disorder in Tourette's syndrome: a double blind placebo‐controlled study with clonidine and desipramine. Pediatrics1995;95(1):74‐81. [PUBMED: 7770313] ">Singer 1995</a> was a cross‐over trial that presented data as means and SDs for each treatment type, rather than in a paired analysis. We were unable to perform a meta‐analysis of <a href="./references#CD007990-bbs2-0006" title="SingerHS , BrownJ , QuaskeyS , RosenbergLA , MellitsED , DencklaMB . The treatment of attention deficit hyperactivity disorder in Tourette's syndrome: a double blind placebo‐controlled study with clonidine and desipramine. Pediatrics1995;95(1):74‐81. [PUBMED: 7770313] ">Singer 1995</a> and <a href="./references#CD007990-bbs2-0007" title="SpencerT , BiedermannJ , CoffeyB , GellerD , CrawfordM , BearmanSK , et al. A double‐blind comparison of desipramine and placebo in children and adolescents with chronic tic disorder and comorbid attention‐deficit/hyperactivity disorder. Archives of General Psychiatry2002;59(7):649‐56. [PUBMED: 12090818] ">Spencer 2002</a> because of the risk of a unit‐of‐analysis error. </p> </section> <section id="CD007990-sec-0077"> <h5 class="title">Deprenyl</h5> <p>In the <a href="./references#CD007990-bbs2-0003" title="FeiginA , KurlanR , McDermottMP , BeachJ , DimitsopulosT , BrowerCA , et al. A controlled trial of deprenyl in children with Tourette's syndrome and attention deficit hyperactivity disorder. Neurology1996;46(4):965‐8. [PUBMED: 8780073] ">Feigin 1996</a> cross‐over trial of deprenyl versus placebo, the primary outcome measure for ADHD was the total score on the DuPaul ADHD Scale, and the primary outcome measure for tics was the total score on the YGTSS. The primary analysis revealed no significant improvement on the DuPaul ADHD Scale with deprenyl (mean improvement 1.3 points, 95% CI –2.7 to 5.3; P = 0.50). The YGTSS total score improved by a mean of 9.3 points with deprenyl (95% CI –0.4 to 19.0; P = 0.06), but this was not statistically significant. Nine of the 24 participants dropped out of the study before entering the second treatment period (six who had received deprenyl and three who had received placebo). </p> </section> </section> <section id="CD007990-sec-0078"> <h4 class="title">Secondary outcomes: adverse effects</h4> <section id="CD007990-sec-0079"> <h5 class="title">Methylphenidate</h5> <p>In <a href="./references#CD007990-bbs2-0004" title="GadowKD , NolanEE , SprafkinJ , SverdJ . School observations of children with attention deficit hyperactivity disorder and comorbid tic disorder: effects of methylphenidate treatment. Journal of Developmental and Behavioural Pediatrics1995;16(3):167‐76. [PUBMED: 7560119] GadowKD , NolanEE , SverdJ . Methylphenidate in hyperactive boys with comorbid tic disorder: II. Short‐term behavioral effects in school settings. Journal of the American Academy of Child and Adolescent Psychiatry1992;31(3):462‐71. [DOI: 10.1097/00004583‐199205000‐00012; PUBMED: 1592778] GadowKD , NolanEE , SverdJ , SprafkinJ , ScheiderJ . Methylphenidate in children with oppositional defiant disorder and both comorbid chronic multiple tic disorder and ADHD. Journal of Child Neurology2008;23(9):981‐90. [DOI: 10.1177/0883073808315412; PUBMED: 18474932] GadowKD , NolanEE , SverdJ , SprafkinJ , SchwartzJ . Anxiety and depression symptoms and response to methylphenidate in children with attention deficit hyperactivity disorder and tic disorder. Journal of Clinical Psychopharmacology2002;22(3):267‐74. [PUBMED: 12006897] GadowKD , SverdJ , NolanEE , SprafkinJ , SchneiderJ . Immediate‐release methylphenidate for ADHD in children with comorbid chronic multiple tic disorder. Journal of the American Academy of Child and Adolescent Psychiatry2007;46(7):840‐8. [DOI: 10.1097/chi.0b013e31805c0860; PUBMED: 17581448] GadowKD , SverdJ , SprafkinJ , NolanEE , EzorSN . Efficacy of methylphenidate for attention deficit hyperactivity disorder in children with tic disorder. Archives of General Psychiatry1995;52(6):444‐55. [PUBMED: 7771914] GadowKD , SverdJ , SprafkinJ , NolanEE , GrossmanS . Long‐term methylphenidate therapy in children with comorbid attention deficit hyperactivity disorder and chronic multiple tic disorder. Archives of General Psychiatry1999;56(4):330‐6. [PUBMED: 10197827] NolanEE , GadowKD . Children with ADHD and tic disorder and their classmates: behavioural normalization with methylphenidate. Journal of the American Academy of Child and Adolescent Psychiatry1997;36(5):597‐604. [DOI: 10.1097/00004583‐199705000‐00009; PUBMED: 9136493] ">Gadow 2007</a>, there were higher levels of somatic symptoms (sleep and appetite problems, headache, stomach upset, dizziness) on the Stimulant Side Effects Checklist during methylphenidate treatment than with placebo (F = 8.1; P &lt; 0.001). Diastolic blood pressure was higher during treatment with methylphenidate 0.5 mg/kg or 0.1 mg/kg compared with placebo; and heart rate was higher during treatment with methylphenidate 0.3 mg/kg and 0.5 mg/kg compared to placebo. </p> <p>In <a href="./references#CD007990-bbs2-0002" title="CastellanosFX , GieddJN , EliaJ , MarshWL , RitchieGF , HamburgerSD , et al. Controlled stimulant treatment of ADHD and comorbid Tourette's syndrome: effects of stimulant and dose. Journal of the American Academy of Child and Adolescent Psychiatry1997;36(5):589‐96. [DOI: 10.1097/00004583‐199705000‐00008; PUBMED: 9136492] ">Castellanos 1997</a>, appetite suppression with transient weight loss occurred in three children during methylphenidate treatment, and initial insomnia occurred in two children with methylphenidate. </p> </section> <section id="CD007990-sec-0080"> <h5 class="title">Dextroamphetamine</h5> <p>In <a href="./references#CD007990-bbs2-0002" title="CastellanosFX , GieddJN , EliaJ , MarshWL , RitchieGF , HamburgerSD , et al. Controlled stimulant treatment of ADHD and comorbid Tourette's syndrome: effects of stimulant and dose. Journal of the American Academy of Child and Adolescent Psychiatry1997;36(5):589‐96. [DOI: 10.1097/00004583‐199705000‐00008; PUBMED: 9136492] ">Castellanos 1997</a>, appetite suppression with transient weight loss occurred in four children on dextroamphetamine. Initial insomnia occurred in 10 children on dextroamphetamine. </p> </section> <section id="CD007990-sec-0081"> <h5 class="title">Clonidine</h5> <p>In <a href="./references#CD007990-bbs2-0008" title="Tourette's Syndrome Study Group. Treatment of ADHD in children with tics: a randomized controlled trial. Neurology2002;58(4):527‐36. [PUBMED: 11865128] ">Tourette's Syndrome Study Group 2002</a>, sedation was common in children receiving clonidine, with 48% of the clonidine‐treated participants reporting this adverse effect compared to 14% of participants treated with methylphenidate and 6% with placebo. </p> <p>In <a href="./references#CD007990-bbs2-0006" title="SingerHS , BrownJ , QuaskeyS , RosenbergLA , MellitsED , DencklaMB . The treatment of attention deficit hyperactivity disorder in Tourette's syndrome: a double blind placebo‐controlled study with clonidine and desipramine. Pediatrics1995;95(1):74‐81. [PUBMED: 7770313] ">Singer 1995</a>, specific adverse effects were not reported. The authors reported that 15/34 children experienced at least one drug‐related problem during placebo treatment, compared to 28/34 children during clonidine treatment. </p> </section> <section id="CD007990-sec-0082"> <h5 class="title">Guanfacine</h5> <p>In <a href="./references#CD007990-bbs2-0005" title="ScahillL , ChappellPB , KimYS , SchultzRT , KatsovichL , ShepherdE , et al. A placebo‐controlled study of guanfacine in the treatment of children with tic disorders and attention deficit hyperactivity disorder. American Journal of Psychiatry2001;158(7):1067‐74. [DOI: 10.1176/appi.ajp.158.7.1067; PUBMED: 11431228] ">Scahill 2001</a>, there was no significant difference between the guanfacine and placebo groups in any adverse effects, including laboratory test results, weight, or cardiovascular parameters. One participant in the guanfacine group withdrew at week four of the study due to sedation. </p> </section> <section id="CD007990-sec-0083"> <h5 class="title">Atomoxetine</h5> <p>In <a href="./references#CD007990-bbs2-0001" title="AllenAJ , KurlanRM , GilbertDL , CoffeyBJ , LinderSL , LewisDW , et al. Atomoxetine treatment in children and adolescents with ADHD and comorbid tic disorders. Neurology2005;65(12):1941‐9. [DOI: 10.1212/01.wnl.0000188869.58300.a7; PUBMED: 16380617] SpencerTJ , SalleFR , GilbertDL , DunnDW , McCrackenJT , CoffeyBJ , et al. Atomoxetine treatment of ADHD in children with comorbid Tourette syndrome. Journal of Attention Disorders2008;11(4):470‐81. [DOI: 10.1177/1087054707306109; PUBMED: 17934184] ">Allen 2005</a>, rates of decreased appetite and nausea were significantly higher in participants treated with atomoxetine than with placebo (decreased appetite: 16% with atomoxetine versus 3% with placebo; P = 0.01; nausea: 16% with atomoxetine versus 1% with placebo; P = 0.002). The atomoxetine group showed a mean decrease of bodyweight at endpoint (–0.9 (SD 1.9) kg) that was significantly different from the weight gain seen in the placebo group (1.6 (SD 2.3) kg). Participants receiving atomoxetine also had a significant increase in heart rate (+8.3 (SD 12.0) beats per minute) compared to the decrease in heart rate seen in the placebo group (–1.2 (SD 12.7) beats per minute). Electrocardiography revealed a decrease in QT interval in the atomoxetine group versus a slight increase in the placebo group. </p> </section> <section id="CD007990-sec-0084"> <h5 class="title">Desipramine</h5> <p>In <a href="./references#CD007990-bbs2-0007" title="SpencerT , BiedermannJ , CoffeyB , GellerD , CrawfordM , BearmanSK , et al. A double‐blind comparison of desipramine and placebo in children and adolescents with chronic tic disorder and comorbid attention‐deficit/hyperactivity disorder. Archives of General Psychiatry2002;59(7):649‐56. [PUBMED: 12090818] ">Spencer 2002</a>, there were no serious adverse events. Children treated with desipramine had significantly higher rates of appetite suppression (24%) compared to placebo (0%) (P &lt; 0.02). Mild but statistically significant increases in diastolic blood pressure and pulse rate also occurred in the desipramine‐treated participants. </p> <p>In <a href="./references#CD007990-bbs2-0006" title="SingerHS , BrownJ , QuaskeyS , RosenbergLA , MellitsED , DencklaMB . The treatment of attention deficit hyperactivity disorder in Tourette's syndrome: a double blind placebo‐controlled study with clonidine and desipramine. Pediatrics1995;95(1):74‐81. [PUBMED: 7770313] ">Singer 1995</a>, specific adverse effects were not reported. The authors stated that 15/34 children reported at least one drug‐related problem during placebo treatment compared to 26/34 children during desipramine treatment. </p> </section> <section id="CD007990-sec-0085"> <h5 class="title">Deprenyl</h5> <p>In <a href="./references#CD007990-bbs2-0003" title="FeiginA , KurlanR , McDermottMP , BeachJ , DimitsopulosT , BrowerCA , et al. A controlled trial of deprenyl in children with Tourette's syndrome and attention deficit hyperactivity disorder. Neurology1996;46(4):965‐8. [PUBMED: 8780073] ">Feigin 1996</a>, adverse events were not reported to have occurred more frequently with treatment with deprenyl than with placebo; however, the authors did not include a description of adverse events by treatment group. </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD007990-sec-0086" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD007990-sec-0086"></div> <section id="CD007990-sec-0087"> <h3 class="title" id="CD007990-sec-0087">Summary of main results</h3> <p>The findings of this review suggest that there are a number of medicines available to treat children with ADHD and comorbid tic disorders. All the agents, with the exception of deprenyl, reported improvements in symptoms of ADHD in children with tic disorders, however, the quality of evidence available was low. </p> <p>The data from <a href="./references#CD007990-bbs2-0008" title="Tourette's Syndrome Study Group. Treatment of ADHD in children with tics: a randomized controlled trial. Neurology2002;58(4):527‐36. [PUBMED: 11865128] ">Tourette's Syndrome Study Group 2002</a> suggest that methylphenidate and clonidine have similar efficacy in treating symptoms of ADHD, and their combination is superior to either treatment alone. These findings may be seen as contrary to clinical experience, which has traditionally proposed that stimulants are more effective in treating ADHD symptoms than alpha agonists (<a href="./references#CD007990-bbs2-0028" title="ConnorDF , FletcherKE , SwansonJM . A meta‐analysis of clonidine for symptoms of attention‐deficit hyperactivity disorder. Journal of the American Academy of Child and Adolescent Psychiatry1999;38(12):1551‐9. [DOI: 10.1097/00004583‐199912000‐00017; PUBMED: 10596256] ">Connor 1999</a>). This unexpected result may have been due to the doses of methylphenidate used in the study which, at 25 mg/day, is lower than doses used in clinical practice for all but very young children. In <a href="./references#CD007990-bbs2-0006" title="SingerHS , BrownJ , QuaskeyS , RosenbergLA , MellitsED , DencklaMB . The treatment of attention deficit hyperactivity disorder in Tourette's syndrome: a double blind placebo‐controlled study with clonidine and desipramine. Pediatrics1995;95(1):74‐81. [PUBMED: 7770313] ">Singer 1995</a>, desipramine was superior to clonidine for the treatment of ADHD symptoms. However, this trial has limited applicability for two reasons. First, in general, the effects of clonidine may take several months to become apparent and a six‐week trial of this medication would likely be inadequate to evaluate efficacy. Second, desipramine is now used only on rare occasions in children because of concerns about cardiac toxicity (<a href="./references#CD007990-bbs2-0015" title="AmitaiY , FrischerH . Excess fatality from desipramine in children and adolescents. Journal of the American Academy of Child and Adolescent Psychiatry2006;45(1):54‐60. [DOI: 10.1097/01.chi.0000184931.26176.4a; PUBMED: 16327581] ">Amitai 2006</a>). </p> <p>The three studies of methylphenidate suggested that this drug does not worsen tics in the majority of children. It should be noted that the dose of methylphenidate in <a href="./references#CD007990-bbs2-0008" title="Tourette's Syndrome Study Group. Treatment of ADHD in children with tics: a randomized controlled trial. Neurology2002;58(4):527‐36. [PUBMED: 11865128] ">Tourette's Syndrome Study Group 2002</a> was on the lower end of what is used in clinical practice (mean 26 mg daily). There has been only one study of dextroamphetamine on tic symptoms. <a href="./references#CD007990-bbs2-0002" title="CastellanosFX , GieddJN , EliaJ , MarshWL , RitchieGF , HamburgerSD , et al. Controlled stimulant treatment of ADHD and comorbid Tourette's syndrome: effects of stimulant and dose. Journal of the American Academy of Child and Adolescent Psychiatry1997;36(5):589‐96. [DOI: 10.1097/00004583‐199705000‐00008; PUBMED: 9136492] ">Castellanos 1997</a> found worsening of tics during the second (15 mg twice daily) and third (22.5 mg twice daily) weeks of dextroamphetamine treatment compared to the weeks on placebo. As treatment was for only three weeks, it is not clear if worsening of tic symptoms would have resolved over time. The dosages used in this study are on the high end of what is used in clinical practice. There was no further clinical benefit for ADHD symptoms with the higher doses of dextroamphetamine compared to the lower dosage used (7.5 mg twice daily), which did not worsen tics. The result from this single study suggested that the lower dosage of dextroamphetamine could be considered when treating children with comorbid ADHD and tics. </p> <p>Tics do not appear to worsen with alpha agonists, and the majority of studies reported an improvement in tic severity with this class of drug. Tics significantly improved in both trials studying desipramine (<a href="./references#CD007990-bbs2-0006" title="SingerHS , BrownJ , QuaskeyS , RosenbergLA , MellitsED , DencklaMB . The treatment of attention deficit hyperactivity disorder in Tourette's syndrome: a double blind placebo‐controlled study with clonidine and desipramine. Pediatrics1995;95(1):74‐81. [PUBMED: 7770313] ">Singer 1995</a>; <a href="./references#CD007990-bbs2-0007" title="SpencerT , BiedermannJ , CoffeyB , GellerD , CrawfordM , BearmanSK , et al. A double‐blind comparison of desipramine and placebo in children and adolescents with chronic tic disorder and comorbid attention‐deficit/hyperactivity disorder. Archives of General Psychiatry2002;59(7):649‐56. [PUBMED: 12090818] ">Spencer 2002</a>); however, safety concerns have meant that it is no longer routinely used in children (<a href="./references#CD007990-bbs2-0047" title="RiddleMA , GellerB , RyanN . Another sudden death in a child treated with desipramine. Journal of the American Academy of Child and Adoelscent Psychiatry1993;32(4):792‐7. [DOI: 10.1097/00004583‐199307000‐00013; PUBMED: 8340300] ">Riddle 1993</a>). The effect of atomoxetine on tic severity was non‐inferior to placebo (<a href="./references#CD007990-bbs2-0001" title="AllenAJ , KurlanRM , GilbertDL , CoffeyBJ , LinderSL , LewisDW , et al. Atomoxetine treatment in children and adolescents with ADHD and comorbid tic disorders. Neurology2005;65(12):1941‐9. [DOI: 10.1212/01.wnl.0000188869.58300.a7; PUBMED: 16380617] SpencerTJ , SalleFR , GilbertDL , DunnDW , McCrackenJT , CoffeyBJ , et al. Atomoxetine treatment of ADHD in children with comorbid Tourette syndrome. Journal of Attention Disorders2008;11(4):470‐81. [DOI: 10.1177/1087054707306109; PUBMED: 17934184] ">Allen 2005</a>). </p> </section> <section id="CD007990-sec-0088"> <h3 class="title" id="CD007990-sec-0088">Overall completeness and applicability of evidence</h3> <p>Overall, there was a small number of trials assessing pharmacological treatments for ADHD in children with tic disorders. There are some gaps in the current available evidence, with no trials of long‐acting stimulants in children with tic disorders or trials using a number of newer ADHD treatments (see <a href="#CD007990-sec-0094">Implications for research</a>). As ADHD and tic disorders frequently occur together, the evidence is applicable clinically. The evidence is limited by the short duration of the majority of trials. </p> </section> <section id="CD007990-sec-0089"> <h3 class="title" id="CD007990-sec-0089">Quality of the evidence</h3> <p>Important methodological limitations reduced the impact of most of the trials included in this review, with the body of evidence considered low for methylphenidate, atomoxetine, and clonidine, and very low for desipramine, dextroamphetamine, guanfacine, and deprenyl. Many of the trials were small, selective outcome reporting was occasionally an issue, and reporting of results from cross‐over trials was generally poor with no studies presenting paired data for analysis. </p> </section> <section id="CD007990-sec-0090"> <h3 class="title" id="CD007990-sec-0090">Potential biases in the review process</h3> <p>We did not identify any potential biases in the review process.</p> </section> <section id="CD007990-sec-0091"> <h3 class="title" id="CD007990-sec-0091">Agreements and disagreements with other studies or reviews</h3> <p><a href="./references#CD007990-bbs2-0021" title="BlochMH , PanzaKE , Landeros‐WeisenbergerA , LeckmanJF . Meta‐analysis: treatment of attention‐deficit/hyperactivity disorder in children with comorbid tic disorders. Journal of the American Academy of Child and Adolescent Psychiatry2009;48(9):884‐93. [DOI: 10.1097/CHI.0b013e3181b26e9f; PMC3943246; PUBMED: 19625978] ">Bloch 2009</a> conducted a meta‐analysis on the treatment of ADHD in children with comorbid tic disorders. Their study included the same trials as those reported in our review but they double counted one trial as two, mistaking a separate report, <a href="./references#CD007990-bbs2-0004" title="GadowKD , NolanEE , SprafkinJ , SverdJ . School observations of children with attention deficit hyperactivity disorder and comorbid tic disorder: effects of methylphenidate treatment. Journal of Developmental and Behavioural Pediatrics1995;16(3):167‐76. [PUBMED: 7560119] GadowKD , NolanEE , SverdJ . Methylphenidate in hyperactive boys with comorbid tic disorder: II. Short‐term behavioral effects in school settings. Journal of the American Academy of Child and Adolescent Psychiatry1992;31(3):462‐71. [DOI: 10.1097/00004583‐199205000‐00012; PUBMED: 1592778] GadowKD , NolanEE , SverdJ , SprafkinJ , ScheiderJ . Methylphenidate in children with oppositional defiant disorder and both comorbid chronic multiple tic disorder and ADHD. Journal of Child Neurology2008;23(9):981‐90. [DOI: 10.1177/0883073808315412; PUBMED: 18474932] GadowKD , NolanEE , SverdJ , SprafkinJ , SchwartzJ . Anxiety and depression symptoms and response to methylphenidate in children with attention deficit hyperactivity disorder and tic disorder. Journal of Clinical Psychopharmacology2002;22(3):267‐74. [PUBMED: 12006897] GadowKD , SverdJ , NolanEE , SprafkinJ , SchneiderJ . Immediate‐release methylphenidate for ADHD in children with comorbid chronic multiple tic disorder. Journal of the American Academy of Child and Adolescent Psychiatry2007;46(7):840‐8. [DOI: 10.1097/chi.0b013e31805c0860; PUBMED: 17581448] GadowKD , SverdJ , SprafkinJ , NolanEE , EzorSN . Efficacy of methylphenidate for attention deficit hyperactivity disorder in children with tic disorder. Archives of General Psychiatry1995;52(6):444‐55. [PUBMED: 7771914] GadowKD , SverdJ , SprafkinJ , NolanEE , GrossmanS . Long‐term methylphenidate therapy in children with comorbid attention deficit hyperactivity disorder and chronic multiple tic disorder. Archives of General Psychiatry1999;56(4):330‐6. [PUBMED: 10197827] NolanEE , GadowKD . Children with ADHD and tic disorder and their classmates: behavioural normalization with methylphenidate. Journal of the American Academy of Child and Adolescent Psychiatry1997;36(5):597‐604. [DOI: 10.1097/00004583‐199705000‐00009; PUBMED: 9136493] ">Gadow 2007</a>, as an additional trial. They have drawn similar conclusions to our systematic review but elected to perform a meta‐analysis of the data, despite the degree of clinical heterogeneity and the unit‐of‐analysis issues identified above, which, in our view, would preclude such an analysis. Additionally, <a href="./references#CD007990-bbs2-0025" title="CohenSC , MulqueenJM , Ferracioli‐OdaE , StuckelmanZD , CoughlinCG , LeckmanJF , et al. Meta‐analysis: risk of tics associated with psychostimulant use in randomized, placebo‐controlled trials. Journal of the American Academy of Child and Adolescent Psychiatry2015;54(9):728‐36. [DOI: 10.1016/j.jaac.2015.06.011; PUBMED: 26299294] ">Cohen 2015</a> conducted a meta‐analysis of RCTs of psychostimulants for ADHD, focusing specifically on data related to the onset of tics reported in these trials. They concluded that the use of psychostimulants was not associated with new onset of, or increase in, the severity of pre‐existing tics. Their study included 22 trials, none of which are included in our review, and their findings supported our conclusions. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD007990-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007990.pub3/media/CDSR/CD007990/urn:x-wiley:14651858:media:CD007990:CD007990-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007990.pub3/media/CDSR/CD007990/image_t/tCD007990-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram illustrating the process for inclusion of studies." data-id="CD007990-fig-0001" src="/cdsr/doi/10.1002/14651858.CD007990.pub3/media/CDSR/CD007990/image_n/nCD007990-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram illustrating the process for inclusion of studies.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007990.pub3/full#CD007990-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007990.pub3/media/CDSR/CD007990/image_n/nCD007990-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007990-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007990.pub3/media/CDSR/CD007990/urn:x-wiley:14651858:media:CD007990:CD007990-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007990.pub3/media/CDSR/CD007990/image_t/tCD007990-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD007990-fig-0002" src="/cdsr/doi/10.1002/14651858.CD007990.pub3/media/CDSR/CD007990/image_n/nCD007990-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007990.pub3/full#CD007990-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007990.pub3/media/CDSR/CD007990/image_n/nCD007990-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD007990-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Methylphenidate compared with placebo for attention deficit hyperactivity disorder (ADHD) in children with comorbid tic disorders</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Methylphenidate compared with placebo for attention deficit hyperactivity disorder (ADHD) in children with comorbid tic disorders</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Patient or population:</b> children with ADHD and comorbid tic disorders </p> <p><b>Intervention:</b> methylphenidate </p> <p><b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Effect of treatment</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>ADHD symptom‐related behavior</b> </p> <p>Measured by standardized rating scales: Conners' Abbreviated Teacher Rating Scale, Conners' Abbreviated Parent Rating Scale, IOWA Conners' Teacher Rating Scale, Mothers' Objective Method for Subgrouping, Continuous Performance Task, Conners' Teacher Rating Scale, Conners' Continuous Performance Task </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007990-bbs2-0008" title="Tourette's Syndrome Study Group. Treatment of ADHD in children with tics: a randomized controlled trial. Neurology2002;58(4):527‐36. [PUBMED: 11865128] ">Tourette's Syndrome Study Group 2002</a> showed a significant treatment effect using the Conners' Abbreviated Teacher Rating Scale (3.3 points, 98.3% CI −0.2 to 6.8; P = 0.02). </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="3" valign="top"> <p>229 (3 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low<sup>a</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>–</p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007990-bbs2-0004" title="GadowKD , NolanEE , SprafkinJ , SverdJ . School observations of children with attention deficit hyperactivity disorder and comorbid tic disorder: effects of methylphenidate treatment. Journal of Developmental and Behavioural Pediatrics1995;16(3):167‐76. [PUBMED: 7560119] GadowKD , NolanEE , SverdJ . Methylphenidate in hyperactive boys with comorbid tic disorder: II. Short‐term behavioral effects in school settings. Journal of the American Academy of Child and Adolescent Psychiatry1992;31(3):462‐71. [DOI: 10.1097/00004583‐199205000‐00012; PUBMED: 1592778] GadowKD , NolanEE , SverdJ , SprafkinJ , ScheiderJ . Methylphenidate in children with oppositional defiant disorder and both comorbid chronic multiple tic disorder and ADHD. Journal of Child Neurology2008;23(9):981‐90. [DOI: 10.1177/0883073808315412; PUBMED: 18474932] GadowKD , NolanEE , SverdJ , SprafkinJ , SchwartzJ . Anxiety and depression symptoms and response to methylphenidate in children with attention deficit hyperactivity disorder and tic disorder. Journal of Clinical Psychopharmacology2002;22(3):267‐74. [PUBMED: 12006897] GadowKD , SverdJ , NolanEE , SprafkinJ , SchneiderJ . Immediate‐release methylphenidate for ADHD in children with comorbid chronic multiple tic disorder. Journal of the American Academy of Child and Adolescent Psychiatry2007;46(7):840‐8. [DOI: 10.1097/chi.0b013e31805c0860; PUBMED: 17581448] GadowKD , SverdJ , SprafkinJ , NolanEE , EzorSN . Efficacy of methylphenidate for attention deficit hyperactivity disorder in children with tic disorder. Archives of General Psychiatry1995;52(6):444‐55. [PUBMED: 7771914] GadowKD , SverdJ , SprafkinJ , NolanEE , GrossmanS . Long‐term methylphenidate therapy in children with comorbid attention deficit hyperactivity disorder and chronic multiple tic disorder. Archives of General Psychiatry1999;56(4):330‐6. [PUBMED: 10197827] NolanEE , GadowKD . Children with ADHD and tic disorder and their classmates: behavioural normalization with methylphenidate. Journal of the American Academy of Child and Adolescent Psychiatry1997;36(5):597‐604. [DOI: 10.1097/00004583‐199705000‐00009; PUBMED: 9136493] ">Gadow 2007</a> showed that all doses (0.1 mg/kg, 0.3 mg/kg, 0.5 mg/kg) of methylphenidate were superior to placebo on all rating scales (Conners' Abbreviated Teacher/Parent Rating Scale, IOWA Conners' Teacher Rating Scale, Mothers' Objective Method for Subgrouping, Continuous Performance Test), with a dose‐dependent effect (F = 24.7; P = 0.001) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007990-bbs2-0002" title="CastellanosFX , GieddJN , EliaJ , MarshWL , RitchieGF , HamburgerSD , et al. Controlled stimulant treatment of ADHD and comorbid Tourette's syndrome: effects of stimulant and dose. Journal of the American Academy of Child and Adolescent Psychiatry1997;36(5):589‐96. [DOI: 10.1097/00004583‐199705000‐00008; PUBMED: 9136492] ">Castellanos 1997</a> showed significantly decreased hyperactivity at all doses (15 mg, 25 mg, 45 mg). </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Tic severity</b> </p> <p>Measured by standardized rating scales: Yale Global Tic Severity Scale, Tourette Syndrome Severity Scale, Tourette Syndrome Clinical Global Impression Scale, Global Tic Rating Scale, 2‐Minute Tic and Habit Count, Tic Symptom Self‐Report </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007990-bbs2-0008" title="Tourette's Syndrome Study Group. Treatment of ADHD in children with tics: a randomized controlled trial. Neurology2002;58(4):527‐36. [PUBMED: 11865128] ">Tourette's Syndrome Study Group 2002</a> found a significant treatment effect using the Yale Global Tic Severity Scale (11.0 points, 98.3% CI 2.1 to 19.8; P = 0.003). </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="3" valign="top"> <p>229 (3 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low<sup>a</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>–</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007990-bbs2-0004" title="GadowKD , NolanEE , SprafkinJ , SverdJ . School observations of children with attention deficit hyperactivity disorder and comorbid tic disorder: effects of methylphenidate treatment. Journal of Developmental and Behavioural Pediatrics1995;16(3):167‐76. [PUBMED: 7560119] GadowKD , NolanEE , SverdJ . Methylphenidate in hyperactive boys with comorbid tic disorder: II. Short‐term behavioral effects in school settings. Journal of the American Academy of Child and Adolescent Psychiatry1992;31(3):462‐71. [DOI: 10.1097/00004583‐199205000‐00012; PUBMED: 1592778] GadowKD , NolanEE , SverdJ , SprafkinJ , ScheiderJ . Methylphenidate in children with oppositional defiant disorder and both comorbid chronic multiple tic disorder and ADHD. Journal of Child Neurology2008;23(9):981‐90. [DOI: 10.1177/0883073808315412; PUBMED: 18474932] GadowKD , NolanEE , SverdJ , SprafkinJ , SchwartzJ . Anxiety and depression symptoms and response to methylphenidate in children with attention deficit hyperactivity disorder and tic disorder. Journal of Clinical Psychopharmacology2002;22(3):267‐74. [PUBMED: 12006897] GadowKD , SverdJ , NolanEE , SprafkinJ , SchneiderJ . Immediate‐release methylphenidate for ADHD in children with comorbid chronic multiple tic disorder. Journal of the American Academy of Child and Adolescent Psychiatry2007;46(7):840‐8. [DOI: 10.1097/chi.0b013e31805c0860; PUBMED: 17581448] GadowKD , SverdJ , SprafkinJ , NolanEE , EzorSN . Efficacy of methylphenidate for attention deficit hyperactivity disorder in children with tic disorder. Archives of General Psychiatry1995;52(6):444‐55. [PUBMED: 7771914] GadowKD , SverdJ , SprafkinJ , NolanEE , GrossmanS . Long‐term methylphenidate therapy in children with comorbid attention deficit hyperactivity disorder and chronic multiple tic disorder. Archives of General Psychiatry1999;56(4):330‐6. [PUBMED: 10197827] NolanEE , GadowKD . Children with ADHD and tic disorder and their classmates: behavioural normalization with methylphenidate. Journal of the American Academy of Child and Adolescent Psychiatry1997;36(5):597‐604. [DOI: 10.1097/00004583‐199705000‐00009; PUBMED: 9136493] ">Gadow 2007</a> found no difference on the Yale Global Tic Severity Scale but found an improvement in tic severity at all doses (0.1 mg/kg, 0.3 mg/kg, 0.5 mg/kg) on the Global Tic Rating Scale completed by teachers (F = 5.33; P = 0.002) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007990-bbs2-0002" title="CastellanosFX , GieddJN , EliaJ , MarshWL , RitchieGF , HamburgerSD , et al. Controlled stimulant treatment of ADHD and comorbid Tourette's syndrome: effects of stimulant and dose. Journal of the American Academy of Child and Adolescent Psychiatry1997;36(5):589‐96. [DOI: 10.1097/00004583‐199705000‐00008; PUBMED: 9136492] ">Castellanos 1997</a> found no effect of drug on tic severity for second and third cohorts. Tic severity was significantly greater during week 2 in the first cohort (P &lt; 0.01) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><b>ADHD:</b> attention deficit hyperactivity disorder; <b>CI:</b> confidence interval. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> we are very confidence that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p><sup>a</sup>Downgraded two levels due to limitations in study design and implementation, and imprecision of results. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Methylphenidate compared with placebo for attention deficit hyperactivity disorder (ADHD) in children with comorbid tic disorders</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007990.pub3/full#CD007990-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD007990-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Clonidine compared with placebo for attention deficit hyperactivity disorder (ADHD) in children with comorbid tic disorders</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Clonidine compared with placebo for attention deficit hyperactivity disorder (ADHD) in children with comorbid tic disorders</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Patient or population:</b> children with ADHD and comorbid tic disorders </p> <p><b>Intervention:</b> clonidine </p> <p><b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Effect of treatment</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>ADHD symptom‐related behavior</b> </p> <p>Measured by standardized rating scales: Conners' Abbreviated Teacher Rating Scale, Conners' Abbreviated Parent Rating Scale, IOWA Conners' Teacher Rating Scale, Conners' Continuous Performance Task, Child Behaviour Checklist, Gordon Diagnostic System, Clinical Evaluation of Language Function, Matching Familial Figures Test, Porteus Maze Test, Restricted Academic Test </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007990-bbs2-0008" title="Tourette's Syndrome Study Group. Treatment of ADHD in children with tics: a randomized controlled trial. Neurology2002;58(4):527‐36. [PUBMED: 11865128] ">Tourette's Syndrome Study Group 2002</a> found a significant treatment effect using the Conners' Abbreviated Teacher Rating Scale (3.3 points, 98.3% CI −0.2 to 6.8; P = 0.02). </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>170 (2 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low<sup>a</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>–</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007990-bbs2-0006" title="SingerHS , BrownJ , QuaskeyS , RosenbergLA , MellitsED , DencklaMB . The treatment of attention deficit hyperactivity disorder in Tourette's syndrome: a double blind placebo‐controlled study with clonidine and desipramine. Pediatrics1995;95(1):74‐81. [PUBMED: 7770313] ">Singer 1995</a> found no significant difference on any ADHD outcome measures, except the nervous/overactive subscale of the Child Behaviour Checklist (boys aged 6‐11 years). </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Tic severity</b> </p> <p>Measured by standardized rating scales: Yale Global Tic Severity Scale, Tourette Syndrome Severity Scale, Global Tic Rating Scale, Tic Symptom Self‐Report, Hopkins Motor/Vocal Scale </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007990-bbs2-0008" title="Tourette's Syndrome Study Group. Treatment of ADHD in children with tics: a randomized controlled trial. Neurology2002;58(4):527‐36. [PUBMED: 11865128] ">Tourette's Syndrome Study Group 2002</a> showed a significant treatment effect using the Yale Global Tic Severity Scale (10.9 points, 98.3% CI 2.1 to 19.7; P = 0.003). </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>170 (2 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low<sup>a</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>–</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007990-bbs2-0006" title="SingerHS , BrownJ , QuaskeyS , RosenbergLA , MellitsED , DencklaMB . The treatment of attention deficit hyperactivity disorder in Tourette's syndrome: a double blind placebo‐controlled study with clonidine and desipramine. Pediatrics1995;95(1):74‐81. [PUBMED: 7770313] ">Singer 1995</a> found no significant difference on measures of tic severity. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>ADHD:</b> attention deficit hyperactivity disorder; <b>CI:</b> confidence interval. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> we are very confidence that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p><sup>a</sup>Downgraded two levels due to limitations in study design and implementation, and imprecision of results. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Clonidine compared with placebo for attention deficit hyperactivity disorder (ADHD) in children with comorbid tic disorders</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007990.pub3/full#CD007990-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD007990-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Desipramine compared with placebo for attention deficit hyperactivity disorder (ADHD) in children with comorbid tic disorders</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Desipramine compared with placebo for attention deficit hyperactivity disorder (ADHD) in children with comorbid tic disorders</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Patient or population:</b> children with ADHD and comorbid tic disorders </p> <p><b>Intervention:</b> desipramine </p> <p><b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Effect of treatment</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>ADHD symptom‐related behavior</b> </p> <p>Measured by standardized rating scales: Child Behaviour Checklist, Gordon Diagnostic System, Clinical Evaluation of Language Function, Matching Familial Figures Test, Porteus Maze Test, Restricted Academic Test, ADHD Rating Scale IV ‐ Parent Version; ADHD Parent Linear Analogue Scale </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007990-bbs2-0007" title="SpencerT , BiedermannJ , CoffeyB , GellerD , CrawfordM , BearmanSK , et al. A double‐blind comparison of desipramine and placebo in children and adolescents with chronic tic disorder and comorbid attention‐deficit/hyperactivity disorder. Archives of General Psychiatry2002;59(7):649‐56. [PUBMED: 12090818] ">Spencer 2002</a> showed a decrease in scores on the ADHD Rating Scale IV ‐ Parent Version (week 0 = 46 (SD 5.9) points; week 6 = 24 (SD 12) points; P &lt; 0.001). </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>75 (2 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low<sup>a</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>–</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007990-bbs2-0006" title="SingerHS , BrownJ , QuaskeyS , RosenbergLA , MellitsED , DencklaMB . The treatment of attention deficit hyperactivity disorder in Tourette's syndrome: a double blind placebo‐controlled study with clonidine and desipramine. Pediatrics1995;95(1):74‐81. [PUBMED: 7770313] ">Singer 1995</a> showed that desipramine was superior to placebo on the Parent Linear Analogue Scale for Hyperactivity (desipramine: 32.8 (SD 1.3) points; placebo: 64.4 (SD 0.6) points; P &lt; 0.05). Hyperactivity subscale of the Child Behavior Checklist showed drug effects for males aged 6 to 11 years (desipramine: 68.6 (SD 1.4) points; placebo: 75.8 (SD 1.0) points; P &lt; 0.05). </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Tic severity</b> </p> <p>Measured by standardized rating scales: Yale Global Tic Severity Scale, Tourette Syndrome Severity Scale, Hopkins Motor/Vocal Scale; ADHD Parent Linear Analogue Scale </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007990-bbs2-0007" title="SpencerT , BiedermannJ , CoffeyB , GellerD , CrawfordM , BearmanSK , et al. A double‐blind comparison of desipramine and placebo in children and adolescents with chronic tic disorder and comorbid attention‐deficit/hyperactivity disorder. Archives of General Psychiatry2002;59(7):649‐56. [PUBMED: 12090818] ">Spencer 2002</a> showed a decrease in scores on the Yale Global Tic Severity Scale (week 0 = 63 (SD 18) points; week 6: 43 (SD 23) points; P &lt; 0.001). </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>75 (2 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low<sup>a</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>–</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007990-bbs2-0006" title="SingerHS , BrownJ , QuaskeyS , RosenbergLA , MellitsED , DencklaMB . The treatment of attention deficit hyperactivity disorder in Tourette's syndrome: a double blind placebo‐controlled study with clonidine and desipramine. Pediatrics1995;95(1):74‐81. [PUBMED: 7770313] ">Singer 1995</a> showed that desipramine was superior to placebo on the Parent Linear Analogue Scale of tic severity (desipramine: 30.0 (SD 0.7) points; placebo: 47.4 SD 1.8 points; P &lt; 0.05). There were no differences on the other measures of tic severity (Tourette Syndrome Severity Scale, Hopkins Motor/vocal scale, Yale Global Tic Severity Scale). </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><b>ADHD:</b> attention deficit hyperactivity disorder; <b>SD:</b> standard deviation. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p>GRADE Working Group grades of evidence</p> <p><b>High quality:</b> we are very confidence that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p><sup>a</sup>Downgraded two levels due to limitations in study design and implementation, and imprecision of results. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Desipramine compared with placebo for attention deficit hyperactivity disorder (ADHD) in children with comorbid tic disorders</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007990.pub3/full#CD007990-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD007990-tbl-0004"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Comparisons</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Comparisons</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Trial(s)</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Methylphenidate versus placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007990-bbs2-0002" title="CastellanosFX , GieddJN , EliaJ , MarshWL , RitchieGF , HamburgerSD , et al. Controlled stimulant treatment of ADHD and comorbid Tourette's syndrome: effects of stimulant and dose. Journal of the American Academy of Child and Adolescent Psychiatry1997;36(5):589‐96. [DOI: 10.1097/00004583‐199705000‐00008; PUBMED: 9136492] ">Castellanos 1997</a> </p> <p><a href="./references#CD007990-bbs2-0004" title="GadowKD , NolanEE , SprafkinJ , SverdJ . School observations of children with attention deficit hyperactivity disorder and comorbid tic disorder: effects of methylphenidate treatment. Journal of Developmental and Behavioural Pediatrics1995;16(3):167‐76. [PUBMED: 7560119] GadowKD , NolanEE , SverdJ . Methylphenidate in hyperactive boys with comorbid tic disorder: II. Short‐term behavioral effects in school settings. Journal of the American Academy of Child and Adolescent Psychiatry1992;31(3):462‐71. [DOI: 10.1097/00004583‐199205000‐00012; PUBMED: 1592778] GadowKD , NolanEE , SverdJ , SprafkinJ , ScheiderJ . Methylphenidate in children with oppositional defiant disorder and both comorbid chronic multiple tic disorder and ADHD. Journal of Child Neurology2008;23(9):981‐90. [DOI: 10.1177/0883073808315412; PUBMED: 18474932] GadowKD , NolanEE , SverdJ , SprafkinJ , SchwartzJ . Anxiety and depression symptoms and response to methylphenidate in children with attention deficit hyperactivity disorder and tic disorder. Journal of Clinical Psychopharmacology2002;22(3):267‐74. [PUBMED: 12006897] GadowKD , SverdJ , NolanEE , SprafkinJ , SchneiderJ . Immediate‐release methylphenidate for ADHD in children with comorbid chronic multiple tic disorder. Journal of the American Academy of Child and Adolescent Psychiatry2007;46(7):840‐8. [DOI: 10.1097/chi.0b013e31805c0860; PUBMED: 17581448] GadowKD , SverdJ , SprafkinJ , NolanEE , EzorSN . Efficacy of methylphenidate for attention deficit hyperactivity disorder in children with tic disorder. Archives of General Psychiatry1995;52(6):444‐55. [PUBMED: 7771914] GadowKD , SverdJ , SprafkinJ , NolanEE , GrossmanS . Long‐term methylphenidate therapy in children with comorbid attention deficit hyperactivity disorder and chronic multiple tic disorder. Archives of General Psychiatry1999;56(4):330‐6. [PUBMED: 10197827] NolanEE , GadowKD . Children with ADHD and tic disorder and their classmates: behavioural normalization with methylphenidate. Journal of the American Academy of Child and Adolescent Psychiatry1997;36(5):597‐604. [DOI: 10.1097/00004583‐199705000‐00009; PUBMED: 9136493] ">Gadow 2007</a> </p> <p><a href="./references#CD007990-bbs2-0008" title="Tourette's Syndrome Study Group. Treatment of ADHD in children with tics: a randomized controlled trial. Neurology2002;58(4):527‐36. [PUBMED: 11865128] ">Tourette's Syndrome Study Group 2002</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clonidine versus placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007990-bbs2-0006" title="SingerHS , BrownJ , QuaskeyS , RosenbergLA , MellitsED , DencklaMB . The treatment of attention deficit hyperactivity disorder in Tourette's syndrome: a double blind placebo‐controlled study with clonidine and desipramine. Pediatrics1995;95(1):74‐81. [PUBMED: 7770313] ">Singer 1995</a> </p> <p><a href="./references#CD007990-bbs2-0008" title="Tourette's Syndrome Study Group. Treatment of ADHD in children with tics: a randomized controlled trial. Neurology2002;58(4):527‐36. [PUBMED: 11865128] ">Tourette's Syndrome Study Group 2002</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Methylphenidate plus clonidine versus placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007990-bbs2-0008" title="Tourette's Syndrome Study Group. Treatment of ADHD in children with tics: a randomized controlled trial. Neurology2002;58(4):527‐36. [PUBMED: 11865128] ">Tourette's Syndrome Study Group 2002</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dextroamphetamine versus placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007990-bbs2-0002" title="CastellanosFX , GieddJN , EliaJ , MarshWL , RitchieGF , HamburgerSD , et al. Controlled stimulant treatment of ADHD and comorbid Tourette's syndrome: effects of stimulant and dose. Journal of the American Academy of Child and Adolescent Psychiatry1997;36(5):589‐96. [DOI: 10.1097/00004583‐199705000‐00008; PUBMED: 9136492] ">Castellanos 1997</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Guanfacine versus placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007990-bbs2-0005" title="ScahillL , ChappellPB , KimYS , SchultzRT , KatsovichL , ShepherdE , et al. A placebo‐controlled study of guanfacine in the treatment of children with tic disorders and attention deficit hyperactivity disorder. American Journal of Psychiatry2001;158(7):1067‐74. [DOI: 10.1176/appi.ajp.158.7.1067; PUBMED: 11431228] ">Scahill 2001</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Atomoxetine versus placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007990-bbs2-0001" title="AllenAJ , KurlanRM , GilbertDL , CoffeyBJ , LinderSL , LewisDW , et al. Atomoxetine treatment in children and adolescents with ADHD and comorbid tic disorders. Neurology2005;65(12):1941‐9. [DOI: 10.1212/01.wnl.0000188869.58300.a7; PUBMED: 16380617] SpencerTJ , SalleFR , GilbertDL , DunnDW , McCrackenJT , CoffeyBJ , et al. Atomoxetine treatment of ADHD in children with comorbid Tourette syndrome. Journal of Attention Disorders2008;11(4):470‐81. [DOI: 10.1177/1087054707306109; PUBMED: 17934184] ">Allen 2005</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Desipramine versus placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007990-bbs2-0006" title="SingerHS , BrownJ , QuaskeyS , RosenbergLA , MellitsED , DencklaMB . The treatment of attention deficit hyperactivity disorder in Tourette's syndrome: a double blind placebo‐controlled study with clonidine and desipramine. Pediatrics1995;95(1):74‐81. [PUBMED: 7770313] ">Singer 1995</a> </p> <p><a href="./references#CD007990-bbs2-0007" title="SpencerT , BiedermannJ , CoffeyB , GellerD , CrawfordM , BearmanSK , et al. A double‐blind comparison of desipramine and placebo in children and adolescents with chronic tic disorder and comorbid attention‐deficit/hyperactivity disorder. Archives of General Psychiatry2002;59(7):649‐56. [PUBMED: 12090818] ">Spencer 2002</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Deprenyl versus placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007990-bbs2-0003" title="FeiginA , KurlanR , McDermottMP , BeachJ , DimitsopulosT , BrowerCA , et al. A controlled trial of deprenyl in children with Tourette's syndrome and attention deficit hyperactivity disorder. Neurology1996;46(4):965‐8. [PUBMED: 8780073] ">Feigin 1996</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Desipramine versus clonidine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007990-bbs2-0006" title="SingerHS , BrownJ , QuaskeyS , RosenbergLA , MellitsED , DencklaMB . The treatment of attention deficit hyperactivity disorder in Tourette's syndrome: a double blind placebo‐controlled study with clonidine and desipramine. Pediatrics1995;95(1):74‐81. [PUBMED: 7770313] ">Singer 1995</a> </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Comparisons</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007990.pub3/full#CD007990-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD007990-tbl-0005"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Attention deficit hyperactivity disorder symptom severity scales used in this review</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Scale/measure</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007990-bbs2-0001" title="AllenAJ , KurlanRM , GilbertDL , CoffeyBJ , LinderSL , LewisDW , et al. Atomoxetine treatment in children and adolescents with ADHD and comorbid tic disorders. Neurology2005;65(12):1941‐9. [DOI: 10.1212/01.wnl.0000188869.58300.a7; PUBMED: 16380617] SpencerTJ , SalleFR , GilbertDL , DunnDW , McCrackenJT , CoffeyBJ , et al. Atomoxetine treatment of ADHD in children with comorbid Tourette syndrome. Journal of Attention Disorders2008;11(4):470‐81. [DOI: 10.1177/1087054707306109; PUBMED: 17934184] "><b>Allen 2005</b> </a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007990-bbs2-0002" title="CastellanosFX , GieddJN , EliaJ , MarshWL , RitchieGF , HamburgerSD , et al. Controlled stimulant treatment of ADHD and comorbid Tourette's syndrome: effects of stimulant and dose. Journal of the American Academy of Child and Adolescent Psychiatry1997;36(5):589‐96. [DOI: 10.1097/00004583‐199705000‐00008; PUBMED: 9136492] "><b>Castellanos 1997</b> </a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007990-bbs2-0003" title="FeiginA , KurlanR , McDermottMP , BeachJ , DimitsopulosT , BrowerCA , et al. A controlled trial of deprenyl in children with Tourette's syndrome and attention deficit hyperactivity disorder. Neurology1996;46(4):965‐8. [PUBMED: 8780073] "><b>Feigin 1996</b> </a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007990-bbs2-0004" title="GadowKD , NolanEE , SprafkinJ , SverdJ . School observations of children with attention deficit hyperactivity disorder and comorbid tic disorder: effects of methylphenidate treatment. Journal of Developmental and Behavioural Pediatrics1995;16(3):167‐76. [PUBMED: 7560119] GadowKD , NolanEE , SverdJ . Methylphenidate in hyperactive boys with comorbid tic disorder: II. Short‐term behavioral effects in school settings. Journal of the American Academy of Child and Adolescent Psychiatry1992;31(3):462‐71. [DOI: 10.1097/00004583‐199205000‐00012; PUBMED: 1592778] GadowKD , NolanEE , SverdJ , SprafkinJ , ScheiderJ . Methylphenidate in children with oppositional defiant disorder and both comorbid chronic multiple tic disorder and ADHD. Journal of Child Neurology2008;23(9):981‐90. [DOI: 10.1177/0883073808315412; PUBMED: 18474932] GadowKD , NolanEE , SverdJ , SprafkinJ , SchwartzJ . Anxiety and depression symptoms and response to methylphenidate in children with attention deficit hyperactivity disorder and tic disorder. Journal of Clinical Psychopharmacology2002;22(3):267‐74. [PUBMED: 12006897] GadowKD , SverdJ , NolanEE , SprafkinJ , SchneiderJ . Immediate‐release methylphenidate for ADHD in children with comorbid chronic multiple tic disorder. Journal of the American Academy of Child and Adolescent Psychiatry2007;46(7):840‐8. [DOI: 10.1097/chi.0b013e31805c0860; PUBMED: 17581448] GadowKD , SverdJ , SprafkinJ , NolanEE , EzorSN . Efficacy of methylphenidate for attention deficit hyperactivity disorder in children with tic disorder. Archives of General Psychiatry1995;52(6):444‐55. [PUBMED: 7771914] GadowKD , SverdJ , SprafkinJ , NolanEE , GrossmanS . Long‐term methylphenidate therapy in children with comorbid attention deficit hyperactivity disorder and chronic multiple tic disorder. Archives of General Psychiatry1999;56(4):330‐6. [PUBMED: 10197827] NolanEE , GadowKD . Children with ADHD and tic disorder and their classmates: behavioural normalization with methylphenidate. Journal of the American Academy of Child and Adolescent Psychiatry1997;36(5):597‐604. [DOI: 10.1097/00004583‐199705000‐00009; PUBMED: 9136493] "><b>Gadow 2007</b> </a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007990-bbs2-0005" title="ScahillL , ChappellPB , KimYS , SchultzRT , KatsovichL , ShepherdE , et al. A placebo‐controlled study of guanfacine in the treatment of children with tic disorders and attention deficit hyperactivity disorder. American Journal of Psychiatry2001;158(7):1067‐74. [DOI: 10.1176/appi.ajp.158.7.1067; PUBMED: 11431228] "><b>Scahill 2001</b> </a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007990-bbs2-0006" title="SingerHS , BrownJ , QuaskeyS , RosenbergLA , MellitsED , DencklaMB . The treatment of attention deficit hyperactivity disorder in Tourette's syndrome: a double blind placebo‐controlled study with clonidine and desipramine. Pediatrics1995;95(1):74‐81. [PUBMED: 7770313] "><b>Singer 1995</b> </a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007990-bbs2-0007" title="SpencerT , BiedermannJ , CoffeyB , GellerD , CrawfordM , BearmanSK , et al. A double‐blind comparison of desipramine and placebo in children and adolescents with chronic tic disorder and comorbid attention‐deficit/hyperactivity disorder. Archives of General Psychiatry2002;59(7):649‐56. [PUBMED: 12090818] "><b>Spencer 2002</b> </a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007990-bbs2-0008" title="Tourette's Syndrome Study Group. Treatment of ADHD in children with tics: a randomized controlled trial. Neurology2002;58(4):527‐36. [PUBMED: 11865128] "><b>Tourette's Syndrome Study Group 2002</b> </a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Conners Abbreviated Teacher Rating Scale</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Conners Abbreviated Parent Rating Scale</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IOWA Conners Teacher Rating Scale</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mothers' Objective Method for Subgrouping</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Continuous Performance Task</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ADHD Rating Scale‐IV: Parent Version</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical Global Impression Scale – Overall – Severity</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical Global Impression Scale – ADHD/Psychiatric Symptoms</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ADHD Teacher 39‐Item Conners Rating Scale</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>DuPaul ADHD Scale</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Parent Conners Questionnaire Hyperactivity Index</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Child Behaviour Checklist</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gordon Diagnostic System</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical Evaluation of Language Function</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Matching Familial Figures Test</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Porteus Maze Test</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Restricted Academic Test</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Conners Continuous Performance Task</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="9"> <div class="table-footnote"> <p>ADHD: attention deficit hyperactivity disorder; IOWA: inattention/overactivity with aggression. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Attention deficit hyperactivity disorder symptom severity scales used in this review</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007990.pub3/full#CD007990-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD007990-tbl-0006"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Tic severity symptom scales used in this review</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Scale/measure</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007990-bbs2-0001" title="AllenAJ , KurlanRM , GilbertDL , CoffeyBJ , LinderSL , LewisDW , et al. Atomoxetine treatment in children and adolescents with ADHD and comorbid tic disorders. Neurology2005;65(12):1941‐9. [DOI: 10.1212/01.wnl.0000188869.58300.a7; PUBMED: 16380617] SpencerTJ , SalleFR , GilbertDL , DunnDW , McCrackenJT , CoffeyBJ , et al. Atomoxetine treatment of ADHD in children with comorbid Tourette syndrome. Journal of Attention Disorders2008;11(4):470‐81. [DOI: 10.1177/1087054707306109; PUBMED: 17934184] "><b>Allen 2005</b> </a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007990-bbs2-0002" title="CastellanosFX , GieddJN , EliaJ , MarshWL , RitchieGF , HamburgerSD , et al. Controlled stimulant treatment of ADHD and comorbid Tourette's syndrome: effects of stimulant and dose. Journal of the American Academy of Child and Adolescent Psychiatry1997;36(5):589‐96. [DOI: 10.1097/00004583‐199705000‐00008; PUBMED: 9136492] "><b>Castellanos 1997</b> </a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007990-bbs2-0003" title="FeiginA , KurlanR , McDermottMP , BeachJ , DimitsopulosT , BrowerCA , et al. A controlled trial of deprenyl in children with Tourette's syndrome and attention deficit hyperactivity disorder. Neurology1996;46(4):965‐8. [PUBMED: 8780073] "><b>Feigin 1996</b> </a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007990-bbs2-0004" title="GadowKD , NolanEE , SprafkinJ , SverdJ . School observations of children with attention deficit hyperactivity disorder and comorbid tic disorder: effects of methylphenidate treatment. Journal of Developmental and Behavioural Pediatrics1995;16(3):167‐76. [PUBMED: 7560119] GadowKD , NolanEE , SverdJ . Methylphenidate in hyperactive boys with comorbid tic disorder: II. Short‐term behavioral effects in school settings. Journal of the American Academy of Child and Adolescent Psychiatry1992;31(3):462‐71. [DOI: 10.1097/00004583‐199205000‐00012; PUBMED: 1592778] GadowKD , NolanEE , SverdJ , SprafkinJ , ScheiderJ . Methylphenidate in children with oppositional defiant disorder and both comorbid chronic multiple tic disorder and ADHD. Journal of Child Neurology2008;23(9):981‐90. [DOI: 10.1177/0883073808315412; PUBMED: 18474932] GadowKD , NolanEE , SverdJ , SprafkinJ , SchwartzJ . Anxiety and depression symptoms and response to methylphenidate in children with attention deficit hyperactivity disorder and tic disorder. Journal of Clinical Psychopharmacology2002;22(3):267‐74. [PUBMED: 12006897] GadowKD , SverdJ , NolanEE , SprafkinJ , SchneiderJ . Immediate‐release methylphenidate for ADHD in children with comorbid chronic multiple tic disorder. Journal of the American Academy of Child and Adolescent Psychiatry2007;46(7):840‐8. [DOI: 10.1097/chi.0b013e31805c0860; PUBMED: 17581448] GadowKD , SverdJ , SprafkinJ , NolanEE , EzorSN . Efficacy of methylphenidate for attention deficit hyperactivity disorder in children with tic disorder. Archives of General Psychiatry1995;52(6):444‐55. [PUBMED: 7771914] GadowKD , SverdJ , SprafkinJ , NolanEE , GrossmanS . Long‐term methylphenidate therapy in children with comorbid attention deficit hyperactivity disorder and chronic multiple tic disorder. Archives of General Psychiatry1999;56(4):330‐6. [PUBMED: 10197827] NolanEE , GadowKD . Children with ADHD and tic disorder and their classmates: behavioural normalization with methylphenidate. Journal of the American Academy of Child and Adolescent Psychiatry1997;36(5):597‐604. [DOI: 10.1097/00004583‐199705000‐00009; PUBMED: 9136493] "><b>Gadow 2007</b> </a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007990-bbs2-0005" title="ScahillL , ChappellPB , KimYS , SchultzRT , KatsovichL , ShepherdE , et al. A placebo‐controlled study of guanfacine in the treatment of children with tic disorders and attention deficit hyperactivity disorder. American Journal of Psychiatry2001;158(7):1067‐74. [DOI: 10.1176/appi.ajp.158.7.1067; PUBMED: 11431228] "><b>Scahill 2001</b> </a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007990-bbs2-0006" title="SingerHS , BrownJ , QuaskeyS , RosenbergLA , MellitsED , DencklaMB . The treatment of attention deficit hyperactivity disorder in Tourette's syndrome: a double blind placebo‐controlled study with clonidine and desipramine. Pediatrics1995;95(1):74‐81. [PUBMED: 7770313] "><b>Singer 1995</b> </a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007990-bbs2-0007" title="SpencerT , BiedermannJ , CoffeyB , GellerD , CrawfordM , BearmanSK , et al. A double‐blind comparison of desipramine and placebo in children and adolescents with chronic tic disorder and comorbid attention‐deficit/hyperactivity disorder. Archives of General Psychiatry2002;59(7):649‐56. [PUBMED: 12090818] "><b>Spencer 2002</b> </a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007990-bbs2-0008" title="Tourette's Syndrome Study Group. Treatment of ADHD in children with tics: a randomized controlled trial. Neurology2002;58(4):527‐36. [PUBMED: 11865128] "><b>Tourette's Syndrome Study Group 2002</b> </a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yale Global Tic</p> <p>Severity Scale</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tourette Syndrome</p> <p>Severity Scale</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tourette Syndrome</p> <p>Clinical Global</p> <p>Improvement</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Global Tic Rating</p> <p>Scale</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2‐Minute Tic and</p> <p>Habit Count</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tic Symptom Self‐Report</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Goetz Tic Severity</p> <p>Scale</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hopkins Motor/Vocal Scale</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Tic severity symptom scales used in this review</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007990.pub3/full#CD007990-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD007990-tbl-0007"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Description of scales used in included studies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Scale/measure</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number of items</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Scoring</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Conners' Abbreviated Symptoms Questionnaire for Teachers (ASQ)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 items pertaining to the child's behavior</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rated on a 4‐point Likert scale, ranging from 0 (not at all), 1 (just a little), 2 (pretty much) to 3 (very much true), with a possible total score ranging from 0 to 30. Higher scores indicate worse symptoms </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yale Global Tic Severity Scale (YGTSS)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 items on the number, frequency, intensity, complexity, and interference from motor tics, and 5 items on the number, frequency, intensity, complexity, and interference from vocal tics, and 1 item on overall impairment </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The Total Motor Tic Score is derived by adding the 5 motor tics items (each item ranges from 0 to 5, total motor tic score ranges from 0 to 25). The Total Vocal Tic Score is derived by adding the 5 phonic tics items (each item ranges from 0 to 5, total vocal tic ranges from 0 to 25). The Total Tic Score is a summation of the Total Motor Tic and Total Vocal Tic Scores. The Overall Impairment Rating is rated on a 51‐point scale anchored by 0 (no impairment) and 50 (severe impairment). Finally, the Global Severity Score is a summation of the Total Motor Tic Score, Total Vocal Tic Score, and Overall Impairment Rating (range 0 to 100). Higher scores indicate worse symptoms. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Global Tic Rating Scale</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9 items, with the first 5 referring to the frequency of motor (3 items) and phonic tics (2 items) according to body region, which are summed to produce motor and phonic tic frequency subscores, respectively </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All items are rated on a scale from 0 (never) to 3 (very much). Total score ranges from 0 to 27. </p> <p>Higher scores indicate worse symptoms</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ADHD Rating Scale IV ‐ Parent Version</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18‐item questionnaire. 9 questions each on inattention and hyperactivity‐impulsivity, where the odd‐numbered items represent the inattention subscale, and the even‐numbered items represent the hyperactive/impulsive subscale </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Items coded on 4‐point Likert scale using scores 1 (never or rarely), 2 (sometimes), 3 (often), or 4 (very often). Total score ranges from 18 to 52. Raw scores are converted to percentiles. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ADHD Parent Linear Analogue Scale</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10‐cm line on which both the parent and physician separately rank symptoms</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The ends of each line represent 0 (no symptoms) and 10 (most severe)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Child Behaviour Checklist (CBCL)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>113 items across 8 subscales assessing maladaptive behavioral and emotional problems:</p> <p> <ul id="CD007990-list-0010"> <li> <p>withdrawn</p> </li> <li> <p>somatic complaints</p> </li> <li> <p>anxious/depressed</p> </li> <li> <p>social problems</p> </li> <li> <p>thought problems</p> </li> <li> <p>attention problems</p> </li> <li> <p>delinquent problems</p> </li> <li> <p>aggressive behavior</p> </li> </ul> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Items are coded from 0 to 2, scored 0 (not at all), 1 (somewhat true), or 2 (very true). CBCL profile for each category, with scores below the 95th percentile in the normal range, and above the 98th percentile in the clinical range. Higher scores indicate worse symptoms. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Conners' Abbreviated Parent Rating Scale</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48 items across 6 subscales:</p> <p> <ul id="CD007990-list-0011"> <li> <p>conduct problems</p> </li> <li> <p>learning problems</p> </li> <li> <p>psychosomatic</p> </li> <li> <p>impulsive/hyperactive</p> </li> <li> <p>anxiety</p> </li> <li> <p>hyperactivity index</p> </li> </ul> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All items are rated on a scale from 0 (never) to 3 (very much). Total score ranges from 0 to 144. </p> <p>Higher scores indicate worse symptoms</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IOWA Conners' Teacher Rating Scale</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 items. Consists of 5‐item subscales designed to assess inattention/overactivity and aggression </p> <p>Inattention/overactivity: </p> <p> <ul id="CD007990-list-0012"> <li> <p>fidgeting</p> </li> <li> <p>hums and makes other odd noises</p> </li> <li> <p>excitable, impulsive</p> </li> <li> <p>inattentive, easily distracted</p> </li> <li> <p>fails to finish things he starts (short attention span)</p> </li> </ul> </p> <p>Aggression: </p> <p> <ul id="CD007990-list-0013"> <li> <p>quarrelsome</p> </li> <li> <p>acts "smart,"</p> </li> <li> <p>temper outbursts (explosive and unpredictable behavior)</p> </li> <li> <p>defiant</p> </li> <li> <p>unco‐operative</p> </li> </ul> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Scored 0 (not at all), 1 (just a little), 2 (pretty much), or 3 (very much). Total score ranges from 0 to 30. Higher scores indicate worse symptoms </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mothers' Objective Method for Subgrouping</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Contains 10 (hyperactivity or ADHD, or both) symptoms arranged in a checklist format. Generates a hyperactivity scale score and an aggression scale score </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 indicates checked and 0 unchecked. Total score ranges from 0 to 10. Higher scores indicate worse symptoms </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Continuous Performance Task (CPT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Computer‐administered and scored measure of sustained visual attention and motor response inhibition. The test takes about 15 minutes to administer and yields measures of omissions, commissions, and reaction time. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Omission errors measure inattention, commission errors measure impulsivity</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Conners' Teacher Rating Scale</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39 items clustered into 5 factors, including conduct problems, daydreaming, inattention, anxious‐fearful, and hyperactive behavior </p> <p>ADHD Teacher 39‐Item</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All items are rated on a scale from 0 (never) to 3 (very much). Total score ranges from 0 to 137. </p> <p>Raw scores for each scale are converted to T scores, incorporating normative adjustments for age and sex, with scores of at least 70 considered clinically elevated </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Conners' Continuous Performance Task (CPT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Visual‐motor task. Respondents must rapidly and accurately hit the space bar after every letter presented except the letter 'X'. Several variables may be derived from the Conners' CPT, including errors of omission and commission, mean hit reaction time (RT), mean hit RT standard error. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Omission errors measure inattention, commission errors measure impulsivity</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tourette Syndrome Severity Scale</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5‐item scale</p> <p> <ul id="CD007990-list-0014"> <li> <p>Are the tics noticeable to others?</p> </li> <li> <p>Do the tics elicit comments?</p> </li> <li> <p>Is the patient considered odd or bizarre?</p> </li> <li> <p>Do the tics interfere with functioning?</p> </li> <li> <p>Is the patient incapacitated, homebound, or hospitalized?</p> </li> </ul> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Higher scores indicates worse symptoms</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tourette Syndrome Clinical Global Impression (CGI) Scale</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Observer‐rated scale that measures illness severity (CGI‐S), or global improvement (CGI‐I) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7‐point scale, with the severity of illness scale (CGI‐S) using a range of responses from 1 (normal) to 7 (among the most severely ill people). CGI‐I scores range from 1 (very much improved) to 7 (very much worse) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2‐Minute Tic and Habit Count</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The physician counts separately the number of brief, jerky (i.e. tics) and rhythmic (i.e. stereotypic, habit) movements and vocalizations during quiet conversation in an office setting. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Higher scores indicates worse symptoms</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tic Symptom Self‐Report</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40‐item checklist containing 20 motor tic items and 20 phonic tic items</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0–3 scale corresponding with absent (score of 0) to very frequent and forceful (score of 3). Total score ranges from 0 to 120. Higher scores indicate worse symptoms </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Goetz Tic Severity Scale</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Videotape protocol involving a 10‐minute film of people placed in front of a video camera in a quiet room. 2 body views are recorded, full frontal body (far) and head and shoulders only (near), under 2 conditions: relaxed with the examiner in the room, and relaxed with the patient alone in the room </p> <p>5 domains are rated:</p> <p> <ul id="CD007990-list-0015"> <li> <p>number of body areas involved with tics</p> </li> <li> <p>motor tic intensity</p> </li> <li> <p>phonic tic intensity</p> </li> <li> <p>frequency of motor tics</p> </li> <li> <p>frequency of phonic tics</p> </li> </ul> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0–4 scoring format. For all domains, 0 represents normal function without evidence of tic disability. Higher scores indicate worse symptoms </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hopkins Motor/Vocal Scale</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Consists of a series of linear analog scales (10 cm) on which both the parent and physician separately rank each tic (motor and vocal) symptom, taking into consideration its frequency, intensity, degree of interference, and impairment </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The ends of each line represent 0 (no tics) and 10 (most severe). The</p> <p>line can be subdivided roughly into 4 ranges: mild, moderate, moderately severe, and severe </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Du Paul ADHD Rating Scale</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14 items, assessing separate factors of inattention and hyperactivity‐impulsivity</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rated on a 0 (normal) to 3 (severe) scale, yielding a total score ranging from 0 to 42. Higher scores indicate worse symptoms </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Parent Conners' Questionnaire Hyperactivity Index</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10‐item rating scale identifying hyperactive children</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Each item is rated from 0 to 3 (range 0–30). Higher scores indicate worse symptoms</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="3"> <div class="table-footnote"> <p>ADHD: attention deficit hyperactivity disorder.</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Description of scales used in included studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007990.pub3/full#CD007990-tbl-0007">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD007990.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD007990-note-0002">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD007990-note-0003">فارسی</a> </li> <li class="section-language"> <a class="" href="ms#CD007990-note-0001">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD007990-note-0011">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007990\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007990\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007990\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007990\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007990\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007990\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007990\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007990\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007990\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007990\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007990\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007990\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007990\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007990\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007990\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007990\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007990\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007990\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=mvgXlmVk&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007990.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD007990.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD007990.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD007990.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007990.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"/> <span class="taglib-text hide-accessible">Sign In</span> </span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740719708294"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD007990.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"/> <span class="taglib-text hide-accessible">Sign In</span> </span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740719708298"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD007990.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918def576cd79371',t:'MTc0MDcxOTcwOC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 